#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Dopamine-related disruption of functional topography of striatal connections in unmedicated patients with schizophrenia
#Text=Importance
#Text=Despite the well-established role of striatal dopamine in psychosis, current views generally agree that cortical dysfunction is likely necessary for the emergence of psychotic symptoms.
1-1	0-16	Dopamine-related	_	
1-2	17-27	disruption	_	
1-3	28-30	of	_	
1-4	31-41	functional	_	
1-5	42-52	topography	_	
1-6	53-55	of	_	
1-7	56-64	striatal	_	
1-8	65-76	connections	_	
1-9	77-79	in	_	
1-10	80-91	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[2]	
1-11	92-100	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[2]	
1-12	101-105	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[2]	
1-13	106-119	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[2]	
1-14	120-130	Importance	_	
1-15	131-138	Despite	_	
1-16	139-142	the	_	
1-17	143-159	well-established	_	
1-18	160-164	role	_	
1-19	165-167	of	_	
1-20	168-176	striatal	_	
1-21	177-185	dopamine	_	
1-22	186-188	in	_	
1-23	189-198	psychosis	_	
1-24	198-199	,	_	
1-25	200-207	current	_	
1-26	208-213	views	_	
1-27	214-223	generally	_	
1-28	224-229	agree	_	
1-29	230-234	that	_	
1-30	235-243	cortical	_	
1-31	244-255	dysfunction	_	
1-32	256-258	is	_	
1-33	259-265	likely	_	
1-34	266-275	necessary	_	
1-35	276-279	for	_	
1-36	280-283	the	_	
1-37	284-293	emergence	_	
1-38	294-296	of	_	
1-39	297-306	psychotic	_	
1-40	307-315	symptoms	_	
1-41	315-316	.	_	

#Text=The topographical organization of striatal-cortical connections is central to gating and integration of higher-order information, so a disruption of such topography via dysregulated dopamine could lead to cortical dysfunction in schizophrenia.
2-1	317-320	The	_	
2-2	321-334	topographical	_	
2-3	335-347	organization	_	
2-4	348-350	of	_	
2-5	351-368	striatal-cortical	_	
2-6	369-380	connections	_	
2-7	381-383	is	_	
2-8	384-391	central	_	
2-9	392-394	to	_	
2-10	395-401	gating	_	
2-11	402-405	and	_	
2-12	406-417	integration	_	
2-13	418-420	of	_	
2-14	421-433	higher-order	_	
2-15	434-445	information	_	
2-16	445-446	,	_	
2-17	447-449	so	_	
2-18	450-451	a	_	
2-19	452-462	disruption	_	
2-20	463-465	of	_	
2-21	466-470	such	_	
2-22	471-481	topography	_	
2-23	482-485	via	_	
2-24	486-498	dysregulated	_	
2-25	499-507	dopamine	_	
2-26	508-513	could	_	
2-27	514-518	lead	_	
2-28	519-521	to	_	
2-29	522-530	cortical	_	
2-30	531-542	dysfunction	_	
2-31	543-545	in	_	
2-32	546-559	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-33	559-560	.	_	

#Text=However, this hypothesis remains to be tested using multivariate methods ascertaining the global pattern of striatal connectivity and without the confounding effects of anti-dopaminergic medication.
3-1	561-568	However	_	
3-2	568-569	,	_	
3-3	570-574	this	_	
3-4	575-585	hypothesis	_	
3-5	586-593	remains	_	
3-6	594-596	to	_	
3-7	597-599	be	_	
3-8	600-606	tested	_	
3-9	607-612	using	_	
3-10	613-625	multivariate	_	
3-11	626-633	methods	_	
3-12	634-646	ascertaining	_	
3-13	647-650	the	_	
3-14	651-657	global	_	
3-15	658-665	pattern	_	
3-16	666-668	of	_	
3-17	669-677	striatal	_	
3-18	678-690	connectivity	_	
3-19	691-694	and	_	
3-20	695-702	without	_	
3-21	703-706	the	_	
3-22	707-718	confounding	_	
3-23	719-726	effects	_	
3-24	727-729	of	_	
3-25	730-747	anti-dopaminergic	_	
3-26	748-758	medication	_	
3-27	758-759	.	_	

#Text=Objective
#Text=To determine whether the pattern of brain connectivity across striatal subregions is abnormal in unmedicated patients with schizophrenia, and whether this abnormality relates to psychotic symptoms and extrastriatal dopaminergic transmission.
4-1	760-769	Objective	_	
4-2	770-772	To	_	
4-3	773-782	determine	_	
4-4	783-790	whether	_	
4-5	791-794	the	_	
4-6	795-802	pattern	_	
4-7	803-805	of	_	
4-8	806-811	brain	_	
4-9	812-824	connectivity	_	
4-10	825-831	across	_	
4-11	832-840	striatal	_	
4-12	841-851	subregions	_	
4-13	852-854	is	_	
4-14	855-863	abnormal	_	
4-15	864-866	in	_	
4-16	867-878	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[3]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-17	879-887	patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[3]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-18	888-892	with	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[3]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-19	893-906	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[3]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
4-20	906-907	,	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[3]	
4-21	908-911	and	_	
4-22	912-919	whether	_	
4-23	920-924	this	_	
4-24	925-936	abnormality	_	
4-25	937-944	relates	_	
4-26	945-947	to	_	
4-27	948-957	psychotic	_	
4-28	958-966	symptoms	_	
4-29	967-970	and	_	
4-30	971-984	extrastriatal	_	
4-31	985-997	dopaminergic	_	
4-32	998-1010	transmission	_	
4-33	1010-1011	.	_	

#Text=Design and Participants
#Text=In this multimodal, case-control study, we obtained resting-state functional Magnetic Resonance Imaging (fMRI) data in 18 unmedicated patients with schizophrenia and 24 matched healthy controls.
5-1	1012-1018	Design	_	
5-2	1019-1022	and	_	
5-3	1023-1035	Participants	_	
5-4	1036-1038	In	_	
5-5	1039-1043	this	_	
5-6	1044-1054	multimodal	_	
5-7	1054-1055	,	_	
5-8	1056-1068	case-control	_	
5-9	1069-1074	study	_	
5-10	1074-1075	,	_	
5-11	1076-1078	we	_	
5-12	1079-1087	obtained	_	
5-13	1088-1101	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-14	1102-1112	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-15	1113-1121	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-16	1122-1131	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-17	1132-1139	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-18	1140-1141	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-19	1141-1145	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-20	1145-1146	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-21	1147-1151	data	_	
5-22	1152-1154	in	_	
5-23	1155-1157	18	_	
5-24	1158-1169	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[7]	
5-25	1170-1178	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[7]	
5-26	1179-1183	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[7]	
5-27	1184-1197	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[7]	
5-28	1198-1201	and	_	
5-29	1202-1204	24	_	
5-30	1205-1212	matched	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
5-31	1213-1220	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
5-32	1221-1229	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
5-33	1229-1230	.	_	

#Text=A subset of these (12 and 17, respectively) underwent Positron Emission Tomographic (PET) imaging with the dopamine D2-receptor radiotracer [11C]FLB457, before and after amphetamine.
6-1	1231-1232	A	_	
6-2	1233-1239	subset	_	
6-3	1240-1242	of	_	
6-4	1243-1248	these	_	
6-5	1249-1250	(	_	
6-6	1250-1252	12	_	
6-7	1253-1256	and	_	
6-8	1257-1259	17	_	
6-9	1259-1260	,	_	
6-10	1261-1273	respectively	_	
6-11	1273-1274	)	_	
6-12	1275-1284	underwent	_	
6-13	1285-1293	Positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]	
6-14	1294-1302	Emission	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]	
6-15	1303-1314	Tomographic	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]	
6-16	1315-1316	(	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]	
6-17	1316-1319	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]	
6-18	1319-1320	)	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]	
6-19	1321-1328	imaging	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]	
6-20	1329-1333	with	_	
6-21	1334-1337	the	_	
6-22	1338-1346	dopamine	_	
6-23	1347-1349	D2	_	
6-24	1349-1350	-	_	
6-25	1350-1358	receptor	_	
6-26	1359-1370	radiotracer	_	
6-27	1371-1372	[	_	
6-28	1372-1375	11C	_	
6-29	1375-1376	]	_	
6-30	1376-1382	FLB457	_	
6-31	1382-1383	,	_	
6-32	1384-1390	before	_	
6-33	1391-1394	and	_	
6-34	1395-1400	after	_	
6-35	1401-1412	amphetamine	_	
6-36	1412-1413	.	_	

#Text=Data were acquired between June 16, 2011, and February 25, 2014.
7-1	1414-1418	Data	_	
7-2	1419-1423	were	_	
7-3	1424-1432	acquired	_	
7-4	1433-1440	between	_	
7-5	1441-1445	June	_	
7-6	1446-1448	16	_	
7-7	1448-1449	,	_	
7-8	1450-1454	2011	_	
7-9	1454-1455	,	_	
7-10	1456-1459	and	_	
7-11	1460-1468	February	_	
7-12	1469-1471	25	_	
7-13	1471-1472	,	_	
7-14	1473-1477	2014	_	
7-15	1477-1478	.	_	

#Text=Main Outcomes
#Text=(1) Group differences in the striatal connectivity pattern (assessed via multivariable logistic regression) across striatal subregions, and the relationship between the multivariate striatal connectivity pattern (2) with extrastriatal baseline D2-receptor binding potential and its change following amphetamine (BPND and ΔBPND), and (3) with severity of positive symptoms evaluated with the PANSS scale.
8-1	1479-1483	Main	_	
8-2	1484-1492	Outcomes	_	
8-3	1493-1494	(	_	
8-4	1494-1495	1	_	
8-5	1495-1496	)	_	
8-6	1497-1502	Group	_	
8-7	1503-1514	differences	_	
8-8	1515-1517	in	_	
8-9	1518-1521	the	_	
8-10	1522-1530	striatal	_	
8-11	1531-1543	connectivity	_	
8-12	1544-1551	pattern	_	
8-13	1552-1553	(	_	
8-14	1553-1561	assessed	_	
8-15	1562-1565	via	_	
8-16	1566-1579	multivariable	_	
8-17	1580-1588	logistic	_	
8-18	1589-1599	regression	_	
8-19	1599-1600	)	_	
8-20	1601-1607	across	_	
8-21	1608-1616	striatal	_	
8-22	1617-1627	subregions	_	
8-23	1627-1628	,	_	
8-24	1629-1632	and	_	
8-25	1633-1636	the	_	
8-26	1637-1649	relationship	_	
8-27	1650-1657	between	_	
8-28	1658-1661	the	_	
8-29	1662-1674	multivariate	_	
8-30	1675-1683	striatal	_	
8-31	1684-1696	connectivity	_	
8-32	1697-1704	pattern	_	
8-33	1705-1706	(	_	
8-34	1706-1707	2	_	
8-35	1707-1708	)	_	
8-36	1709-1713	with	_	
8-37	1714-1727	extrastriatal	_	
8-38	1728-1736	baseline	_	
8-39	1737-1739	D2	_	
8-40	1739-1740	-	_	
8-41	1740-1748	receptor	_	
8-42	1749-1756	binding	_	
8-43	1757-1766	potential	_	
8-44	1767-1770	and	_	
8-45	1771-1774	its	_	
8-46	1775-1781	change	_	
8-47	1782-1791	following	_	
8-48	1792-1803	amphetamine	_	
8-49	1804-1805	(	_	
8-50	1805-1809	BPND	_	
8-51	1810-1813	and	_	
8-52	1814-1819	ΔBPND	_	
8-53	1819-1820	)	_	
8-54	1820-1821	,	_	
8-55	1822-1825	and	_	
8-56	1826-1827	(	_	
8-57	1827-1828	3	_	
8-58	1828-1829	)	_	
8-59	1830-1834	with	_	
8-60	1835-1843	severity	_	
8-61	1844-1846	of	_	
8-62	1847-1855	positive	_	
8-63	1856-1864	symptoms	_	
8-64	1865-1874	evaluated	_	
8-65	1875-1879	with	_	
8-66	1880-1883	the	_	
8-67	1884-1889	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
8-68	1890-1895	scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
8-69	1895-1896	.	_	

#Text=Results
#Text=Patients exhibited an abnormal pattern of striatal connectivity, which included abnormal caudate connections with a distributed set of associative cortex regions (p=0.0036).
9-1	1897-1904	Results	_	
9-2	1905-1913	Patients	_	
9-3	1914-1923	exhibited	_	
9-4	1924-1926	an	_	
9-5	1927-1935	abnormal	_	
9-6	1936-1943	pattern	_	
9-7	1944-1946	of	_	
9-8	1947-1955	striatal	_	
9-9	1956-1968	connectivity	_	
9-10	1968-1969	,	_	
9-11	1970-1975	which	_	
9-12	1976-1984	included	_	
9-13	1985-1993	abnormal	_	
9-14	1994-2001	caudate	_	
9-15	2002-2013	connections	_	
9-16	2014-2018	with	_	
9-17	2019-2020	a	_	
9-18	2021-2032	distributed	_	
9-19	2033-2036	set	_	
9-20	2037-2039	of	_	
9-21	2040-2051	associative	_	
9-22	2052-2058	cortex	_	
9-23	2059-2066	regions	_	
9-24	2067-2068	(	_	
9-25	2068-2069	p	_	
9-26	2069-2070	=	_	
9-27	2070-2076	0.0036	_	
9-28	2076-2077	)	_	
9-29	2077-2078	.	_	

#Text=In patients, more deviation from the multivariate pattern of striatal connectivity found in controls correlated specifically with more severe positive symptoms (p=0.0021).
10-1	2079-2081	In	_	
10-2	2082-2090	patients	_	
10-3	2090-2091	,	_	
10-4	2092-2096	more	_	
10-5	2097-2106	deviation	_	
10-6	2107-2111	from	_	
10-7	2112-2115	the	_	
10-8	2116-2128	multivariate	_	
10-9	2129-2136	pattern	_	
10-10	2137-2139	of	_	
10-11	2140-2148	striatal	_	
10-12	2149-2161	connectivity	_	
10-13	2162-2167	found	_	
10-14	2168-2170	in	_	
10-15	2171-2179	controls	_	
10-16	2180-2190	correlated	_	
10-17	2191-2203	specifically	_	
10-18	2204-2208	with	_	
10-19	2209-2213	more	_	
10-20	2214-2220	severe	_	
10-21	2221-2229	positive	_	
10-22	2230-2238	symptoms	_	
10-23	2239-2240	(	_	
10-24	2240-2241	p	_	
10-25	2241-2242	=	_	
10-26	2242-2248	0.0021	_	
10-27	2248-2249	)	_	
10-28	2249-2250	.	_	

#Text=Striatal connectivity also correlated with baseline BPND across cortical and extrastriatal subcortical regions (p=0.0116, Bonferroni-corrected) but not with ΔBPND.
11-1	2251-2259	Striatal	_	
11-2	2260-2272	connectivity	_	
11-3	2273-2277	also	_	
11-4	2278-2288	correlated	_	
11-5	2289-2293	with	_	
11-6	2294-2302	baseline	_	
11-7	2303-2307	BPND	_	
11-8	2308-2314	across	_	
11-9	2315-2323	cortical	_	
11-10	2324-2327	and	_	
11-11	2328-2341	extrastriatal	_	
11-12	2342-2353	subcortical	_	
11-13	2354-2361	regions	_	
11-14	2362-2363	(	_	
11-15	2363-2364	p	_	
11-16	2364-2365	=	_	
11-17	2365-2371	0.0116	_	
11-18	2371-2372	,	_	
11-19	2373-2393	Bonferroni-corrected	_	
11-20	2393-2394	)	_	
11-21	2395-2398	but	_	
11-22	2399-2402	not	_	
11-23	2403-2407	with	_	
11-24	2408-2413	ΔBPND	_	
11-25	2413-2414	.	_	

#Text=Conclusions and Relevance
#Text=Using a multimodal, circuit-level interrogation of striatal-cortical connections, we provide a first demonstration that the functional topography of these connections is globally disrupted in unmedicated patients with schizophrenia.
12-1	2415-2426	Conclusions	_	
12-2	2427-2430	and	_	
12-3	2431-2440	Relevance	_	
12-4	2441-2446	Using	_	
12-5	2447-2448	a	_	
12-6	2449-2459	multimodal	_	
12-7	2459-2460	,	_	
12-8	2461-2474	circuit-level	_	
12-9	2475-2488	interrogation	_	
12-10	2489-2491	of	_	
12-11	2492-2509	striatal-cortical	_	
12-12	2510-2521	connections	_	
12-13	2521-2522	,	_	
12-14	2523-2525	we	_	
12-15	2526-2533	provide	_	
12-16	2534-2535	a	_	
12-17	2536-2541	first	_	
12-18	2542-2555	demonstration	_	
12-19	2556-2560	that	_	
12-20	2561-2564	the	_	
12-21	2565-2575	functional	_	
12-22	2576-2586	topography	_	
12-23	2587-2589	of	_	
12-24	2590-2595	these	_	
12-25	2596-2607	connections	_	
12-26	2608-2610	is	_	
12-27	2611-2619	globally	_	
12-28	2620-2629	disrupted	_	
12-29	2630-2632	in	_	
12-30	2633-2644	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[12]	
12-31	2645-2653	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[12]	
12-32	2654-2658	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[12]	
12-33	2659-2672	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[12]	
12-34	2672-2673	.	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[12]	

#Text=These findings suggest that striatal-cortical dysconnectivity may underlie the effects of dopamine dysregulation on the pathophysiology of psychotic symptoms.
13-1	2674-2679	These	_	
13-2	2680-2688	findings	_	
13-3	2689-2696	suggest	_	
13-4	2697-2701	that	_	
13-5	2702-2719	striatal-cortical	_	
13-6	2720-2735	dysconnectivity	_	
13-7	2736-2739	may	_	
13-8	2740-2748	underlie	_	
13-9	2749-2752	the	_	
13-10	2753-2760	effects	_	
13-11	2761-2763	of	_	
13-12	2764-2772	dopamine	_	
13-13	2773-2786	dysregulation	_	
13-14	2787-2789	on	_	
13-15	2790-2793	the	_	
13-16	2794-2809	pathophysiology	_	
13-17	2810-2812	of	_	
13-18	2813-2822	psychotic	_	
13-19	2823-2831	symptoms	_	
13-20	2831-2832	.	_	

#Text=INTRODUCTION
#Text=The striatum, in particular the associative striatum, is a central site of pathology in schizophrenia.
14-1	2833-2845	INTRODUCTION	_	
14-2	2846-2849	The	_	
14-3	2850-2858	striatum	_	
14-4	2858-2859	,	_	
14-5	2860-2862	in	_	
14-6	2863-2873	particular	_	
14-7	2874-2877	the	_	
14-8	2878-2889	associative	_	
14-9	2890-2898	striatum	_	
14-10	2898-2899	,	_	
14-11	2900-2902	is	_	
14-12	2903-2904	a	_	
14-13	2905-2912	central	_	
14-14	2913-2917	site	_	
14-15	2918-2920	of	_	
14-16	2921-2930	pathology	_	
14-17	2931-2933	in	_	
14-18	2934-2947	schizophrenia	_	
14-19	2947-2948	.	_	

#Text=Excessive dopamine in the associative striatum is an established finding in unmedicated patients with schizophrenia, in whom capacity for amphetamine-induced dopamine release correlates with worsening of psychotic symptoms.
15-1	2949-2958	Excessive	_	
15-2	2959-2967	dopamine	_	
15-3	2968-2970	in	_	
15-4	2971-2974	the	_	
15-5	2975-2986	associative	_	
15-6	2987-2995	striatum	_	
15-7	2996-2998	is	_	
15-8	2999-3001	an	_	
15-9	3002-3013	established	_	
15-10	3014-3021	finding	_	
15-11	3022-3024	in	_	
15-12	3025-3036	unmedicated	_	
15-13	3037-3045	patients	_	
15-14	3046-3050	with	_	
15-15	3051-3064	schizophrenia	_	
15-16	3064-3065	,	_	
15-17	3066-3068	in	_	
15-18	3069-3073	whom	_	
15-19	3074-3082	capacity	_	
15-20	3083-3086	for	_	
15-21	3087-3106	amphetamine-induced	_	
15-22	3107-3115	dopamine	_	
15-23	3116-3123	release	_	
15-24	3124-3134	correlates	_	
15-25	3135-3139	with	_	
15-26	3140-3149	worsening	_	
15-27	3150-3152	of	_	
15-28	3153-3162	psychotic	_	
15-29	3163-3171	symptoms	_	
15-30	3171-3172	.	_	

#Text=Such striatal excess of dopamine is thought to mediate its effects on cognition via basal-ganglia-thalamo-cortical (BGTC) circuits, which normally modulate cortical function by gating incoming information to the cortex.
16-1	3173-3177	Such	_	
16-2	3178-3186	striatal	_	
16-3	3187-3193	excess	_	
16-4	3194-3196	of	_	
16-5	3197-3205	dopamine	_	
16-6	3206-3208	is	_	
16-7	3209-3216	thought	_	
16-8	3217-3219	to	_	
16-9	3220-3227	mediate	_	
16-10	3228-3231	its	_	
16-11	3232-3239	effects	_	
16-12	3240-3242	on	_	
16-13	3243-3252	cognition	_	
16-14	3253-3256	via	_	
16-15	3257-3287	basal-ganglia-thalamo-cortical	_	
16-16	3288-3289	(	_	
16-17	3289-3293	BGTC	_	
16-18	3293-3294	)	_	
16-19	3295-3303	circuits	_	
16-20	3303-3304	,	_	
16-21	3305-3310	which	_	
16-22	3311-3319	normally	_	
16-23	3320-3328	modulate	_	
16-24	3329-3337	cortical	_	
16-25	3338-3346	function	_	
16-26	3347-3349	by	_	
16-27	3350-3356	gating	_	
16-28	3357-3365	incoming	_	
16-29	3366-3377	information	_	
16-30	3378-3380	to	_	
16-31	3381-3384	the	_	
16-32	3385-3391	cortex	_	
16-33	3391-3392	.	_	

#Text=A topographical organization within BGTC circuits is thus crucial for anatomically selective gating of information to relevant cortical targets, and its disruption could produce various symptoms characteristic of schizophrenia.
17-1	3393-3394	A	_	
17-2	3395-3408	topographical	_	
17-3	3409-3421	organization	_	
17-4	3422-3428	within	_	
17-5	3429-3433	BGTC	_	
17-6	3434-3442	circuits	_	
17-7	3443-3445	is	_	
17-8	3446-3450	thus	_	
17-9	3451-3458	crucial	_	
17-10	3459-3462	for	_	
17-11	3463-3475	anatomically	_	
17-12	3476-3485	selective	_	
17-13	3486-3492	gating	_	
17-14	3493-3495	of	_	
17-15	3496-3507	information	_	
17-16	3508-3510	to	_	
17-17	3511-3519	relevant	_	
17-18	3520-3528	cortical	_	
17-19	3529-3536	targets	_	
17-20	3536-3537	,	_	
17-21	3538-3541	and	_	
17-22	3542-3545	its	_	
17-23	3546-3556	disruption	_	
17-24	3557-3562	could	_	
17-25	3563-3570	produce	_	
17-26	3571-3578	various	_	
17-27	3579-3587	symptoms	_	
17-28	3588-3602	characteristic	_	
17-29	3603-3605	of	_	
17-30	3606-3619	schizophrenia	_	
17-31	3619-3620	.	_	

#Text=In health, cortical inputs to the striatum are topographically organized in semi-parallel loops.
18-1	3621-3623	In	_	
18-2	3624-3630	health	_	
18-3	3630-3631	,	_	
18-4	3632-3640	cortical	_	
18-5	3641-3647	inputs	_	
18-6	3648-3650	to	_	
18-7	3651-3654	the	_	
18-8	3655-3663	striatum	_	
18-9	3664-3667	are	_	
18-10	3668-3683	topographically	_	
18-11	3684-3693	organized	_	
18-12	3694-3696	in	_	
18-13	3697-3710	semi-parallel	_	
18-14	3711-3716	loops	_	
18-15	3716-3717	.	_	

#Text=In addition, ‘hotspot’ territories of converging inputs exist in the associative striatum which may be necessary to integrate disparate sources of reward and cognitive information.
19-1	3718-3720	In	_	
19-2	3721-3729	addition	_	
19-3	3729-3730	,	_	
19-4	3731-3732	‘	_	
19-5	3732-3739	hotspot	_	
19-6	3739-3740	’	_	
19-7	3741-3752	territories	_	
19-8	3753-3755	of	_	
19-9	3756-3766	converging	_	
19-10	3767-3773	inputs	_	
19-11	3774-3779	exist	_	
19-12	3780-3782	in	_	
19-13	3783-3786	the	_	
19-14	3787-3798	associative	_	
19-15	3799-3807	striatum	_	
19-16	3808-3813	which	_	
19-17	3814-3817	may	_	
19-18	3818-3820	be	_	
19-19	3821-3830	necessary	_	
19-20	3831-3833	to	_	
19-21	3834-3843	integrate	_	
19-22	3844-3853	disparate	_	
19-23	3854-3861	sources	_	
19-24	3862-3864	of	_	
19-25	3865-3871	reward	_	
19-26	3872-3875	and	_	
19-27	3876-3885	cognitive	_	
19-28	3886-3897	information	_	
19-29	3897-3898	.	_	

#Text=In schizophrenia, although the pairwise connectivity of specific striatal subregions with other brain regions has been assessed to some extent with univariate fMRI analyses, it is largely unknown whether such functional topography of striatal connections as a whole (i.e., the global pattern of connections across striatal subregions rather than connection strengths between specific pairs of striatal subregions and extrastriatal regions) is disrupted.
20-1	3899-3901	In	_	
20-2	3902-3915	schizophrenia	_	
20-3	3915-3916	,	_	
20-4	3917-3925	although	_	
20-5	3926-3929	the	_	
20-6	3930-3938	pairwise	_	
20-7	3939-3951	connectivity	_	
20-8	3952-3954	of	_	
20-9	3955-3963	specific	_	
20-10	3964-3972	striatal	_	
20-11	3973-3983	subregions	_	
20-12	3984-3988	with	_	
20-13	3989-3994	other	_	
20-14	3995-4000	brain	_	
20-15	4001-4008	regions	_	
20-16	4009-4012	has	_	
20-17	4013-4017	been	_	
20-18	4018-4026	assessed	_	
20-19	4027-4029	to	_	
20-20	4030-4034	some	_	
20-21	4035-4041	extent	_	
20-22	4042-4046	with	_	
20-23	4047-4057	univariate	_	
20-24	4058-4062	fMRI	_	
20-25	4063-4071	analyses	_	
20-26	4071-4072	,	_	
20-27	4073-4075	it	_	
20-28	4076-4078	is	_	
20-29	4079-4086	largely	_	
20-30	4087-4094	unknown	_	
20-31	4095-4102	whether	_	
20-32	4103-4107	such	_	
20-33	4108-4118	functional	_	
20-34	4119-4129	topography	_	
20-35	4130-4132	of	_	
20-36	4133-4141	striatal	_	
20-37	4142-4153	connections	_	
20-38	4154-4156	as	_	
20-39	4157-4158	a	_	
20-40	4159-4164	whole	_	
20-41	4165-4166	(	_	
20-42	4166-4169	i.e	_	
20-43	4169-4170	.	_	
20-44	4170-4171	,	_	
20-45	4172-4175	the	_	
20-46	4176-4182	global	_	
20-47	4183-4190	pattern	_	
20-48	4191-4193	of	_	
20-49	4194-4205	connections	_	
20-50	4206-4212	across	_	
20-51	4213-4221	striatal	_	
20-52	4222-4232	subregions	_	
20-53	4233-4239	rather	_	
20-54	4240-4244	than	_	
20-55	4245-4255	connection	_	
20-56	4256-4265	strengths	_	
20-57	4266-4273	between	_	
20-58	4274-4282	specific	_	
20-59	4283-4288	pairs	_	
20-60	4289-4291	of	_	
20-61	4292-4300	striatal	_	
20-62	4301-4311	subregions	_	
20-63	4312-4315	and	_	
20-64	4316-4329	extrastriatal	_	
20-65	4330-4337	regions	_	
20-66	4337-4338	)	_	
20-67	4339-4341	is	_	
20-68	4342-4351	disrupted	_	
20-69	4351-4352	.	_	

#Text=A key modulator of synaptic connectivity and plasticity in the striatum is dopamine.
21-1	4353-4354	A	_	
21-2	4355-4358	key	_	
21-3	4359-4368	modulator	_	
21-4	4369-4371	of	_	
21-5	4372-4380	synaptic	_	
21-6	4381-4393	connectivity	_	
21-7	4394-4397	and	_	
21-8	4398-4408	plasticity	_	
21-9	4409-4411	in	_	
21-10	4412-4415	the	_	
21-11	4416-4424	striatum	_	
21-12	4425-4427	is	_	
21-13	4428-4436	dopamine	_	
21-14	4436-4437	.	_	

#Text=Indeed, a fundamental role of dopamine in learning depends on its ability to modulate synaptic plasticity, and thus the functional efficacy of neuronal connections at striatal synapses and elsewhere.
22-1	4438-4444	Indeed	_	
22-2	4444-4445	,	_	
22-3	4446-4447	a	_	
22-4	4448-4459	fundamental	_	
22-5	4460-4464	role	_	
22-6	4465-4467	of	_	
22-7	4468-4476	dopamine	_	
22-8	4477-4479	in	_	
22-9	4480-4488	learning	_	
22-10	4489-4496	depends	_	
22-11	4497-4499	on	_	
22-12	4500-4503	its	_	
22-13	4504-4511	ability	_	
22-14	4512-4514	to	_	
22-15	4515-4523	modulate	_	
22-16	4524-4532	synaptic	_	
22-17	4533-4543	plasticity	_	
22-18	4543-4544	,	_	
22-19	4545-4548	and	_	
22-20	4549-4553	thus	_	
22-21	4554-4557	the	_	
22-22	4558-4568	functional	_	
22-23	4569-4577	efficacy	_	
22-24	4578-4580	of	_	
22-25	4581-4589	neuronal	_	
22-26	4590-4601	connections	_	
22-27	4602-4604	at	_	
22-28	4605-4613	striatal	_	
22-29	4614-4622	synapses	_	
22-30	4623-4626	and	_	
22-31	4627-4636	elsewhere	_	
22-32	4636-4637	.	_	

#Text=Therefore, excessive dopamine transmission in the associative striatum could disrupt the organization of striatal-cortical connections, ultimately leading to aberrant information processing and psychosis.
23-1	4638-4647	Therefore	_	
23-2	4647-4648	,	_	
23-3	4649-4658	excessive	_	
23-4	4659-4667	dopamine	_	
23-5	4668-4680	transmission	_	
23-6	4681-4683	in	_	
23-7	4684-4687	the	_	
23-8	4688-4699	associative	_	
23-9	4700-4708	striatum	_	
23-10	4709-4714	could	_	
23-11	4715-4722	disrupt	_	
23-12	4723-4726	the	_	
23-13	4727-4739	organization	_	
23-14	4740-4742	of	_	
23-15	4743-4760	striatal-cortical	_	
23-16	4761-4772	connections	_	
23-17	4772-4773	,	_	
23-18	4774-4784	ultimately	_	
23-19	4785-4792	leading	_	
23-20	4793-4795	to	_	
23-21	4796-4804	aberrant	_	
23-22	4805-4816	information	_	
23-23	4817-4827	processing	_	
23-24	4828-4831	and	_	
23-25	4832-4841	psychosis	_	
23-26	4841-4842	.	_	

#Text=Disrupted connectivity could be further compounded by a deficit in extrastriatal dopamine, as recently demonstrated in schizophrenia.
24-1	4843-4852	Disrupted	_	
24-2	4853-4865	connectivity	_	
24-3	4866-4871	could	_	
24-4	4872-4874	be	_	
24-5	4875-4882	further	_	
24-6	4883-4893	compounded	_	
24-7	4894-4896	by	_	
24-8	4897-4898	a	_	
24-9	4899-4906	deficit	_	
24-10	4907-4909	in	_	
24-11	4910-4923	extrastriatal	_	
24-12	4924-4932	dopamine	_	
24-13	4932-4933	,	_	
24-14	4934-4936	as	_	
24-15	4937-4945	recently	_	
24-16	4946-4958	demonstrated	_	
24-17	4959-4961	in	_	
24-18	4962-4975	schizophrenia	_	
24-19	4975-4976	.	_	

#Text=At the same time, the established effects of dopamine on striatal connectivity in health suggest that antipsychotic drugs may critically mask underlying abnormalities in striatal connectivity in medicated patients.
25-1	4977-4979	At	_	
25-2	4980-4983	the	_	
25-3	4984-4988	same	_	
25-4	4989-4993	time	_	
25-5	4993-4994	,	_	
25-6	4995-4998	the	_	
25-7	4999-5010	established	_	
25-8	5011-5018	effects	_	
25-9	5019-5021	of	_	
25-10	5022-5030	dopamine	_	
25-11	5031-5033	on	_	
25-12	5034-5042	striatal	_	
25-13	5043-5055	connectivity	_	
25-14	5056-5058	in	_	
25-15	5059-5065	health	_	
25-16	5066-5073	suggest	_	
25-17	5074-5078	that	_	
25-18	5079-5092	antipsychotic	_	
25-19	5093-5098	drugs	_	
25-20	5099-5102	may	_	
25-21	5103-5113	critically	_	
25-22	5114-5118	mask	_	
25-23	5119-5129	underlying	_	
25-24	5130-5143	abnormalities	_	
25-25	5144-5146	in	_	
25-26	5147-5155	striatal	_	
25-27	5156-5168	connectivity	_	
25-28	5169-5171	in	_	
25-29	5172-5181	medicated	_	
25-30	5182-5190	patients	_	
25-31	5190-5191	.	_	

#Text=As this confound may affect most fMRI connectivity studies in schizophrenia, conducted in medicated patients, it is therefore imperative to examine this question in unmedicated patients.
26-1	5192-5194	As	_	
26-2	5195-5199	this	_	
26-3	5200-5208	confound	_	
26-4	5209-5212	may	_	
26-5	5213-5219	affect	_	
26-6	5220-5224	most	_	
26-7	5225-5229	fMRI	_	
26-8	5230-5242	connectivity	_	
26-9	5243-5250	studies	_	
26-10	5251-5253	in	_	
26-11	5254-5267	schizophrenia	_	
26-12	5267-5268	,	_	
26-13	5269-5278	conducted	_	
26-14	5279-5281	in	_	
26-15	5282-5291	medicated	_	
26-16	5292-5300	patients	_	
26-17	5300-5301	,	_	
26-18	5302-5304	it	_	
26-19	5305-5307	is	_	
26-20	5308-5317	therefore	_	
26-21	5318-5328	imperative	_	
26-22	5329-5331	to	_	
26-23	5332-5339	examine	_	
26-24	5340-5344	this	_	
26-25	5345-5353	question	_	
26-26	5354-5356	in	_	
26-27	5357-5368	unmedicated	_	
26-28	5369-5377	patients	_	
26-29	5377-5378	.	_	

#Text=Here, we investigated the pattern of resting-state functional connectivity across subregions of the striatum in unmedicated patients with schizophrenia and healthy controls using a multivariate approach.
27-1	5379-5383	Here	_	
27-2	5383-5384	,	_	
27-3	5385-5387	we	_	
27-4	5388-5400	investigated	_	
27-5	5401-5404	the	_	
27-6	5405-5412	pattern	_	
27-7	5413-5415	of	_	
27-8	5416-5429	resting-state	_	
27-9	5430-5440	functional	_	
27-10	5441-5453	connectivity	_	
27-11	5454-5460	across	_	
27-12	5461-5471	subregions	_	
27-13	5472-5474	of	_	
27-14	5475-5478	the	_	
27-15	5479-5487	striatum	_	
27-16	5488-5490	in	_	
27-17	5491-5502	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[14]	
27-18	5503-5511	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[14]	
27-19	5512-5516	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[14]	
27-20	5517-5530	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[14]	
27-21	5531-5534	and	_	
27-22	5535-5542	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
27-23	5543-5551	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
27-24	5552-5557	using	_	
27-25	5558-5559	a	_	
27-26	5560-5572	multivariate	_	
27-27	5573-5581	approach	_	
27-28	5581-5582	.	_	

#Text=Our main aims were to test (1) whether the functional topography of striatal connections is altered in schizophrenia, and whether such abnormalities correlate with (2) severity of psychotic symptoms and with (3) amphetamine-induced dopamine release and D2 receptor (D2R) density.
28-1	5583-5586	Our	_	
28-2	5587-5591	main	_	
28-3	5592-5596	aims	_	
28-4	5597-5601	were	_	
28-5	5602-5604	to	_	
28-6	5605-5609	test	_	
28-7	5610-5611	(	_	
28-8	5611-5612	1	_	
28-9	5612-5613	)	_	
28-10	5614-5621	whether	_	
28-11	5622-5625	the	_	
28-12	5626-5636	functional	_	
28-13	5637-5647	topography	_	
28-14	5648-5650	of	_	
28-15	5651-5659	striatal	_	
28-16	5660-5671	connections	_	
28-17	5672-5674	is	_	
28-18	5675-5682	altered	_	
28-19	5683-5685	in	_	
28-20	5686-5699	schizophrenia	_	
28-21	5699-5700	,	_	
28-22	5701-5704	and	_	
28-23	5705-5712	whether	_	
28-24	5713-5717	such	_	
28-25	5718-5731	abnormalities	_	
28-26	5732-5741	correlate	_	
28-27	5742-5746	with	_	
28-28	5747-5748	(	_	
28-29	5748-5749	2	_	
28-30	5749-5750	)	_	
28-31	5751-5759	severity	_	
28-32	5760-5762	of	_	
28-33	5763-5772	psychotic	_	
28-34	5773-5781	symptoms	_	
28-35	5782-5785	and	_	
28-36	5786-5790	with	_	
28-37	5791-5792	(	_	
28-38	5792-5793	3	_	
28-39	5793-5794	)	_	
28-40	5795-5814	amphetamine-induced	_	
28-41	5815-5823	dopamine	_	
28-42	5824-5831	release	_	
28-43	5832-5835	and	_	
28-44	5836-5838	D2	_	
28-45	5839-5847	receptor	_	
28-46	5848-5849	(	_	
28-47	5849-5852	D2R	_	
28-48	5852-5853	)	_	
28-49	5854-5861	density	_	
28-50	5861-5862	.	_	

#Text=METHODS
#Text=Participants
#Text=Unmedicated patients with schizophrenia (n=19) and healthy controls (n=24) were recruited at New York State Psychiatric Institute (NYSPI) and through advertisements.
29-1	5863-5870	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
29-2	5871-5883	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-3	5884-5895	Unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[17]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]	
29-4	5896-5904	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[17]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]	
29-5	5905-5909	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[17]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]	
29-6	5910-5923	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[17]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]	
29-7	5924-5925	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-8	5925-5926	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-9	5926-5927	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-10	5927-5929	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-11	5929-5930	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-12	5931-5934	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-13	5935-5942	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
29-14	5943-5951	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
29-15	5952-5953	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-16	5953-5954	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-17	5954-5955	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-18	5955-5957	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-19	5957-5958	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-20	5959-5963	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-21	5964-5973	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-22	5974-5976	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-23	5977-5980	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-24	5981-5985	York	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-25	5986-5991	State	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-26	5992-6003	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-27	6004-6013	Institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-28	6014-6015	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-29	6015-6020	NYSPI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-30	6020-6021	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-31	6022-6025	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-32	6026-6033	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-33	6034-6048	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
29-34	6048-6049	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=All participants provided written informed consent as approved by the Institutional Review Boards of the NYSPI and Yale University.
30-1	6050-6053	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-2	6054-6066	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-3	6067-6075	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-4	6076-6083	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-5	6084-6092	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-6	6093-6100	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-7	6101-6103	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-8	6104-6112	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-9	6113-6115	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-10	6116-6119	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-11	6120-6133	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-12	6134-6140	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-13	6141-6147	Boards	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-14	6148-6150	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-15	6151-6154	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-16	6155-6160	NYSPI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-17	6161-6164	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-18	6165-6169	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-19	6170-6180	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
30-20	6180-6181	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Inclusion criteria for healthy controls were: absence of (1) any DSM-IV Axis-I diagnosis and of (2) psychotic illness in first-degree relatives.
31-1	6182-6191	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-2	6192-6200	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-3	6201-6204	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-4	6205-6212	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]	
31-5	6213-6221	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]	
31-6	6222-6226	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-7	6226-6227	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-8	6228-6235	absence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-9	6236-6238	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-10	6239-6240	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-11	6240-6241	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-12	6241-6242	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-13	6243-6246	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-14	6247-6253	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-15	6254-6260	Axis-I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-16	6261-6270	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-17	6271-6274	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-18	6275-6277	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-19	6278-6279	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-20	6279-6280	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-21	6280-6281	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-22	6282-6291	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-23	6292-6299	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-24	6300-6302	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-25	6303-6315	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-26	6316-6325	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
31-27	6325-6326	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Inclusion criteria for patients were: (1) lifetime DSM-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder (based on the Diagnostic Interview for Genetic Studies and consensus diagnosis); (2) no antipsychotics for 3 weeks before study enrollment; (3) no violent behavior.
32-1	6327-6336	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-2	6337-6345	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-3	6346-6349	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-4	6350-6358	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-5	6359-6363	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-6	6363-6364	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-7	6365-6366	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-8	6366-6367	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-9	6367-6368	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-10	6369-6377	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-11	6378-6384	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-12	6385-6394	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-13	6395-6397	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-14	6398-6411	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[21]	
32-15	6411-6412	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[21]	
32-16	6413-6428	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[21]	
32-17	6429-6431	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[21]	
32-18	6432-6448	schizophreniform	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[21]	
32-19	6449-6457	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[21]	
32-20	6458-6459	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-21	6459-6464	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-22	6465-6467	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-23	6468-6471	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-24	6472-6482	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[22]	
32-25	6483-6492	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[22]	
32-26	6493-6496	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[22]	
32-27	6497-6504	Genetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[22]	
32-28	6505-6512	Studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[22]	
32-29	6513-6516	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-30	6517-6526	consensus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-31	6527-6536	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-32	6536-6537	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-33	6537-6538	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-34	6539-6540	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-35	6540-6541	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-36	6541-6542	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-37	6543-6545	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-38	6546-6560	antipsychotics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-39	6561-6564	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-40	6565-6566	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-41	6567-6572	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-42	6573-6579	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-43	6580-6585	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-44	6586-6596	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-45	6596-6597	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-46	6598-6599	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-47	6599-6600	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-48	6600-6601	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-49	6602-6604	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-50	6605-6612	violent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-51	6613-6621	behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-52	6621-6622	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Common exclusion criteria were significant medical illnesses, misuse of substances other than nicotine, positive urine drug screen, pregnancy and nursing.
33-1	6623-6629	Common	_	
33-2	6630-6639	exclusion	_	
33-3	6640-6648	criteria	_	
33-4	6649-6653	were	_	
33-5	6654-6665	significant	_	
33-6	6666-6673	medical	_	
33-7	6674-6683	illnesses	_	
33-8	6683-6684	,	_	
33-9	6685-6691	misuse	_	
33-10	6692-6694	of	_	
33-11	6695-6705	substances	_	
33-12	6706-6711	other	_	
33-13	6712-6716	than	_	
33-14	6717-6725	nicotine	_	
33-15	6725-6726	,	_	
33-16	6727-6735	positive	_	
33-17	6736-6741	urine	_	
33-18	6742-6746	drug	_	
33-19	6747-6753	screen	_	
33-20	6753-6754	,	_	
33-21	6755-6764	pregnancy	_	
33-22	6765-6768	and	_	
33-23	6769-6776	nursing	_	
33-24	6776-6777	.	_	

#Text=PET and task-based fMRI data on 28 of the 42 subjects was previously published.
34-1	6778-6781	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
34-2	6782-6785	and	_	
34-3	6786-6796	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[23]	
34-4	6797-6801	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[23]	
34-5	6802-6806	data	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[23]	
34-6	6807-6809	on	_	
34-7	6810-6812	28	_	
34-8	6813-6815	of	_	
34-9	6816-6819	the	_	
34-10	6820-6822	42	_	
34-11	6823-6831	subjects	_	
34-12	6832-6835	was	_	
34-13	6836-6846	previously	_	
34-14	6847-6856	published	_	
34-15	6856-6857	.	_	

#Text=Symptom severity was assessed with the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Positive Symptoms (SAPS), and the Scale for Assessment of Negative Symptoms (SANS).
35-1	6858-6865	Symptom	_	
35-2	6866-6874	severity	_	
35-3	6875-6878	was	_	
35-4	6879-6887	assessed	_	
35-5	6888-6892	with	_	
35-6	6893-6896	the	_	
35-7	6897-6905	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-8	6906-6909	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-9	6910-6918	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-10	6919-6927	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-11	6928-6933	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-12	6934-6935	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-13	6935-6940	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-14	6940-6941	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[24]	
35-15	6941-6942	,	_	
35-16	6943-6946	the	_	
35-17	6947-6952	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-18	6953-6956	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-19	6957-6960	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-20	6961-6971	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-21	6972-6974	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-22	6975-6983	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-23	6984-6992	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-24	6993-6994	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-25	6994-6998	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[25]	
35-26	6998-6999	)	_	
35-27	6999-7000	,	_	
35-28	7001-7004	and	_	
35-29	7005-7008	the	_	
35-30	7009-7014	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-31	7015-7018	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-32	7019-7029	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-33	7030-7032	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-34	7033-7041	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-35	7042-7050	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-36	7051-7052	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-37	7052-7056	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-38	7056-7057	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[26]	
35-39	7057-7058	.	_	

#Text=The Hollingshead scale, the Edinburgh Handedness Inventory and the MATRICS Consensus Cognitive Battery were also obtained.
36-1	7059-7062	The	_	
36-2	7063-7075	Hollingshead	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[27]	
36-3	7076-7081	scale	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus[27]	
36-4	7081-7082	,	_	
36-5	7083-7086	the	_	
36-6	7087-7096	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[28]	
36-7	7097-7107	Handedness	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[28]	
36-8	7108-7117	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[28]	
36-9	7118-7121	and	_	
36-10	7122-7125	the	_	
36-11	7126-7133	MATRICS	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
36-12	7134-7143	Consensus	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
36-13	7144-7153	Cognitive	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
36-14	7154-7161	Battery	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
36-15	7162-7166	were	_	
36-16	7167-7171	also	_	
36-17	7172-7180	obtained	_	
36-18	7180-7181	.	_	

#Text=Resting-state fMRI data acquisition
#Text=Participants completed 2 runs of 165 volumes each on a Philips 1.5T scanner.
37-1	7182-7195	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[30]	
37-2	7196-7200	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[30]	
37-3	7201-7205	data	_	
37-4	7206-7217	acquisition	_	
37-5	7218-7230	Participants	_	
37-6	7231-7240	completed	_	
37-7	7241-7242	2	_	
37-8	7243-7247	runs	_	
37-9	7248-7250	of	_	
37-10	7251-7254	165	_	
37-11	7255-7262	volumes	_	
37-12	7263-7267	each	_	
37-13	7268-7270	on	_	
37-14	7271-7272	a	_	
37-15	7273-7280	Philips	_	
37-16	7281-7285	1.5T	_	
37-17	7286-7293	scanner	_	
37-18	7293-7294	.	_	

#Text=They were instructed to relax and keep their eyes open.
38-1	7295-7299	They	_	
38-2	7300-7304	were	_	
38-3	7305-7315	instructed	_	
38-4	7316-7318	to	_	
38-5	7319-7324	relax	_	
38-6	7325-7328	and	_	
38-7	7329-7333	keep	_	
38-8	7334-7339	their	_	
38-9	7340-7344	eyes	_	
38-10	7345-7349	open	_	
38-11	7349-7350	.	_	

#Text=Participants were spoken to before and after each sequence to ensure wakefulness.
39-1	7351-7363	Participants	_	
39-2	7364-7368	were	_	
39-3	7369-7375	spoken	_	
39-4	7376-7378	to	_	
39-5	7379-7385	before	_	
39-6	7386-7389	and	_	
39-7	7390-7395	after	_	
39-8	7396-7400	each	_	
39-9	7401-7409	sequence	_	
39-10	7410-7412	to	_	
39-11	7413-7419	ensure	_	
39-12	7420-7431	wakefulness	_	
39-13	7431-7432	.	_	

#Text=Whole-brain functional echo-planar images were obtained using an 8-channel coil (3-mm isotropic voxels; eMethods).
#Text=fMRI preprocessing
#Text=Preprocessing followed standard procedures in SPM8 and ‘scrubbing’ procedures for resting-state fMRI (eMethods).
40-1	7433-7444	Whole-brain	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]	
40-2	7445-7455	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]	
40-3	7456-7467	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]	
40-4	7468-7474	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]	
40-5	7475-7479	were	_	
40-6	7480-7488	obtained	_	
40-7	7489-7494	using	_	
40-8	7495-7497	an	_	
40-9	7498-7499	8	_	
40-10	7499-7500	-	_	
40-11	7500-7507	channel	_	
40-12	7508-7512	coil	_	
40-13	7513-7514	(	_	
40-14	7514-7515	3	_	
40-15	7515-7516	-	_	
40-16	7516-7518	mm	_	
40-17	7519-7528	isotropic	_	
40-18	7529-7535	voxels	_	
40-19	7535-7536	;	_	
40-20	7537-7545	eMethods	_	
40-21	7545-7546	)	_	
40-22	7546-7547	.	_	
40-23	7548-7552	fMRI	_	
40-24	7553-7566	preprocessing	_	
40-25	7567-7580	Preprocessing	_	
40-26	7581-7589	followed	_	
40-27	7590-7598	standard	_	
40-28	7599-7609	procedures	_	
40-29	7610-7612	in	_	
40-30	7613-7617	SPM8	_	
40-31	7618-7621	and	_	
40-32	7622-7623	‘	_	
40-33	7623-7632	scrubbing	_	
40-34	7632-7633	’	_	
40-35	7634-7644	procedures	_	
40-36	7645-7648	for	_	
40-37	7649-7662	resting-state	_	
40-38	7663-7667	fMRI	_	
40-39	7668-7669	(	_	
40-40	7669-7677	eMethods	_	
40-41	7677-7678	)	_	
40-42	7678-7679	.	_	

#Text=‘Scrubbing’ cutoffs were established based on a larger dataset for two indices of motion-related data quality reflecting the rate of change in brain-wide signal (DVARS) and total instantaneous framewise displacement (FD), respectively.
41-1	7680-7681	‘	_	
41-2	7681-7690	Scrubbing	_	
41-3	7690-7691	’	_	
41-4	7692-7699	cutoffs	_	
41-5	7700-7704	were	_	
41-6	7705-7716	established	_	
41-7	7717-7722	based	_	
41-8	7723-7725	on	_	
41-9	7726-7727	a	_	
41-10	7728-7734	larger	_	
41-11	7735-7742	dataset	_	
41-12	7743-7746	for	_	
41-13	7747-7750	two	_	
41-14	7751-7758	indices	_	
41-15	7759-7761	of	_	
41-16	7762-7776	motion-related	_	
41-17	7777-7781	data	_	
41-18	7782-7789	quality	_	
41-19	7790-7800	reflecting	_	
41-20	7801-7804	the	_	
41-21	7805-7809	rate	_	
41-22	7810-7812	of	_	
41-23	7813-7819	change	_	
41-24	7820-7822	in	_	
41-25	7823-7833	brain-wide	_	
41-26	7834-7840	signal	_	
41-27	7841-7842	(	_	
41-28	7842-7847	DVARS	_	
41-29	7847-7848	)	_	
41-30	7849-7852	and	_	
41-31	7853-7858	total	_	
41-32	7859-7872	instantaneous	_	
41-33	7873-7882	framewise	_	
41-34	7883-7895	displacement	_	
41-35	7896-7897	(	_	
41-36	7897-7899	FD	_	
41-37	7899-7900	)	_	
41-38	7900-7901	,	_	
41-39	7902-7914	respectively	_	
41-40	7914-7915	.	_	

#Text=One patient was excluded due to excessive motion.
42-1	7916-7919	One	_	
42-2	7920-7927	patient	_	
42-3	7928-7931	was	_	
42-4	7932-7940	excluded	_	
42-5	7941-7944	due	_	
42-6	7945-7947	to	_	
42-7	7948-7957	excessive	_	
42-8	7958-7964	motion	_	
42-9	7964-7965	.	_	

#Text=Temporal band-pass filtering, spatial smoothing, and voxelwise z-scoring of time series were applied.
43-1	7966-7974	Temporal	_	
43-2	7975-7984	band-pass	_	
43-3	7985-7994	filtering	_	
43-4	7994-7995	,	_	
43-5	7996-8003	spatial	_	
43-6	8004-8013	smoothing	_	
43-7	8013-8014	,	_	
43-8	8015-8018	and	_	
43-9	8019-8028	voxelwise	_	
43-10	8029-8038	z-scoring	_	
43-11	8039-8041	of	_	
43-12	8042-8046	time	_	
43-13	8047-8053	series	_	
43-14	8054-8058	were	_	
43-15	8059-8066	applied	_	
43-16	8066-8067	.	_	

#Text=Region-of-interest (ROI) definition
#Text=Striatal and extrastriatal ROIs were manually drawn on individual T1-weighted scans as defined previously.
44-1	8068-8086	Region-of-interest	_	
44-2	8087-8088	(	_	
44-3	8088-8091	ROI	_	
44-4	8091-8092	)	_	
44-5	8093-8103	definition	_	
44-6	8104-8112	Striatal	_	
44-7	8113-8116	and	_	
44-8	8117-8130	extrastriatal	_	
44-9	8131-8135	ROIs	_	
44-10	8136-8140	were	_	
44-11	8141-8149	manually	_	
44-12	8150-8155	drawn	_	
44-13	8156-8158	on	_	
44-14	8159-8169	individual	_	
44-15	8170-8172	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
44-16	8172-8173	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
44-17	8173-8181	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
44-18	8182-8187	scans	_	
44-19	8188-8190	as	_	
44-20	8191-8198	defined	_	
44-21	8199-8209	previously	_	
44-22	8209-8210	.	_	

#Text=The striatum was divided into 5 subregions: (1) ventral striatum, (2) anterior (pre-commissural) caudate, (3) posterior (post-commissural) caudate, (4) anterior putamen, and (5) posterior putamen.
45-1	8211-8214	The	_	
45-2	8215-8223	striatum	_	
45-3	8224-8227	was	_	
45-4	8228-8235	divided	_	
45-5	8236-8240	into	_	
45-6	8241-8242	5	_	
45-7	8243-8253	subregions	_	
45-8	8253-8254	:	_	
45-9	8255-8256	(	_	
45-10	8256-8257	1	_	
45-11	8257-8258	)	_	
45-12	8259-8266	ventral	_	
45-13	8267-8275	striatum	_	
45-14	8275-8276	,	_	
45-15	8277-8278	(	_	
45-16	8278-8279	2	_	
45-17	8279-8280	)	_	
45-18	8281-8289	anterior	_	
45-19	8290-8291	(	_	
45-20	8291-8306	pre-commissural	_	
45-21	8306-8307	)	_	
45-22	8308-8315	caudate	_	
45-23	8315-8316	,	_	
45-24	8317-8318	(	_	
45-25	8318-8319	3	_	
45-26	8319-8320	)	_	
45-27	8321-8330	posterior	_	
45-28	8331-8332	(	_	
45-29	8332-8348	post-commissural	_	
45-30	8348-8349	)	_	
45-31	8350-8357	caudate	_	
45-32	8357-8358	,	_	
45-33	8359-8360	(	_	
45-34	8360-8361	4	_	
45-35	8361-8362	)	_	
45-36	8363-8371	anterior	_	
45-37	8372-8379	putamen	_	
45-38	8379-8380	,	_	
45-39	8381-8384	and	_	
45-40	8385-8386	(	_	
45-41	8386-8387	5	_	
45-42	8387-8388	)	_	
45-43	8389-8398	posterior	_	
45-44	8399-8406	putamen	_	
45-45	8406-8407	.	_	

#Text=Unsmoothed fMRI data from each subregion was averaged across the containing voxels (collapsing across hemispheres; eMethods) and z-scored to construct seed timeseries.
46-1	8408-8418	Unsmoothed	_	
46-2	8419-8423	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
46-3	8424-8428	data	_	
46-4	8429-8433	from	_	
46-5	8434-8438	each	_	
46-6	8439-8448	subregion	_	
46-7	8449-8452	was	_	
46-8	8453-8461	averaged	_	
46-9	8462-8468	across	_	
46-10	8469-8472	the	_	
46-11	8473-8483	containing	_	
46-12	8484-8490	voxels	_	
46-13	8491-8492	(	_	
46-14	8492-8502	collapsing	_	
46-15	8503-8509	across	_	
46-16	8510-8521	hemispheres	_	
46-17	8521-8522	;	_	
46-18	8523-8531	eMethods	_	
46-19	8531-8532	)	_	
46-20	8533-8536	and	_	
46-21	8537-8545	z-scored	_	
46-22	8546-8548	to	_	
46-23	8549-8558	construct	_	
46-24	8559-8563	seed	_	
46-25	8564-8574	timeseries	_	
46-26	8574-8575	.	_	

#Text=Extracting the first eigenvariate instead of the mean yielded almost identical results, indicating high functional homogeneity within subregions.
47-1	8576-8586	Extracting	_	
47-2	8587-8590	the	_	
47-3	8591-8596	first	_	
47-4	8597-8609	eigenvariate	_	
47-5	8610-8617	instead	_	
47-6	8618-8620	of	_	
47-7	8621-8624	the	_	
47-8	8625-8629	mean	_	
47-9	8630-8637	yielded	_	
47-10	8638-8644	almost	_	
47-11	8645-8654	identical	_	
47-12	8655-8662	results	_	
47-13	8662-8663	,	_	
47-14	8664-8674	indicating	_	
47-15	8675-8679	high	_	
47-16	8680-8690	functional	_	
47-17	8691-8702	homogeneity	_	
47-18	8703-8709	within	_	
47-19	8710-8720	subregions	_	
47-20	8720-8721	.	_	

#Text=Ipsilateral and contralateral connectivity were highly consistent within subregions (Supplement).
#Text=fMRI data analysis
#Text=Subject-level analyses consisted of a Generalized Linear Model (GLM) in SPM8 including the following regressors: (1–5) spatially averaged timeseries for each of the 5 striatal subregions (seeds), (6–7) timeseries for white-matter and cerebrospinal fluid (CSF) regions-of-no-interest (eMethods), (8–19) six head motion (realignment) parameters and their first derivatives (all band-pass filtered), and (20–21) run and global intercepts.
48-1	8722-8733	Ipsilateral	_	
48-2	8734-8737	and	_	
48-3	8738-8751	contralateral	_	
48-4	8752-8764	connectivity	_	
48-5	8765-8769	were	_	
48-6	8770-8776	highly	_	
48-7	8777-8787	consistent	_	
48-8	8788-8794	within	_	
48-9	8795-8805	subregions	_	
48-10	8806-8807	(	_	
48-11	8807-8817	Supplement	_	
48-12	8817-8818	)	_	
48-13	8818-8819	.	_	
48-14	8820-8824	fMRI	_	
48-15	8825-8829	data	_	
48-16	8830-8838	analysis	_	
48-17	8839-8852	Subject-level	_	
48-18	8853-8861	analyses	_	
48-19	8862-8871	consisted	_	
48-20	8872-8874	of	_	
48-21	8875-8876	a	_	
48-22	8877-8888	Generalized	_	
48-23	8889-8895	Linear	_	
48-24	8896-8901	Model	_	
48-25	8902-8903	(	_	
48-26	8903-8906	GLM	_	
48-27	8906-8907	)	_	
48-28	8908-8910	in	_	
48-29	8911-8915	SPM8	_	
48-30	8916-8925	including	_	
48-31	8926-8929	the	_	
48-32	8930-8939	following	_	
48-33	8940-8950	regressors	_	
48-34	8950-8951	:	_	
48-35	8952-8953	(	_	
48-36	8953-8954	1	_	
48-37	8954-8955	–	_	
48-38	8955-8956	5	_	
48-39	8956-8957	)	_	
48-40	8958-8967	spatially	_	
48-41	8968-8976	averaged	_	
48-42	8977-8987	timeseries	_	
48-43	8988-8991	for	_	
48-44	8992-8996	each	_	
48-45	8997-8999	of	_	
48-46	9000-9003	the	_	
48-47	9004-9005	5	_	
48-48	9006-9014	striatal	_	
48-49	9015-9025	subregions	_	
48-50	9026-9027	(	_	
48-51	9027-9032	seeds	_	
48-52	9032-9033	)	_	
48-53	9033-9034	,	_	
48-54	9035-9036	(	_	
48-55	9036-9037	6	_	
48-56	9037-9038	–	_	
48-57	9038-9039	7	_	
48-58	9039-9040	)	_	
48-59	9041-9051	timeseries	_	
48-60	9052-9055	for	_	
48-61	9056-9068	white-matter	_	
48-62	9069-9072	and	_	
48-63	9073-9086	cerebrospinal	_	
48-64	9087-9092	fluid	_	
48-65	9093-9094	(	_	
48-66	9094-9097	CSF	_	
48-67	9097-9098	)	_	
48-68	9099-9121	regions-of-no-interest	_	
48-69	9122-9123	(	_	
48-70	9123-9131	eMethods	_	
48-71	9131-9132	)	_	
48-72	9132-9133	,	_	
48-73	9134-9135	(	_	
48-74	9135-9136	8	_	
48-75	9136-9137	–	_	
48-76	9137-9139	19	_	
48-77	9139-9140	)	_	
48-78	9141-9144	six	_	
48-79	9145-9149	head	_	
48-80	9150-9156	motion	_	
48-81	9157-9158	(	_	
48-82	9158-9169	realignment	_	
48-83	9169-9170	)	_	
48-84	9171-9181	parameters	_	
48-85	9182-9185	and	_	
48-86	9186-9191	their	_	
48-87	9192-9197	first	_	
48-88	9198-9209	derivatives	_	
48-89	9210-9211	(	_	
48-90	9211-9214	all	_	
48-91	9215-9224	band-pass	_	
48-92	9225-9233	filtered	_	
48-93	9233-9234	)	_	
48-94	9234-9235	,	_	
48-95	9236-9239	and	_	
48-96	9240-9241	(	_	
48-97	9241-9243	20	_	
48-98	9243-9244	–	_	
48-99	9244-9246	21	_	
48-100	9246-9247	)	_	
48-101	9248-9251	run	_	
48-102	9252-9255	and	_	
48-103	9256-9262	global	_	
48-104	9263-9273	intercepts	_	
48-105	9273-9274	.	_	

#Text=One dummy variable was additionally included to censor each artifactual set of adjacent volumes exceeding either the DVARS or FD cutoffs.
49-1	9275-9278	One	_	
49-2	9279-9284	dummy	_	
49-3	9285-9293	variable	_	
49-4	9294-9297	was	_	
49-5	9298-9310	additionally	_	
49-6	9311-9319	included	_	
49-7	9320-9322	to	_	
49-8	9323-9329	censor	_	
49-9	9330-9334	each	_	
49-10	9335-9346	artifactual	_	
49-11	9347-9350	set	_	
49-12	9351-9353	of	_	
49-13	9354-9362	adjacent	_	
49-14	9363-9370	volumes	_	
49-15	9371-9380	exceeding	_	
49-16	9381-9387	either	_	
49-17	9388-9391	the	_	
49-18	9392-9397	DVARS	_	
49-19	9398-9400	or	_	
49-20	9401-9403	FD	_	
49-21	9404-9411	cutoffs	_	
49-22	9411-9412	.	_	

#Text=The resulting regression coefficient (beta) maps for each striatal subregion, representing connection strengths for each brain voxel with one striatal subregion while controlling for the other four (and the nuisance variables), were used subsequently.
50-1	9413-9416	The	_	
50-2	9417-9426	resulting	_	
50-3	9427-9437	regression	_	
50-4	9438-9449	coefficient	_	
50-5	9450-9451	(	_	
50-6	9451-9455	beta	_	
50-7	9455-9456	)	_	
50-8	9457-9461	maps	_	
50-9	9462-9465	for	_	
50-10	9466-9470	each	_	
50-11	9471-9479	striatal	_	
50-12	9480-9489	subregion	_	
50-13	9489-9490	,	_	
50-14	9491-9503	representing	_	
50-15	9504-9514	connection	_	
50-16	9515-9524	strengths	_	
50-17	9525-9528	for	_	
50-18	9529-9533	each	_	
50-19	9534-9539	brain	_	
50-20	9540-9545	voxel	_	
50-21	9546-9550	with	_	
50-22	9551-9554	one	_	
50-23	9555-9563	striatal	_	
50-24	9564-9573	subregion	_	
50-25	9574-9579	while	_	
50-26	9580-9591	controlling	_	
50-27	9592-9595	for	_	
50-28	9596-9599	the	_	
50-29	9600-9605	other	_	
50-30	9606-9610	four	_	
50-31	9611-9612	(	_	
50-32	9612-9615	and	_	
50-33	9616-9619	the	_	
50-34	9620-9628	nuisance	_	
50-35	9629-9638	variables	_	
50-36	9638-9639	)	_	
50-37	9639-9640	,	_	
50-38	9641-9645	were	_	
50-39	9646-9650	used	_	
50-40	9651-9663	subsequently	_	
50-41	9663-9664	.	_	

#Text=Multivariate fMRI analyses
#Text=Our primary goal was to test whether the overall pattern of striatal connectivity predicted group membership using logistic regression.
51-1	9665-9677	Multivariate	_	
51-2	9678-9682	fMRI	_	
51-3	9683-9691	analyses	_	
51-4	9692-9695	Our	_	
51-5	9696-9703	primary	_	
51-6	9704-9708	goal	_	
51-7	9709-9712	was	_	
51-8	9713-9715	to	_	
51-9	9716-9720	test	_	
51-10	9721-9728	whether	_	
51-11	9729-9732	the	_	
51-12	9733-9740	overall	_	
51-13	9741-9748	pattern	_	
51-14	9749-9751	of	_	
51-15	9752-9760	striatal	_	
51-16	9761-9773	connectivity	_	
51-17	9774-9783	predicted	_	
51-18	9784-9789	group	_	
51-19	9790-9800	membership	_	
51-20	9801-9806	using	_	
51-21	9807-9815	logistic	_	
51-22	9816-9826	regression	_	
51-23	9826-9827	.	_	

#Text=We used a multivariate approach rather than univariate analyses because the latter can only test connectivity between individual seeds and target regions but not the overall (multivariate) pattern of connectivity across seeds.
52-1	9828-9830	We	_	
52-2	9831-9835	used	_	
52-3	9836-9837	a	_	
52-4	9838-9850	multivariate	_	
52-5	9851-9859	approach	_	
52-6	9860-9866	rather	_	
52-7	9867-9871	than	_	
52-8	9872-9882	univariate	_	
52-9	9883-9891	analyses	_	
52-10	9892-9899	because	_	
52-11	9900-9903	the	_	
52-12	9904-9910	latter	_	
52-13	9911-9914	can	_	
52-14	9915-9919	only	_	
52-15	9920-9924	test	_	
52-16	9925-9937	connectivity	_	
52-17	9938-9945	between	_	
52-18	9946-9956	individual	_	
52-19	9957-9962	seeds	_	
52-20	9963-9966	and	_	
52-21	9967-9973	target	_	
52-22	9974-9981	regions	_	
52-23	9982-9985	but	_	
52-24	9986-9989	not	_	
52-25	9990-9993	the	_	
52-26	9994-10001	overall	_	
52-27	10002-10003	(	_	
52-28	10003-10015	multivariate	_	
52-29	10015-10016	)	_	
52-30	10017-10024	pattern	_	
52-31	10025-10027	of	_	
52-32	10028-10040	connectivity	_	
52-33	10041-10047	across	_	
52-34	10048-10053	seeds	_	
52-35	10053-10054	.	_	

#Text=Our purpose in using logistic regression, however, was not as a diagnostic classifier, but rather as a test of multivariate differences in connectivity.
53-1	10055-10058	Our	_	
53-2	10059-10066	purpose	_	
53-3	10067-10069	in	_	
53-4	10070-10075	using	_	
53-5	10076-10084	logistic	_	
53-6	10085-10095	regression	_	
53-7	10095-10096	,	_	
53-8	10097-10104	however	_	
53-9	10104-10105	,	_	
53-10	10106-10109	was	_	
53-11	10110-10113	not	_	
53-12	10114-10116	as	_	
53-13	10117-10118	a	_	
53-14	10119-10129	diagnostic	_	
53-15	10130-10140	classifier	_	
53-16	10140-10141	,	_	
53-17	10142-10145	but	_	
53-18	10146-10152	rather	_	
53-19	10153-10155	as	_	
53-20	10156-10157	a	_	
53-21	10158-10162	test	_	
53-22	10163-10165	of	_	
53-23	10166-10178	multivariate	_	
53-24	10179-10190	differences	_	
53-25	10191-10193	in	_	
53-26	10194-10206	connectivity	_	
53-27	10206-10207	.	_	

#Text=Exploratory analyses (Supplement) used a multivariate recursive-feature-elimination support-vector-machine (RFE-SVM) classifier for the former purpose.
54-1	10208-10219	Exploratory	_	
54-2	10220-10228	analyses	_	
54-3	10229-10230	(	_	
54-4	10230-10240	Supplement	_	
54-5	10240-10241	)	_	
54-6	10242-10246	used	_	
54-7	10247-10248	a	_	
54-8	10249-10261	multivariate	_	
54-9	10262-10291	recursive-feature-elimination	_	
54-10	10292-10314	support-vector-machine	_	
54-11	10315-10316	(	_	
54-12	10316-10323	RFE-SVM	_	
54-13	10323-10324	)	_	
54-14	10325-10335	classifier	_	
54-15	10336-10339	for	_	
54-16	10340-10343	the	_	
54-17	10344-10350	former	_	
54-18	10351-10358	purpose	_	
54-19	10358-10359	.	_	

#Text=First, whole-brain connectivity beta maps for each striatal subregion were parcellated into Brodmann areas (BAs) and subcortical nuclei using the Tailarach Daemon atlas in the WFU PickAtlas toolbox (henceforth referred to as target regions), after excluding striatal voxels.
55-1	10360-10365	First	_	
55-2	10365-10366	,	_	
55-3	10367-10378	whole-brain	_	
55-4	10379-10391	connectivity	_	
55-5	10392-10396	beta	_	
55-6	10397-10401	maps	_	
55-7	10402-10405	for	_	
55-8	10406-10410	each	_	
55-9	10411-10419	striatal	_	
55-10	10420-10429	subregion	_	
55-11	10430-10434	were	_	
55-12	10435-10446	parcellated	_	
55-13	10447-10451	into	_	
55-14	10452-10460	Brodmann	_	
55-15	10461-10466	areas	_	
55-16	10467-10468	(	_	
55-17	10468-10471	BAs	_	
55-18	10471-10472	)	_	
55-19	10473-10476	and	_	
55-20	10477-10488	subcortical	_	
55-21	10489-10495	nuclei	_	
55-22	10496-10501	using	_	
55-23	10502-10505	the	_	
55-24	10506-10515	Tailarach	_	
55-25	10516-10522	Daemon	_	
55-26	10523-10528	atlas	_	
55-27	10529-10531	in	_	
55-28	10532-10535	the	_	
55-29	10536-10539	WFU	_	
55-30	10540-10549	PickAtlas	_	
55-31	10550-10557	toolbox	_	
55-32	10558-10559	(	_	
55-33	10559-10569	henceforth	_	
55-34	10570-10578	referred	_	
55-35	10579-10581	to	_	
55-36	10582-10584	as	_	
55-37	10585-10591	target	_	
55-38	10592-10599	regions	_	
55-39	10599-10600	)	_	
55-40	10600-10601	,	_	
55-41	10602-10607	after	_	
55-42	10608-10617	excluding	_	
55-43	10618-10626	striatal	_	
55-44	10627-10633	voxels	_	
55-45	10633-10634	.	_	

#Text=Second, a data-reduction step retained only target regions exhibiting significant connectivity with any of the striatal subregions (p≤0.005, uncorrected, in ≥20% of the voxels) in either group; 29 regions met these criteria (for individual striatal subregions 1–5 the number of target regions to meet criteria were 0, 24, 2, 5, and 4, respectively).
56-1	10635-10641	Second	_	
56-2	10641-10642	,	_	
56-3	10643-10644	a	_	
56-4	10645-10659	data-reduction	_	
56-5	10660-10664	step	_	
56-6	10665-10673	retained	_	
56-7	10674-10678	only	_	
56-8	10679-10685	target	_	
56-9	10686-10693	regions	_	
56-10	10694-10704	exhibiting	_	
56-11	10705-10716	significant	_	
56-12	10717-10729	connectivity	_	
56-13	10730-10734	with	_	
56-14	10735-10738	any	_	
56-15	10739-10741	of	_	
56-16	10742-10745	the	_	
56-17	10746-10754	striatal	_	
56-18	10755-10765	subregions	_	
56-19	10766-10767	(	_	
56-20	10767-10768	p	_	
56-21	10768-10769	≤	_	
56-22	10769-10774	0.005	_	
56-23	10774-10775	,	_	
56-24	10776-10787	uncorrected	_	
56-25	10787-10788	,	_	
56-26	10789-10791	in	_	
56-27	10792-10793	≥	_	
56-28	10793-10796	20%	_	
56-29	10797-10799	of	_	
56-30	10800-10803	the	_	
56-31	10804-10810	voxels	_	
56-32	10810-10811	)	_	
56-33	10812-10814	in	_	
56-34	10815-10821	either	_	
56-35	10822-10827	group	_	
56-36	10827-10828	;	_	
56-37	10829-10831	29	_	
56-38	10832-10839	regions	_	
56-39	10840-10843	met	_	
56-40	10844-10849	these	_	
56-41	10850-10858	criteria	_	
56-42	10859-10860	(	_	
56-43	10860-10863	for	_	
56-44	10864-10874	individual	_	
56-45	10875-10883	striatal	_	
56-46	10884-10894	subregions	_	
56-47	10895-10896	1	_	
56-48	10896-10897	–	_	
56-49	10897-10898	5	_	
56-50	10899-10902	the	_	
56-51	10903-10909	number	_	
56-52	10910-10912	of	_	
56-53	10913-10919	target	_	
56-54	10920-10927	regions	_	
56-55	10928-10930	to	_	
56-56	10931-10935	meet	_	
56-57	10936-10944	criteria	_	
56-58	10945-10949	were	_	
56-59	10950-10951	0	_	
56-60	10951-10952	,	_	
56-61	10953-10955	24	_	
56-62	10955-10956	,	_	
56-63	10957-10958	2	_	
56-64	10958-10959	,	_	
56-65	10960-10961	5	_	
56-66	10961-10962	,	_	
56-67	10963-10966	and	_	
56-68	10967-10968	4	_	
56-69	10968-10969	,	_	
56-70	10970-10982	respectively	_	
56-71	10982-10983	)	_	
56-72	10983-10984	.	_	

#Text=Although these selection criteria were unbiased towards any subregion, they yielded more target regions for the anterior caudate given its stronger widespread connectivity.
57-1	10985-10993	Although	_	
57-2	10994-10999	these	_	
57-3	11000-11009	selection	_	
57-4	11010-11018	criteria	_	
57-5	11019-11023	were	_	
57-6	11024-11032	unbiased	_	
57-7	11033-11040	towards	_	
57-8	11041-11044	any	_	
57-9	11045-11054	subregion	_	
57-10	11054-11055	,	_	
57-11	11056-11060	they	_	
57-12	11061-11068	yielded	_	
57-13	11069-11073	more	_	
57-14	11074-11080	target	_	
57-15	11081-11088	regions	_	
57-16	11089-11092	for	_	
57-17	11093-11096	the	_	
57-18	11097-11105	anterior	_	
57-19	11106-11113	caudate	_	
57-20	11114-11119	given	_	
57-21	11120-11123	its	_	
57-22	11124-11132	stronger	_	
57-23	11133-11143	widespread	_	
57-24	11144-11156	connectivity	_	
57-25	11156-11157	.	_	

#Text=Next, logistic regression was used to predict group membership based on connection strengths for striatal-target pairs (i.e., individual mean connectivity betas for each target region by striatal subregion).
58-1	11158-11162	Next	_	
58-2	11162-11163	,	_	
58-3	11164-11172	logistic	_	
58-4	11173-11183	regression	_	
58-5	11184-11187	was	_	
58-6	11188-11192	used	_	
58-7	11193-11195	to	_	
58-8	11196-11203	predict	_	
58-9	11204-11209	group	_	
58-10	11210-11220	membership	_	
58-11	11221-11226	based	_	
58-12	11227-11229	on	_	
58-13	11230-11240	connection	_	
58-14	11241-11250	strengths	_	
58-15	11251-11254	for	_	
58-16	11255-11270	striatal-target	_	
58-17	11271-11276	pairs	_	
58-18	11277-11278	(	_	
58-19	11278-11281	i.e	_	
58-20	11281-11282	.	_	
58-21	11282-11283	,	_	
58-22	11284-11294	individual	_	
58-23	11295-11299	mean	_	
58-24	11300-11312	connectivity	_	
58-25	11313-11318	betas	_	
58-26	11319-11322	for	_	
58-27	11323-11327	each	_	
58-28	11328-11334	target	_	
58-29	11335-11341	region	_	
58-30	11342-11344	by	_	
58-31	11345-11353	striatal	_	
58-32	11354-11363	subregion	_	
58-33	11363-11364	)	_	
58-34	11364-11365	.	_	

#Text=Because including all pairs each as a predictor variable would result in an underdetermined model, we used model building with step-forward selection to progressively include sets of predictor variables, with each of five possible sets consisting of all connectivity betas for target regions significantly associated with a given striatal subregion.
59-1	11366-11373	Because	_	
59-2	11374-11383	including	_	
59-3	11384-11387	all	_	
59-4	11388-11393	pairs	_	
59-5	11394-11398	each	_	
59-6	11399-11401	as	_	
59-7	11402-11403	a	_	
59-8	11404-11413	predictor	_	
59-9	11414-11422	variable	_	
59-10	11423-11428	would	_	
59-11	11429-11435	result	_	
59-12	11436-11438	in	_	
59-13	11439-11441	an	_	
59-14	11442-11457	underdetermined	_	
59-15	11458-11463	model	_	
59-16	11463-11464	,	_	
59-17	11465-11467	we	_	
59-18	11468-11472	used	_	
59-19	11473-11478	model	_	
59-20	11479-11487	building	_	
59-21	11488-11492	with	_	
59-22	11493-11505	step-forward	_	
59-23	11506-11515	selection	_	
59-24	11516-11518	to	_	
59-25	11519-11532	progressively	_	
59-26	11533-11540	include	_	
59-27	11541-11545	sets	_	
59-28	11546-11548	of	_	
59-29	11549-11558	predictor	_	
59-30	11559-11568	variables	_	
59-31	11568-11569	,	_	
59-32	11570-11574	with	_	
59-33	11575-11579	each	_	
59-34	11580-11582	of	_	
59-35	11583-11587	five	_	
59-36	11588-11596	possible	_	
59-37	11597-11601	sets	_	
59-38	11602-11612	consisting	_	
59-39	11613-11615	of	_	
59-40	11616-11619	all	_	
59-41	11620-11632	connectivity	_	
59-42	11633-11638	betas	_	
59-43	11639-11642	for	_	
59-44	11643-11649	target	_	
59-45	11650-11657	regions	_	
59-46	11658-11671	significantly	_	
59-47	11672-11682	associated	_	
59-48	11683-11687	with	_	
59-49	11688-11689	a	_	
59-50	11690-11695	given	_	
59-51	11696-11704	striatal	_	
59-52	11705-11714	subregion	_	
59-53	11714-11715	.	_	

#Text=First, models consisting of predictors from one set at a time were analyzed, and the set resulting in the lowest p-value was retained.
60-1	11716-11721	First	_	
60-2	11721-11722	,	_	
60-3	11723-11729	models	_	
60-4	11730-11740	consisting	_	
60-5	11741-11743	of	_	
60-6	11744-11754	predictors	_	
60-7	11755-11759	from	_	
60-8	11760-11763	one	_	
60-9	11764-11767	set	_	
60-10	11768-11770	at	_	
60-11	11771-11772	a	_	
60-12	11773-11777	time	_	
60-13	11778-11782	were	_	
60-14	11783-11791	analyzed	_	
60-15	11791-11792	,	_	
60-16	11793-11796	and	_	
60-17	11797-11800	the	_	
60-18	11801-11804	set	_	
60-19	11805-11814	resulting	_	
60-20	11815-11817	in	_	
60-21	11818-11821	the	_	
60-22	11822-11828	lowest	_	
60-23	11829-11836	p-value	_	
60-24	11837-11840	was	_	
60-25	11841-11849	retained	_	
60-26	11849-11850	.	_	

#Text=Additional sets of variables were retained in the model if they significantly improved the model fit (p<0.05, likelihood-ratio test).
61-1	11851-11861	Additional	_	
61-2	11862-11866	sets	_	
61-3	11867-11869	of	_	
61-4	11870-11879	variables	_	
61-5	11880-11884	were	_	
61-6	11885-11893	retained	_	
61-7	11894-11896	in	_	
61-8	11897-11900	the	_	
61-9	11901-11906	model	_	
61-10	11907-11909	if	_	
61-11	11910-11914	they	_	
61-12	11915-11928	significantly	_	
61-13	11929-11937	improved	_	
61-14	11938-11941	the	_	
61-15	11942-11947	model	_	
61-16	11948-11951	fit	_	
61-17	11952-11953	(	_	
61-18	11953-11954	p	_	
61-19	11954-11955	<	_	
61-20	11955-11959	0.05	_	
61-21	11959-11960	,	_	
61-22	11961-11977	likelihood-ratio	_	
61-23	11978-11982	test	_	
61-24	11982-11983	)	_	
61-25	11983-11984	.	_	

#Text=The likelihood-ratio test for the final model was our a priori test of group differences in connectivity patterns (other p-values were only used for data-reduction and model-building steps).
62-1	11985-11988	The	_	
62-2	11989-12005	likelihood-ratio	_	
62-3	12006-12010	test	_	
62-4	12011-12014	for	_	
62-5	12015-12018	the	_	
62-6	12019-12024	final	_	
62-7	12025-12030	model	_	
62-8	12031-12034	was	_	
62-9	12035-12038	our	_	
62-10	12039-12040	a	_	
62-11	12041-12047	priori	_	
62-12	12048-12052	test	_	
62-13	12053-12055	of	_	
62-14	12056-12061	group	_	
62-15	12062-12073	differences	_	
62-16	12074-12076	in	_	
62-17	12077-12089	connectivity	_	
62-18	12090-12098	patterns	_	
62-19	12099-12100	(	_	
62-20	12100-12105	other	_	
62-21	12106-12114	p-values	_	
62-22	12115-12119	were	_	
62-23	12120-12124	only	_	
62-24	12125-12129	used	_	
62-25	12130-12133	for	_	
62-26	12134-12148	data-reduction	_	
62-27	12149-12152	and	_	
62-28	12153-12167	model-building	_	
62-29	12168-12173	steps	_	
62-30	12173-12174	)	_	
62-31	12174-12175	.	_	

#Text=Once the final model was determined, the subject-wise predicted log odds of belonging to the healthy group based on the multivariate connectivity pattern was used as a summary index of degree of abnormality in the striatal connectivity pattern for further correlational analyses with clinical and PET data (note that these analyses were unbiased as the ordering of the log odds across individuals was orthogonal to all clinical and PET data except for group membership, which was controlled for appropriately; eMethods).
63-1	12176-12180	Once	_	
63-2	12181-12184	the	_	
63-3	12185-12190	final	_	
63-4	12191-12196	model	_	
63-5	12197-12200	was	_	
63-6	12201-12211	determined	_	
63-7	12211-12212	,	_	
63-8	12213-12216	the	_	
63-9	12217-12229	subject-wise	_	
63-10	12230-12239	predicted	_	
63-11	12240-12243	log	_	
63-12	12244-12248	odds	_	
63-13	12249-12251	of	_	
63-14	12252-12261	belonging	_	
63-15	12262-12264	to	_	
63-16	12265-12268	the	_	
63-17	12269-12276	healthy	_	
63-18	12277-12282	group	_	
63-19	12283-12288	based	_	
63-20	12289-12291	on	_	
63-21	12292-12295	the	_	
63-22	12296-12308	multivariate	_	
63-23	12309-12321	connectivity	_	
63-24	12322-12329	pattern	_	
63-25	12330-12333	was	_	
63-26	12334-12338	used	_	
63-27	12339-12341	as	_	
63-28	12342-12343	a	_	
63-29	12344-12351	summary	_	
63-30	12352-12357	index	_	
63-31	12358-12360	of	_	
63-32	12361-12367	degree	_	
63-33	12368-12370	of	_	
63-34	12371-12382	abnormality	_	
63-35	12383-12385	in	_	
63-36	12386-12389	the	_	
63-37	12390-12398	striatal	_	
63-38	12399-12411	connectivity	_	
63-39	12412-12419	pattern	_	
63-40	12420-12423	for	_	
63-41	12424-12431	further	_	
63-42	12432-12445	correlational	_	
63-43	12446-12454	analyses	_	
63-44	12455-12459	with	_	
63-45	12460-12468	clinical	_	
63-46	12469-12472	and	_	
63-47	12473-12476	PET	_	
63-48	12477-12481	data	_	
63-49	12482-12483	(	_	
63-50	12483-12487	note	_	
63-51	12488-12492	that	_	
63-52	12493-12498	these	_	
63-53	12499-12507	analyses	_	
63-54	12508-12512	were	_	
63-55	12513-12521	unbiased	_	
63-56	12522-12524	as	_	
63-57	12525-12528	the	_	
63-58	12529-12537	ordering	_	
63-59	12538-12540	of	_	
63-60	12541-12544	the	_	
63-61	12545-12548	log	_	
63-62	12549-12553	odds	_	
63-63	12554-12560	across	_	
63-64	12561-12572	individuals	_	
63-65	12573-12576	was	_	
63-66	12577-12587	orthogonal	_	
63-67	12588-12590	to	_	
63-68	12591-12594	all	_	
63-69	12595-12603	clinical	_	
63-70	12604-12607	and	_	
63-71	12608-12611	PET	_	
63-72	12612-12616	data	_	
63-73	12617-12623	except	_	
63-74	12624-12627	for	_	
63-75	12628-12633	group	_	
63-76	12634-12644	membership	_	
63-77	12644-12645	,	_	
63-78	12646-12651	which	_	
63-79	12652-12655	was	_	
63-80	12656-12666	controlled	_	
63-81	12667-12670	for	_	
63-82	12671-12684	appropriately	_	
63-83	12684-12685	;	_	
63-84	12686-12694	eMethods	_	
63-85	12694-12695	)	_	
63-86	12695-12696	.	_	

#Text=These correlational analyses used parametric tests except when the data were not normally distributed (based on a Lilliefors test), in which case non-parametric tests were used.
64-1	12697-12702	These	_	
64-2	12703-12716	correlational	_	
64-3	12717-12725	analyses	_	
64-4	12726-12730	used	_	
64-5	12731-12741	parametric	_	
64-6	12742-12747	tests	_	
64-7	12748-12754	except	_	
64-8	12755-12759	when	_	
64-9	12760-12763	the	_	
64-10	12764-12768	data	_	
64-11	12769-12773	were	_	
64-12	12774-12777	not	_	
64-13	12778-12786	normally	_	
64-14	12787-12798	distributed	_	
64-15	12799-12800	(	_	
64-16	12800-12805	based	_	
64-17	12806-12808	on	_	
64-18	12809-12810	a	_	
64-19	12811-12821	Lilliefors	_	
64-20	12822-12826	test	_	
64-21	12826-12827	)	_	
64-22	12827-12828	,	_	
64-23	12829-12831	in	_	
64-24	12832-12837	which	_	
64-25	12838-12842	case	_	
64-26	12843-12857	non-parametric	_	
64-27	12858-12863	tests	_	
64-28	12864-12868	were	_	
64-29	12869-12873	used	_	
64-30	12873-12874	.	_	

#Text=Spearman’s rank (partial) correlations were used to assess the relationship between connectivity and severity of positive symptoms within patients, based on the PANSS positive-subscale-total scores (PANSS-PT), while controlling for negative symptoms as measured by the PANSS negative-subscale-total scores (PANSS-NT).
65-1	12875-12883	Spearman	_	
65-2	12883-12884	’	_	
65-3	12884-12885	s	_	
65-4	12886-12890	rank	_	
65-5	12891-12892	(	_	
65-6	12892-12899	partial	_	
65-7	12899-12900	)	_	
65-8	12901-12913	correlations	_	
65-9	12914-12918	were	_	
65-10	12919-12923	used	_	
65-11	12924-12926	to	_	
65-12	12927-12933	assess	_	
65-13	12934-12937	the	_	
65-14	12938-12950	relationship	_	
65-15	12951-12958	between	_	
65-16	12959-12971	connectivity	_	
65-17	12972-12975	and	_	
65-18	12976-12984	severity	_	
65-19	12985-12987	of	_	
65-20	12988-12996	positive	_	
65-21	12997-13005	symptoms	_	
65-22	13006-13012	within	_	
65-23	13013-13021	patients	_	
65-24	13021-13022	,	_	
65-25	13023-13028	based	_	
65-26	13029-13031	on	_	
65-27	13032-13035	the	_	
65-28	13036-13041	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
65-29	13042-13065	positive-subscale-total	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
65-30	13066-13072	scores	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
65-31	13073-13074	(	_	
65-32	13074-13082	PANSS-PT	_	
65-33	13082-13083	)	_	
65-34	13083-13084	,	_	
65-35	13085-13090	while	_	
65-36	13091-13102	controlling	_	
65-37	13103-13106	for	_	
65-38	13107-13115	negative	_	
65-39	13116-13124	symptoms	_	
65-40	13125-13127	as	_	
65-41	13128-13136	measured	_	
65-42	13137-13139	by	_	
65-43	13140-13143	the	_	
65-44	13144-13149	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[34]	
65-45	13150-13173	negative-subscale-total	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[34]	
65-46	13174-13180	scores	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[34]	
65-47	13181-13182	(	_	
65-48	13182-13190	PANSS-NT	_	
65-49	13190-13191	)	_	
65-50	13191-13192	.	_	

#Text=Robust multiple linear regression (iteratively-reweighted least squares with bisquare-weighting function) was used to assess the relationship between connectivity and PET data (baseline BPND or ΔBPND, see below) across all participants while controlling for group and nuisance variables.
66-1	13193-13199	Robust	_	
66-2	13200-13208	multiple	_	
66-3	13209-13215	linear	_	
66-4	13216-13226	regression	_	
66-5	13227-13228	(	_	
66-6	13228-13250	iteratively-reweighted	_	
66-7	13251-13256	least	_	
66-8	13257-13264	squares	_	
66-9	13265-13269	with	_	
66-10	13270-13288	bisquare-weighting	_	
66-11	13289-13297	function	_	
66-12	13297-13298	)	_	
66-13	13299-13302	was	_	
66-14	13303-13307	used	_	
66-15	13308-13310	to	_	
66-16	13311-13317	assess	_	
66-17	13318-13321	the	_	
66-18	13322-13334	relationship	_	
66-19	13335-13342	between	_	
66-20	13343-13355	connectivity	_	
66-21	13356-13359	and	_	
66-22	13360-13363	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
66-23	13364-13368	data	_	
66-24	13369-13370	(	_	
66-25	13370-13378	baseline	_	
66-26	13379-13383	BPND	_	
66-27	13384-13386	or	_	
66-28	13387-13392	ΔBPND	_	
66-29	13392-13393	,	_	
66-30	13394-13397	see	_	
66-31	13398-13403	below	_	
66-32	13403-13404	)	_	
66-33	13405-13411	across	_	
66-34	13412-13415	all	_	
66-35	13416-13428	participants	_	
66-36	13429-13434	while	_	
66-37	13435-13446	controlling	_	
66-38	13447-13450	for	_	
66-39	13451-13456	group	_	
66-40	13457-13460	and	_	
66-41	13461-13469	nuisance	_	
66-42	13470-13479	variables	_	
66-43	13479-13480	.	_	

#Text=Spearman rank correlations were used for exploratory analyses of the MATRICS composite score.
67-1	13481-13489	Spearman	_	
67-2	13490-13494	rank	_	
67-3	13495-13507	correlations	_	
67-4	13508-13512	were	_	
67-5	13513-13517	used	_	
67-6	13518-13521	for	_	
67-7	13522-13533	exploratory	_	
67-8	13534-13542	analyses	_	
67-9	13543-13545	of	_	
67-10	13546-13549	the	_	
67-11	13550-13557	MATRICS	_	
67-12	13558-13567	composite	_	
67-13	13568-13573	score	_	
67-14	13573-13574	.	_	

#Text=Effects surviving a p-value of 0.05 are reported.
68-1	13575-13582	Effects	_	
68-2	13583-13592	surviving	_	
68-3	13593-13594	a	_	
68-4	13595-13602	p-value	_	
68-5	13603-13605	of	_	
68-6	13606-13610	0.05	_	
68-7	13611-13614	are	_	
68-8	13615-13623	reported	_	
68-9	13623-13624	.	_	

#Text=Bonferroni correction for multiple comparisons was used when necessary.
69-1	13625-13635	Bonferroni	_	
69-2	13636-13646	correction	_	
69-3	13647-13650	for	_	
69-4	13651-13659	multiple	_	
69-5	13660-13671	comparisons	_	
69-6	13672-13675	was	_	
69-7	13676-13680	used	_	
69-8	13681-13685	when	_	
69-9	13686-13695	necessary	_	
69-10	13695-13696	.	_	

#Text=Finally, the number of artifactual volumes regressed out for each participant was also used as an fMRI-data-quality score.
70-1	13697-13704	Finally	_	
70-2	13704-13705	,	_	
70-3	13706-13709	the	_	
70-4	13710-13716	number	_	
70-5	13717-13719	of	_	
70-6	13720-13731	artifactual	_	
70-7	13732-13739	volumes	_	
70-8	13740-13749	regressed	_	
70-9	13750-13753	out	_	
70-10	13754-13757	for	_	
70-11	13758-13762	each	_	
70-12	13763-13774	participant	_	
70-13	13775-13778	was	_	
70-14	13779-13783	also	_	
70-15	13784-13788	used	_	
70-16	13789-13791	as	_	
70-17	13792-13794	an	_	
70-18	13795-13812	fMRI-data-quality	_	
70-19	13813-13818	score	_	
70-20	13818-13819	.	_	

#Text=PET preprocessing and data analysis
#Text=A detailed description of PET procedures and results was previously published.
71-1	13820-13823	PET	_	
71-2	13824-13837	preprocessing	_	
71-3	13838-13841	and	_	
71-4	13842-13846	data	_	
71-5	13847-13855	analysis	_	
71-6	13856-13857	A	_	
71-7	13858-13866	detailed	_	
71-8	13867-13878	description	_	
71-9	13879-13881	of	_	
71-10	13882-13885	PET	_	
71-11	13886-13896	procedures	_	
71-12	13897-13900	and	_	
71-13	13901-13908	results	_	
71-14	13909-13912	was	_	
71-15	13913-13923	previously	_	
71-16	13924-13933	published	_	
71-17	13933-13934	.	_	

#Text=Participants underwent two PET scans with the D2 radiotracer [11C]FLB457 on an Siemens HR+ scanner at Yale University: a baseline scan and a second scan 3 h after oral administration of amphetamine (0.5 mg/kg).
72-1	13935-13947	Participants	_	
72-2	13948-13957	underwent	_	
72-3	13958-13961	two	_	
72-4	13962-13965	PET	_	
72-5	13966-13971	scans	_	
72-6	13972-13976	with	_	
72-7	13977-13980	the	_	
72-8	13981-13983	D2	_	
72-9	13984-13995	radiotracer	_	
72-10	13996-13997	[	_	
72-11	13997-14000	11C	_	
72-12	14000-14001	]	_	
72-13	14001-14007	FLB457	_	
72-14	14008-14010	on	_	
72-15	14011-14013	an	_	
72-16	14014-14021	Siemens	_	
72-17	14022-14024	HR	_	
72-18	14024-14025	+	_	
72-19	14026-14033	scanner	_	
72-20	14034-14036	at	_	
72-21	14037-14041	Yale	_	
72-22	14042-14052	University	_	
72-23	14052-14053	:	_	
72-24	14054-14055	a	_	
72-25	14056-14064	baseline	_	
72-26	14065-14069	scan	_	
72-27	14070-14073	and	_	
72-28	14074-14075	a	_	
72-29	14076-14082	second	_	
72-30	14083-14087	scan	_	
72-31	14088-14089	3	_	
72-32	14090-14091	h	_	
72-33	14092-14097	after	_	
72-34	14098-14102	oral	_	
72-35	14103-14117	administration	_	
72-36	14118-14120	of	_	
72-37	14121-14132	amphetamine	_	
72-38	14133-14134	(	_	
72-39	14134-14137	0.5	_	
72-40	14138-14140	mg	_	
72-41	14140-14141	/	_	
72-42	14141-14143	kg	_	
72-43	14143-14144	)	_	
72-44	14144-14145	.	_	

#Text=Arterial plasma was collected to form metabolite-corrected input functions.
73-1	14146-14154	Arterial	_	
73-2	14155-14161	plasma	_	
73-3	14162-14165	was	_	
73-4	14166-14175	collected	_	
73-5	14176-14178	to	_	
73-6	14179-14183	form	_	
73-7	14184-14204	metabolite-corrected	_	
73-8	14205-14210	input	_	
73-9	14211-14220	functions	_	
73-10	14220-14221	.	_	

#Text=Kinetic modeling used a two-tissue compartment model that incorporated a set of shared parameter estimates across predefined ROIs.
74-1	14222-14229	Kinetic	_	
74-2	14230-14238	modeling	_	
74-3	14239-14243	used	_	
74-4	14244-14245	a	_	
74-5	14246-14256	two-tissue	_	
74-6	14257-14268	compartment	_	
74-7	14269-14274	model	_	
74-8	14275-14279	that	_	
74-9	14280-14292	incorporated	_	
74-10	14293-14294	a	_	
74-11	14295-14298	set	_	
74-12	14299-14301	of	_	
74-13	14302-14308	shared	_	
74-14	14309-14318	parameter	_	
74-15	14319-14328	estimates	_	
74-16	14329-14335	across	_	
74-17	14336-14346	predefined	_	
74-18	14347-14351	ROIs	_	
74-19	14351-14352	.	_	

#Text=Binding potential (BPND) and its relative change from baseline following amphetamine (ΔBPND) were estimated in each ROI excluding the striatum – striatal BPND cannot be quantified with [11C]FLB457 due to its slow washout in this high D2R density region.
75-1	14353-14360	Binding	_	
75-2	14361-14370	potential	_	
75-3	14371-14372	(	_	
75-4	14372-14376	BPND	_	
75-5	14376-14377	)	_	
75-6	14378-14381	and	_	
75-7	14382-14385	its	_	
75-8	14386-14394	relative	_	
75-9	14395-14401	change	_	
75-10	14402-14406	from	_	
75-11	14407-14415	baseline	_	
75-12	14416-14425	following	_	
75-13	14426-14437	amphetamine	_	
75-14	14438-14439	(	_	
75-15	14439-14444	ΔBPND	_	
75-16	14444-14445	)	_	
75-17	14446-14450	were	_	
75-18	14451-14460	estimated	_	
75-19	14461-14463	in	_	
75-20	14464-14468	each	_	
75-21	14469-14472	ROI	_	
75-22	14473-14482	excluding	_	
75-23	14483-14486	the	_	
75-24	14487-14495	striatum	_	
75-25	14496-14497	–	_	
75-26	14498-14506	striatal	_	
75-27	14507-14511	BPND	_	
75-28	14512-14518	cannot	_	
75-29	14519-14521	be	_	
75-30	14522-14532	quantified	_	
75-31	14533-14537	with	_	
75-32	14538-14539	[	_	
75-33	14539-14542	11C	_	
75-34	14542-14543	]	_	
75-35	14543-14549	FLB457	_	
75-36	14550-14553	due	_	
75-37	14554-14556	to	_	
75-38	14557-14560	its	_	
75-39	14561-14565	slow	_	
75-40	14566-14573	washout	_	
75-41	14574-14576	in	_	
75-42	14577-14581	this	_	
75-43	14582-14586	high	_	
75-44	14587-14590	D2R	_	
75-45	14591-14598	density	_	
75-46	14599-14605	region	_	
75-47	14605-14606	.	_	

#Text=Both BPND and ΔBPND values were highly correlated across regions (mean r~0.8).
76-1	14607-14611	Both	_	
76-2	14612-14616	BPND	_	
76-3	14617-14620	and	_	
76-4	14621-14626	ΔBPND	_	
76-5	14627-14633	values	_	
76-6	14634-14638	were	_	
76-7	14639-14645	highly	_	
76-8	14646-14656	correlated	_	
76-9	14657-14663	across	_	
76-10	14664-14671	regions	_	
76-11	14672-14673	(	_	
76-12	14673-14677	mean	_	
76-13	14678-14679	r	_	
76-14	14679-14680	~	_	
76-15	14680-14683	0.8	_	
76-16	14683-14684	)	_	
76-17	14684-14685	.	_	

#Text=Thus, as a data-reduction step we performed principal component analyses (PCA) with varimax rotation, separately for BPND and ΔBPND, across regions.
77-1	14686-14690	Thus	_	
77-2	14690-14691	,	_	
77-3	14692-14694	as	_	
77-4	14695-14696	a	_	
77-5	14697-14711	data-reduction	_	
77-6	14712-14716	step	_	
77-7	14717-14719	we	_	
77-8	14720-14729	performed	_	
77-9	14730-14739	principal	_	
77-10	14740-14749	component	_	
77-11	14750-14758	analyses	_	
77-12	14759-14760	(	_	
77-13	14760-14763	PCA	_	
77-14	14763-14764	)	_	
77-15	14765-14769	with	_	
77-16	14770-14777	varimax	_	
77-17	14778-14786	rotation	_	
77-18	14786-14787	,	_	
77-19	14788-14798	separately	_	
77-20	14799-14802	for	_	
77-21	14803-14807	BPND	_	
77-22	14808-14811	and	_	
77-23	14812-14817	ΔBPND	_	
77-24	14817-14818	,	_	
77-25	14819-14825	across	_	
77-26	14826-14833	regions	_	
77-27	14833-14834	.	_	

#Text=Horn’s parallel analyses yielded a 1-factor solution for baseline BPND (corresponding to D2R density across all regions) and a 1-factor solution for ΔBPND (corresponding to dopamine release across all regions).
78-1	14835-14839	Horn	_	
78-2	14839-14840	’	_	
78-3	14840-14841	s	_	
78-4	14842-14850	parallel	_	
78-5	14851-14859	analyses	_	
78-6	14860-14867	yielded	_	
78-7	14868-14869	a	_	
78-8	14870-14871	1	_	
78-9	14871-14872	-	_	
78-10	14872-14878	factor	_	
78-11	14879-14887	solution	_	
78-12	14888-14891	for	_	
78-13	14892-14900	baseline	_	
78-14	14901-14905	BPND	_	
78-15	14906-14907	(	_	
78-16	14907-14920	corresponding	_	
78-17	14921-14923	to	_	
78-18	14924-14927	D2R	_	
78-19	14928-14935	density	_	
78-20	14936-14942	across	_	
78-21	14943-14946	all	_	
78-22	14947-14954	regions	_	
78-23	14954-14955	)	_	
78-24	14956-14959	and	_	
78-25	14960-14961	a	_	
78-26	14962-14963	1	_	
78-27	14963-14964	-	_	
78-28	14964-14970	factor	_	
78-29	14971-14979	solution	_	
78-30	14980-14983	for	_	
78-31	14984-14989	ΔBPND	_	
78-32	14990-14991	(	_	
78-33	14991-15004	corresponding	_	
78-34	15005-15007	to	_	
78-35	15008-15016	dopamine	_	
78-36	15017-15024	release	_	
78-37	15025-15031	across	_	
78-38	15032-15035	all	_	
78-39	15036-15043	regions	_	
78-40	15043-15044	)	_	
78-41	15044-15045	.	_	

#Text=For correlational analyses, individual factor scores were calculated as the weighted sum of factor loadings by the PET measures (BPND or ΔBPND) across ROIs.
79-1	15046-15049	For	_	
79-2	15050-15063	correlational	_	
79-3	15064-15072	analyses	_	
79-4	15072-15073	,	_	
79-5	15074-15084	individual	_	
79-6	15085-15091	factor	_	
79-7	15092-15098	scores	_	
79-8	15099-15103	were	_	
79-9	15104-15114	calculated	_	
79-10	15115-15117	as	_	
79-11	15118-15121	the	_	
79-12	15122-15130	weighted	_	
79-13	15131-15134	sum	_	
79-14	15135-15137	of	_	
79-15	15138-15144	factor	_	
79-16	15145-15153	loadings	_	
79-17	15154-15156	by	_	
79-18	15157-15160	the	_	
79-19	15161-15164	PET	_	
79-20	15165-15173	measures	_	
79-21	15174-15175	(	_	
79-22	15175-15179	BPND	_	
79-23	15180-15182	or	_	
79-24	15183-15188	ΔBPND	_	
79-25	15188-15189	)	_	
79-26	15190-15196	across	_	
79-27	15197-15201	ROIs	_	
79-28	15201-15202	.	_	

#Text=RESULTS
#Text=Sociodemographic and clinical characteristics
#Text=Groups were matched for sociodemographic characteristics, nicotine smoking, and head motion after scrubbing (Table 1).
80-1	15203-15210	RESULTS	_	
80-2	15211-15227	Sociodemographic	_	
80-3	15228-15231	and	_	
80-4	15232-15240	clinical	_	
80-5	15241-15256	characteristics	_	
80-6	15257-15263	Groups	_	
80-7	15264-15268	were	_	
80-8	15269-15276	matched	_	
80-9	15277-15280	for	_	
80-10	15281-15297	sociodemographic	_	
80-11	15298-15313	characteristics	_	
80-12	15313-15314	,	_	
80-13	15315-15323	nicotine	_	
80-14	15324-15331	smoking	_	
80-15	15331-15332	,	_	
80-16	15333-15336	and	_	
80-17	15337-15341	head	_	
80-18	15342-15348	motion	_	
80-19	15349-15354	after	_	
80-20	15355-15364	scrubbing	_	
80-21	15365-15366	(	_	
80-22	15366-15371	Table	_	
80-23	15372-15373	1	_	
80-24	15373-15374	)	_	
80-25	15374-15375	.	_	

#Text=Clinical characteristics are also shown in Table 1.
81-1	15376-15384	Clinical	_	
81-2	15385-15400	characteristics	_	
81-3	15401-15404	are	_	
81-4	15405-15409	also	_	
81-5	15410-15415	shown	_	
81-6	15416-15418	in	_	
81-7	15419-15424	Table	_	
81-8	15425-15426	1	_	
81-9	15426-15427	.	_	

#Text=Functional topography of striatal connections (multivariate fMRI analysis)
#Text=The pattern of connection strengths across striatal-target pairs differed numerically between the groups, particularly for the anterior caudate (Fig. 1).
82-1	15428-15438	Functional	_	
82-2	15439-15449	topography	_	
82-3	15450-15452	of	_	
82-4	15453-15461	striatal	_	
82-5	15462-15473	connections	_	
82-6	15474-15475	(	_	
82-7	15475-15487	multivariate	_	
82-8	15488-15492	fMRI	_	
82-9	15493-15501	analysis	_	
82-10	15501-15502	)	_	
82-11	15503-15506	The	_	
82-12	15507-15514	pattern	_	
82-13	15515-15517	of	_	
82-14	15518-15528	connection	_	
82-15	15529-15538	strengths	_	
82-16	15539-15545	across	_	
82-17	15546-15561	striatal-target	_	
82-18	15562-15567	pairs	_	
82-19	15568-15576	differed	_	
82-20	15577-15588	numerically	_	
82-21	15589-15596	between	_	
82-22	15597-15600	the	_	
82-23	15601-15607	groups	_	
82-24	15607-15608	,	_	
82-25	15609-15621	particularly	_	
82-26	15622-15625	for	_	
82-27	15626-15629	the	_	
82-28	15630-15638	anterior	_	
82-29	15639-15646	caudate	_	
82-30	15647-15648	(	_	
82-31	15648-15651	Fig	_	
82-32	15651-15652	.	_	
82-33	15653-15654	1	_	
82-34	15654-15655	)	_	
82-35	15655-15656	.	_	

#Text=Statistically, the logistic-regression model that best explained group membership (χ2 (29)=53.55, p=0.0036, likelihood-ratio [omnibus] test) was one that included all connection pairs related to the anterior caudate (with 24 pairs) and posterior caudate (with 5 pairs; Fig. 1).
83-1	15657-15670	Statistically	_	
83-2	15670-15671	,	_	
83-3	15672-15675	the	_	
83-4	15676-15695	logistic-regression	_	
83-5	15696-15701	model	_	
83-6	15702-15706	that	_	
83-7	15707-15711	best	_	
83-8	15712-15721	explained	_	
83-9	15722-15727	group	_	
83-10	15728-15738	membership	_	
83-11	15739-15740	(	_	
83-12	15740-15742	χ2	_	
83-13	15743-15744	(	_	
83-14	15744-15746	29	_	
83-15	15746-15747	)	_	
83-16	15747-15748	=	_	
83-17	15748-15753	53.55	_	
83-18	15753-15754	,	_	
83-19	15755-15756	p	_	
83-20	15756-15757	=	_	
83-21	15757-15763	0.0036	_	
83-22	15763-15764	,	_	
83-23	15765-15781	likelihood-ratio	_	
83-24	15782-15783	[	_	
83-25	15783-15790	omnibus	_	
83-26	15790-15791	]	_	
83-27	15792-15796	test	_	
83-28	15796-15797	)	_	
83-29	15798-15801	was	_	
83-30	15802-15805	one	_	
83-31	15806-15810	that	_	
83-32	15811-15819	included	_	
83-33	15820-15823	all	_	
83-34	15824-15834	connection	_	
83-35	15835-15840	pairs	_	
83-36	15841-15848	related	_	
83-37	15849-15851	to	_	
83-38	15852-15855	the	_	
83-39	15856-15864	anterior	_	
83-40	15865-15872	caudate	_	
83-41	15873-15874	(	_	
83-42	15874-15878	with	_	
83-43	15879-15881	24	_	
83-44	15882-15887	pairs	_	
83-45	15887-15888	)	_	
83-46	15889-15892	and	_	
83-47	15893-15902	posterior	_	
83-48	15903-15910	caudate	_	
83-49	15911-15912	(	_	
83-50	15912-15916	with	_	
83-51	15917-15918	5	_	
83-52	15919-15924	pairs	_	
83-53	15924-15925	;	_	
83-54	15926-15929	Fig	_	
83-55	15929-15930	.	_	
83-56	15931-15932	1	_	
83-57	15932-15933	)	_	
83-58	15933-15934	.	_	

#Text=Thus, the pattern of functional connections between the caudate and specific regions of the cortex and thalamus was abnormal in patients.
84-1	15935-15939	Thus	_	
84-2	15939-15940	,	_	
84-3	15941-15944	the	_	
84-4	15945-15952	pattern	_	
84-5	15953-15955	of	_	
84-6	15956-15966	functional	_	
84-7	15967-15978	connections	_	
84-8	15979-15986	between	_	
84-9	15987-15990	the	_	
84-10	15991-15998	caudate	_	
84-11	15999-16002	and	_	
84-12	16003-16011	specific	_	
84-13	16012-16019	regions	_	
84-14	16020-16022	of	_	
84-15	16023-16026	the	_	
84-16	16027-16033	cortex	_	
84-17	16034-16037	and	_	
84-18	16038-16046	thalamus	_	
84-19	16047-16050	was	_	
84-20	16051-16059	abnormal	_	
84-21	16060-16062	in	_	
84-22	16063-16071	patients	_	
84-23	16071-16072	.	_	

#Text=Cortical regions individually contributing to this effect included prefrontal (BAs 8, 10, 44), sensory association (BAs 20, 22, 19, and 7), posterior cingulate (BA 23), and entorhinal (BA 28) cortices.
85-1	16073-16081	Cortical	_	
85-2	16082-16089	regions	_	
85-3	16090-16102	individually	_	
85-4	16103-16115	contributing	_	
85-5	16116-16118	to	_	
85-6	16119-16123	this	_	
85-7	16124-16130	effect	_	
85-8	16131-16139	included	_	
85-9	16140-16150	prefrontal	_	
85-10	16151-16152	(	_	
85-11	16152-16155	BAs	_	
85-12	16156-16157	8	_	
85-13	16157-16158	,	_	
85-14	16159-16161	10	_	
85-15	16161-16162	,	_	
85-16	16163-16165	44	_	
85-17	16165-16166	)	_	
85-18	16166-16167	,	_	
85-19	16168-16175	sensory	_	
85-20	16176-16187	association	_	
85-21	16188-16189	(	_	
85-22	16189-16192	BAs	_	
85-23	16193-16195	20	_	
85-24	16195-16196	,	_	
85-25	16197-16199	22	_	
85-26	16199-16200	,	_	
85-27	16201-16203	19	_	
85-28	16203-16204	,	_	
85-29	16205-16208	and	_	
85-30	16209-16210	7	_	
85-31	16210-16211	)	_	
85-32	16211-16212	,	_	
85-33	16213-16222	posterior	_	
85-34	16223-16232	cingulate	_	
85-35	16233-16234	(	_	
85-36	16234-16236	BA	_	
85-37	16237-16239	23	_	
85-38	16239-16240	)	_	
85-39	16240-16241	,	_	
85-40	16242-16245	and	_	
85-41	16246-16256	entorhinal	_	
85-42	16257-16258	(	_	
85-43	16258-16260	BA	_	
85-44	16261-16263	28	_	
85-45	16263-16264	)	_	
85-46	16265-16273	cortices	_	
85-47	16273-16274	.	_	

#Text=The log odds of belonging to the healthy group did not relate to medication status or age (all p>0.19).
86-1	16275-16278	The	_	
86-2	16279-16282	log	_	
86-3	16283-16287	odds	_	
86-4	16288-16290	of	_	
86-5	16291-16300	belonging	_	
86-6	16301-16303	to	_	
86-7	16304-16307	the	_	
86-8	16308-16315	healthy	_	
86-9	16316-16321	group	_	
86-10	16322-16325	did	_	
86-11	16326-16329	not	_	
86-12	16330-16336	relate	_	
86-13	16337-16339	to	_	
86-14	16340-16350	medication	_	
86-15	16351-16357	status	_	
86-16	16358-16360	or	_	
86-17	16361-16364	age	_	
86-18	16365-16366	(	_	
86-19	16366-16369	all	_	
86-20	16370-16371	p	_	
86-21	16371-16372	>	_	
86-22	16372-16376	0.19	_	
86-23	16376-16377	)	_	
86-24	16377-16378	.	_	

#Text=Alternative definitions of the relevant target regions yielded similar results (Supplement).
87-1	16379-16390	Alternative	_	
87-2	16391-16402	definitions	_	
87-3	16403-16405	of	_	
87-4	16406-16409	the	_	
87-5	16410-16418	relevant	_	
87-6	16419-16425	target	_	
87-7	16426-16433	regions	_	
87-8	16434-16441	yielded	_	
87-9	16442-16449	similar	_	
87-10	16450-16457	results	_	
87-11	16458-16459	(	_	
87-12	16459-16469	Supplement	_	
87-13	16469-16470	)	_	
87-14	16470-16471	.	_	

#Text=Additional analyses suggested that, although connectivity patterns for each striatal subregion could separately predict group membership, that associated with posterior caudate was most discriminative (Supplement).
88-1	16472-16482	Additional	_	
88-2	16483-16491	analyses	_	
88-3	16492-16501	suggested	_	
88-4	16502-16506	that	_	
88-5	16506-16507	,	_	
88-6	16508-16516	although	_	
88-7	16517-16529	connectivity	_	
88-8	16530-16538	patterns	_	
88-9	16539-16542	for	_	
88-10	16543-16547	each	_	
88-11	16548-16556	striatal	_	
88-12	16557-16566	subregion	_	
88-13	16567-16572	could	_	
88-14	16573-16583	separately	_	
88-15	16584-16591	predict	_	
88-16	16592-16597	group	_	
88-17	16598-16608	membership	_	
88-18	16608-16609	,	_	
88-19	16610-16614	that	_	
88-20	16615-16625	associated	_	
88-21	16626-16630	with	_	
88-22	16631-16640	posterior	_	
88-23	16641-16648	caudate	_	
88-24	16649-16652	was	_	
88-25	16653-16657	most	_	
88-26	16658-16672	discriminative	_	
88-27	16673-16674	(	_	
88-28	16674-16684	Supplement	_	
88-29	16684-16685	)	_	
88-30	16685-16686	.	_	

#Text=Finally, an RFE-SVM classifier discriminated patients and controls above chance based on the global pattern of striatal connectivity (including pairs for all subregions except for the ventral striatum; eFigure 1).
89-1	16687-16694	Finally	_	
89-2	16694-16695	,	_	
89-3	16696-16698	an	_	
89-4	16699-16706	RFE-SVM	_	
89-5	16707-16717	classifier	_	
89-6	16718-16731	discriminated	_	
89-7	16732-16740	patients	_	
89-8	16741-16744	and	_	
89-9	16745-16753	controls	_	
89-10	16754-16759	above	_	
89-11	16760-16766	chance	_	
89-12	16767-16772	based	_	
89-13	16773-16775	on	_	
89-14	16776-16779	the	_	
89-15	16780-16786	global	_	
89-16	16787-16794	pattern	_	
89-17	16795-16797	of	_	
89-18	16798-16806	striatal	_	
89-19	16807-16819	connectivity	_	
89-20	16820-16821	(	_	
89-21	16821-16830	including	_	
89-22	16831-16836	pairs	_	
89-23	16837-16840	for	_	
89-24	16841-16844	all	_	
89-25	16845-16855	subregions	_	
89-26	16856-16862	except	_	
89-27	16863-16866	for	_	
89-28	16867-16870	the	_	
89-29	16871-16878	ventral	_	
89-30	16879-16887	striatum	_	
89-31	16887-16888	;	_	
89-32	16889-16896	eFigure	_	
89-33	16897-16898	1	_	
89-34	16898-16899	)	_	
89-35	16899-16900	.	_	

#Text=Clinical correlations
#Text=Patients with a more abnormal (less control-like) striatal connectivity pattern (i.e., lower log odds of belonging to the healthy control group) had more severe positive symptoms (PANSS-PT: ρ=−0.76, p=0.0011; SAPS: ρ=−0.66, p=0.0076; Fig. 2A).
90-1	16901-16909	Clinical	_	
90-2	16910-16922	correlations	_	
90-3	16923-16931	Patients	_	
90-4	16932-16936	with	_	
90-5	16937-16938	a	_	
90-6	16939-16943	more	_	
90-7	16944-16952	abnormal	_	
90-8	16953-16954	(	_	
90-9	16954-16958	less	_	
90-10	16959-16971	control-like	_	
90-11	16971-16972	)	_	
90-12	16973-16981	striatal	_	
90-13	16982-16994	connectivity	_	
90-14	16995-17002	pattern	_	
90-15	17003-17004	(	_	
90-16	17004-17007	i.e	_	
90-17	17007-17008	.	_	
90-18	17008-17009	,	_	
90-19	17010-17015	lower	_	
90-20	17016-17019	log	_	
90-21	17020-17024	odds	_	
90-22	17025-17027	of	_	
90-23	17028-17037	belonging	_	
90-24	17038-17040	to	_	
90-25	17041-17044	the	_	
90-26	17045-17052	healthy	_	
90-27	17053-17060	control	_	
90-28	17061-17066	group	_	
90-29	17066-17067	)	_	
90-30	17068-17071	had	_	
90-31	17072-17076	more	_	
90-32	17077-17083	severe	_	
90-33	17084-17092	positive	_	
90-34	17093-17101	symptoms	_	
90-35	17102-17103	(	_	
90-36	17103-17111	PANSS-PT	_	
90-37	17111-17112	:	_	
90-38	17113-17114	ρ	_	
90-39	17114-17115	=	_	
90-40	17115-17116	−	_	
90-41	17116-17120	0.76	_	
90-42	17120-17121	,	_	
90-43	17122-17123	p	_	
90-44	17123-17124	=	_	
90-45	17124-17130	0.0011	_	
90-46	17130-17131	;	_	
90-47	17132-17136	SAPS	_	
90-48	17136-17137	:	_	
90-49	17138-17139	ρ	_	
90-50	17139-17140	=	_	
90-51	17140-17141	−	_	
90-52	17141-17145	0.66	_	
90-53	17145-17146	,	_	
90-54	17147-17148	p	_	
90-55	17148-17149	=	_	
90-56	17149-17155	0.0076	_	
90-57	17155-17156	;	_	
90-58	17157-17160	Fig	_	
90-59	17160-17161	.	_	
90-60	17162-17164	2A	_	
90-61	17164-17165	)	_	
90-62	17165-17166	.	_	

#Text=This correlation was not observed with negative symptoms (PANSS-NT: ρ=−0.24, p=0.39; SANS: ρ=0.01, p=0.96; Fig. 2B).
91-1	17167-17171	This	_	
91-2	17172-17183	correlation	_	
91-3	17184-17187	was	_	
91-4	17188-17191	not	_	
91-5	17192-17200	observed	_	
91-6	17201-17205	with	_	
91-7	17206-17214	negative	_	
91-8	17215-17223	symptoms	_	
91-9	17224-17225	(	_	
91-10	17225-17233	PANSS-NT	_	
91-11	17233-17234	:	_	
91-12	17235-17236	ρ	_	
91-13	17236-17237	=	_	
91-14	17237-17238	−	_	
91-15	17238-17242	0.24	_	
91-16	17242-17243	,	_	
91-17	17244-17245	p	_	
91-18	17245-17246	=	_	
91-19	17246-17250	0.39	_	
91-20	17250-17251	;	_	
91-21	17252-17256	SANS	_	
91-22	17256-17257	:	_	
91-23	17258-17259	ρ	_	
91-24	17259-17260	=	_	
91-25	17260-17264	0.01	_	
91-26	17264-17265	,	_	
91-27	17266-17267	p	_	
91-28	17267-17268	=	_	
91-29	17268-17272	0.96	_	
91-30	17272-17273	;	_	
91-31	17274-17277	Fig	_	
91-32	17277-17278	.	_	
91-33	17279-17281	2B	_	
91-34	17281-17282	)	_	
91-35	17282-17283	.	_	

#Text=Furthermore, the correlation with PANSS-PT held after controlling for PANSS-NT and fMRI-data-quality scores (ρ=−0.77, p=0.0021).
92-1	17284-17295	Furthermore	_	
92-2	17295-17296	,	_	
92-3	17297-17300	the	_	
92-4	17301-17312	correlation	_	
92-5	17313-17317	with	_	
92-6	17318-17326	PANSS-PT	_	
92-7	17327-17331	held	_	
92-8	17332-17337	after	_	
92-9	17338-17349	controlling	_	
92-10	17350-17353	for	_	
92-11	17354-17362	PANSS-NT	_	
92-12	17363-17366	and	_	
92-13	17367-17384	fMRI-data-quality	_	
92-14	17385-17391	scores	_	
92-15	17392-17393	(	_	
92-16	17393-17394	ρ	_	
92-17	17394-17395	=	_	
92-18	17395-17396	−	_	
92-19	17396-17400	0.77	_	
92-20	17400-17401	,	_	
92-21	17402-17403	p	_	
92-22	17403-17404	=	_	
92-23	17404-17410	0.0021	_	
92-24	17410-17411	)	_	
92-25	17411-17412	.	_	

#Text=Alternative analyses cross-validated this finding (Supplement).
93-1	17413-17424	Alternative	_	
93-2	17425-17433	analyses	_	
93-3	17434-17449	cross-validated	_	
93-4	17450-17454	this	_	
93-5	17455-17462	finding	_	
93-6	17463-17464	(	_	
93-7	17464-17474	Supplement	_	
93-8	17474-17475	)	_	
93-9	17475-17476	.	_	

#Text=PANSS-PT and PANSS-NT scores were not correlated among patients (ρ=0.31, p=0.26).
94-1	17477-17485	PANSS-PT	_	
94-2	17486-17489	and	_	
94-3	17490-17498	PANSS-NT	_	
94-4	17499-17505	scores	_	
94-5	17506-17510	were	_	
94-6	17511-17514	not	_	
94-7	17515-17525	correlated	_	
94-8	17526-17531	among	_	
94-9	17532-17540	patients	_	
94-10	17541-17542	(	_	
94-11	17542-17543	ρ	_	
94-12	17543-17544	=	_	
94-13	17544-17548	0.31	_	
94-14	17548-17549	,	_	
94-15	17550-17551	p	_	
94-16	17551-17552	=	_	
94-17	17552-17556	0.26	_	
94-18	17556-17557	)	_	
94-19	17557-17558	.	_	

#Text=Correlations with [11C]FLB457 PET measures
#Text=We found that more control-like striatal connectivity patterns correlated with higher baseline BPND principal-component scores, even after adjusting for fMRI-data-quality scores and group (beta=0.27, t(25)=3.01, p=0.0058, p=0.0116 Bonferroni-corrected; Fig. 2C), but no interaction of connectivity-pattern-by-group or significant relationships with ΔBPND.
95-1	17559-17571	Correlations	_	
95-2	17572-17576	with	_	
95-3	17577-17578	[	_	
95-4	17578-17581	11C	_	
95-5	17581-17582	]	_	
95-6	17582-17588	FLB457	_	
95-7	17589-17592	PET	_	
95-8	17593-17601	measures	_	
95-9	17602-17604	We	_	
95-10	17605-17610	found	_	
95-11	17611-17615	that	_	
95-12	17616-17620	more	_	
95-13	17621-17633	control-like	_	
95-14	17634-17642	striatal	_	
95-15	17643-17655	connectivity	_	
95-16	17656-17664	patterns	_	
95-17	17665-17675	correlated	_	
95-18	17676-17680	with	_	
95-19	17681-17687	higher	_	
95-20	17688-17696	baseline	_	
95-21	17697-17701	BPND	_	
95-22	17702-17721	principal-component	_	
95-23	17722-17728	scores	_	
95-24	17728-17729	,	_	
95-25	17730-17734	even	_	
95-26	17735-17740	after	_	
95-27	17741-17750	adjusting	_	
95-28	17751-17754	for	_	
95-29	17755-17772	fMRI-data-quality	_	
95-30	17773-17779	scores	_	
95-31	17780-17783	and	_	
95-32	17784-17789	group	_	
95-33	17790-17791	(	_	
95-34	17791-17795	beta	_	
95-35	17795-17796	=	_	
95-36	17796-17800	0.27	_	
95-37	17800-17801	,	_	
95-38	17802-17803	t	_	
95-39	17803-17804	(	_	
95-40	17804-17806	25	_	
95-41	17806-17807	)	_	
95-42	17807-17808	=	_	
95-43	17808-17812	3.01	_	
95-44	17812-17813	,	_	
95-45	17814-17815	p	_	
95-46	17815-17816	=	_	
95-47	17816-17822	0.0058	_	
95-48	17822-17823	,	_	
95-49	17824-17825	p	_	
95-50	17825-17826	=	_	
95-51	17826-17832	0.0116	_	
95-52	17833-17853	Bonferroni-corrected	_	
95-53	17853-17854	;	_	
95-54	17855-17858	Fig	_	
95-55	17858-17859	.	_	
95-56	17860-17862	2C	_	
95-57	17862-17863	)	_	
95-58	17863-17864	,	_	
95-59	17865-17868	but	_	
95-60	17869-17871	no	_	
95-61	17872-17883	interaction	_	
95-62	17884-17886	of	_	
95-63	17887-17916	connectivity-pattern-by-group	_	
95-64	17917-17919	or	_	
95-65	17920-17931	significant	_	
95-66	17932-17945	relationships	_	
95-67	17946-17950	with	_	
95-68	17951-17956	ΔBPND	_	
95-69	17956-17957	.	_	

#Text=Excluding a potentially influential outlier did not alter this result (p=0.002).
96-1	17958-17967	Excluding	_	
96-2	17968-17969	a	_	
96-3	17970-17981	potentially	_	
96-4	17982-17993	influential	_	
96-5	17994-18001	outlier	_	
96-6	18002-18005	did	_	
96-7	18006-18009	not	_	
96-8	18010-18015	alter	_	
96-9	18016-18020	this	_	
96-10	18021-18027	result	_	
96-11	18028-18029	(	_	
96-12	18029-18030	p	_	
96-13	18030-18031	=	_	
96-14	18031-18036	0.002	_	
96-15	18036-18037	)	_	
96-16	18037-18038	.	_	

#Text=This effect was also apparent within patients only (p=0.0051) and was corroborated by alternative analyses and across individual regions (Supplement).
97-1	18039-18043	This	_	
97-2	18044-18050	effect	_	
97-3	18051-18054	was	_	
97-4	18055-18059	also	_	
97-5	18060-18068	apparent	_	
97-6	18069-18075	within	_	
97-7	18076-18084	patients	_	
97-8	18085-18089	only	_	
97-9	18090-18091	(	_	
97-10	18091-18092	p	_	
97-11	18092-18093	=	_	
97-12	18093-18099	0.0051	_	
97-13	18099-18100	)	_	
97-14	18101-18104	and	_	
97-15	18105-18108	was	_	
97-16	18109-18121	corroborated	_	
97-17	18122-18124	by	_	
97-18	18125-18136	alternative	_	
97-19	18137-18145	analyses	_	
97-20	18146-18149	and	_	
97-21	18150-18156	across	_	
97-22	18157-18167	individual	_	
97-23	18168-18175	regions	_	
97-24	18176-18177	(	_	
97-25	18177-18187	Supplement	_	
97-26	18187-18188	)	_	
97-27	18188-18189	.	_	

#Text=Age was unrelated to the PET measures (all p>0.1).
98-1	18190-18193	Age	_	
98-2	18194-18197	was	_	
98-3	18198-18207	unrelated	_	
98-4	18208-18210	to	_	
98-5	18211-18214	the	_	
98-6	18215-18218	PET	_	
98-7	18219-18227	measures	_	
98-8	18228-18229	(	_	
98-9	18229-18232	all	_	
98-10	18233-18234	p	_	
98-11	18234-18235	>	_	
98-12	18235-18238	0.1	_	
98-13	18238-18239	)	_	
98-14	18239-18240	.	_	

#Text=Baseline BPND principal-component scores were similar in both groups (t(27)=0.76, p=0.45).
99-1	18241-18249	Baseline	_	
99-2	18250-18254	BPND	_	
99-3	18255-18274	principal-component	_	
99-4	18275-18281	scores	_	
99-5	18282-18286	were	_	
99-6	18287-18294	similar	_	
99-7	18295-18297	in	_	
99-8	18298-18302	both	_	
99-9	18303-18309	groups	_	
99-10	18310-18311	(	_	
99-11	18311-18312	t	_	
99-12	18312-18313	(	_	
99-13	18313-18315	27	_	
99-14	18315-18316	)	_	
99-15	18316-18317	=	_	
99-16	18317-18321	0.76	_	
99-17	18321-18322	,	_	
99-18	18323-18324	p	_	
99-19	18324-18325	=	_	
99-20	18325-18329	0.45	_	
99-21	18329-18330	)	_	
99-22	18330-18331	.	_	

#Text=Exploratory correlations with neurocognitive measures
#Text=Exploratory analyses showed a correlation between abnormal striatal connectivity patterns and worse MATRICS composite scores in patients (ρ=0.6809, p=0.0302) but not in controls.
100-1	18332-18343	Exploratory	_	
100-2	18344-18356	correlations	_	
100-3	18357-18361	with	_	
100-4	18362-18376	neurocognitive	_	
100-5	18377-18385	measures	_	
100-6	18386-18397	Exploratory	_	
100-7	18398-18406	analyses	_	
100-8	18407-18413	showed	_	
100-9	18414-18415	a	_	
100-10	18416-18427	correlation	_	
100-11	18428-18435	between	_	
100-12	18436-18444	abnormal	_	
100-13	18445-18453	striatal	_	
100-14	18454-18466	connectivity	_	
100-15	18467-18475	patterns	_	
100-16	18476-18479	and	_	
100-17	18480-18485	worse	_	
100-18	18486-18493	MATRICS	_	
100-19	18494-18503	composite	_	
100-20	18504-18510	scores	_	
100-21	18511-18513	in	_	
100-22	18514-18522	patients	_	
100-23	18523-18524	(	_	
100-24	18524-18525	ρ	_	
100-25	18525-18526	=	_	
100-26	18526-18532	0.6809	_	
100-27	18532-18533	,	_	
100-28	18534-18535	p	_	
100-29	18535-18536	=	_	
100-30	18536-18542	0.0302	_	
100-31	18542-18543	)	_	
100-32	18544-18547	but	_	
100-33	18548-18551	not	_	
100-34	18552-18554	in	_	
100-35	18555-18563	controls	_	
100-36	18563-18564	.	_	

#Text=Exploratory analyses of univariate voxelwise functional connectivity and global-brain-connectivity (GBC)
#Text=A test of the group-by-striatal-subregion interaction did not yield significant results, nor did the group effects for individual subregions (Supplement).
101-1	18565-18576	Exploratory	_	
101-2	18577-18585	analyses	_	
101-3	18586-18588	of	_	
101-4	18589-18599	univariate	_	
101-5	18600-18609	voxelwise	_	
101-6	18610-18620	functional	_	
101-7	18621-18633	connectivity	_	
101-8	18634-18637	and	_	
101-9	18638-18663	global-brain-connectivity	_	
101-10	18664-18665	(	_	
101-11	18665-18668	GBC	_	
101-12	18668-18669	)	_	
101-13	18670-18671	A	_	
101-14	18672-18676	test	_	
101-15	18677-18679	of	_	
101-16	18680-18683	the	_	
101-17	18684-18711	group-by-striatal-subregion	_	
101-18	18712-18723	interaction	_	
101-19	18724-18727	did	_	
101-20	18728-18731	not	_	
101-21	18732-18737	yield	_	
101-22	18738-18749	significant	_	
101-23	18750-18757	results	_	
101-24	18757-18758	,	_	
101-25	18759-18762	nor	_	
101-26	18763-18766	did	_	
101-27	18767-18770	the	_	
101-28	18771-18776	group	_	
101-29	18777-18784	effects	_	
101-30	18785-18788	for	_	
101-31	18789-18799	individual	_	
101-32	18800-18810	subregions	_	
101-33	18811-18812	(	_	
101-34	18812-18822	Supplement	_	
101-35	18822-18823	)	_	
101-36	18823-18824	.	_	

#Text=In healthy controls, but not in patients, the anterior caudate showed significantly stronger connectivity than any of the other subregions to prefrontal, parietal, and temporal association cortices, as well as to the thalamus (all p<0.05, FDR-corrected; Fig. 3).
102-1	18825-18827	In	_	
102-2	18828-18835	healthy	_	
102-3	18836-18844	controls	_	
102-4	18844-18845	,	_	
102-5	18846-18849	but	_	
102-6	18850-18853	not	_	
102-7	18854-18856	in	_	
102-8	18857-18865	patients	_	
102-9	18865-18866	,	_	
102-10	18867-18870	the	_	
102-11	18871-18879	anterior	_	
102-12	18880-18887	caudate	_	
102-13	18888-18894	showed	_	
102-14	18895-18908	significantly	_	
102-15	18909-18917	stronger	_	
102-16	18918-18930	connectivity	_	
102-17	18931-18935	than	_	
102-18	18936-18939	any	_	
102-19	18940-18942	of	_	
102-20	18943-18946	the	_	
102-21	18947-18952	other	_	
102-22	18953-18963	subregions	_	
102-23	18964-18966	to	_	
102-24	18967-18977	prefrontal	_	
102-25	18977-18978	,	_	
102-26	18979-18987	parietal	_	
102-27	18987-18988	,	_	
102-28	18989-18992	and	_	
102-29	18993-19001	temporal	_	
102-30	19002-19013	association	_	
102-31	19014-19022	cortices	_	
102-32	19022-19023	,	_	
102-33	19024-19026	as	_	
102-34	19027-19031	well	_	
102-35	19032-19034	as	_	
102-36	19035-19037	to	_	
102-37	19038-19041	the	_	
102-38	19042-19050	thalamus	_	
102-39	19051-19052	(	_	
102-40	19052-19055	all	_	
102-41	19056-19057	p	_	
102-42	19057-19058	<	_	
102-43	19058-19062	0.05	_	
102-44	19062-19063	,	_	
102-45	19064-19077	FDR-corrected	_	
102-46	19077-19078	;	_	
102-47	19079-19082	Fig	_	
102-48	19082-19083	.	_	
102-49	19084-19085	3	_	
102-50	19085-19086	)	_	
102-51	19086-19087	.	_	

#Text=However, the group difference was not significant.
103-1	19088-19095	However	_	
103-2	19095-19096	,	_	
103-3	19097-19100	the	_	
103-4	19101-19106	group	_	
103-5	19107-19117	difference	_	
103-6	19118-19121	was	_	
103-7	19122-19125	not	_	
103-8	19126-19137	significant	_	
103-9	19137-19138	.	_	

#Text=Finally, the anterior caudate had higher GBC (eMethods) or weighted degree centrality, a graph-theoretic index of “hubness”, than the other striatal subregions (all p<0.0162; Fig. 4).
104-1	19139-19146	Finally	_	
104-2	19146-19147	,	_	
104-3	19148-19151	the	_	
104-4	19152-19160	anterior	_	
104-5	19161-19168	caudate	_	
104-6	19169-19172	had	_	
104-7	19173-19179	higher	_	
104-8	19180-19183	GBC	_	
104-9	19184-19185	(	_	
104-10	19185-19193	eMethods	_	
104-11	19193-19194	)	_	
104-12	19195-19197	or	_	
104-13	19198-19206	weighted	_	
104-14	19207-19213	degree	_	
104-15	19214-19224	centrality	_	
104-16	19224-19225	,	_	
104-17	19226-19227	a	_	
104-18	19228-19243	graph-theoretic	_	
104-19	19244-19249	index	_	
104-20	19250-19252	of	_	
104-21	19253-19254	“	_	
104-22	19254-19261	hubness	_	
104-23	19261-19262	”	_	
104-24	19262-19263	,	_	
104-25	19264-19268	than	_	
104-26	19269-19272	the	_	
104-27	19273-19278	other	_	
104-28	19279-19287	striatal	_	
104-29	19288-19298	subregions	_	
104-30	19299-19300	(	_	
104-31	19300-19303	all	_	
104-32	19304-19305	p	_	
104-33	19305-19306	<	_	
104-34	19306-19312	0.0162	_	
104-35	19312-19313	;	_	
104-36	19314-19317	Fig	_	
104-37	19317-19318	.	_	
104-38	19319-19320	4	_	
104-39	19320-19321	)	_	
104-40	19321-19322	.	_	

#Text=GBC of the anterior caudate was numerically but not significantly reduced in patients (Supplement).
105-1	19323-19326	GBC	_	
105-2	19327-19329	of	_	
105-3	19330-19333	the	_	
105-4	19334-19342	anterior	_	
105-5	19343-19350	caudate	_	
105-6	19351-19354	was	_	
105-7	19355-19366	numerically	_	
105-8	19367-19370	but	_	
105-9	19371-19374	not	_	
105-10	19375-19388	significantly	_	
105-11	19389-19396	reduced	_	
105-12	19397-19399	in	_	
105-13	19400-19408	patients	_	
105-14	19409-19410	(	_	
105-15	19410-19420	Supplement	_	
105-16	19420-19421	)	_	
105-17	19421-19422	.	_	

#Text=DISCUSSION
#Text=Our results show that the normal functional topography of striatal connections, particularly but not solely of caudate connections, is disrupted in schizophrenia.
106-1	19423-19433	DISCUSSION	_	
106-2	19434-19437	Our	_	
106-3	19438-19445	results	_	
106-4	19446-19450	show	_	
106-5	19451-19455	that	_	
106-6	19456-19459	the	_	
106-7	19460-19466	normal	_	
106-8	19467-19477	functional	_	
106-9	19478-19488	topography	_	
106-10	19489-19491	of	_	
106-11	19492-19500	striatal	_	
106-12	19501-19512	connections	_	
106-13	19512-19513	,	_	
106-14	19514-19526	particularly	_	
106-15	19527-19530	but	_	
106-16	19531-19534	not	_	
106-17	19535-19541	solely	_	
106-18	19542-19544	of	_	
106-19	19545-19552	caudate	_	
106-20	19553-19564	connections	_	
106-21	19564-19565	,	_	
106-22	19566-19568	is	_	
106-23	19569-19578	disrupted	_	
106-24	19579-19581	in	_	
106-25	19582-19595	schizophrenia	_	
106-26	19595-19596	.	_	

#Text=As our sample was comprised exclusively of unmedicated patients, this disruption is unlikely due to antipsychotic medication and may instead be relevant to the pathophysiology of schizophrenia.
107-1	19597-19599	As	_	
107-2	19600-19603	our	_	
107-3	19604-19610	sample	_	
107-4	19611-19614	was	_	
107-5	19615-19624	comprised	_	
107-6	19625-19636	exclusively	_	
107-7	19637-19639	of	_	
107-8	19640-19651	unmedicated	_	
107-9	19652-19660	patients	_	
107-10	19660-19661	,	_	
107-11	19662-19666	this	_	
107-12	19667-19677	disruption	_	
107-13	19678-19680	is	_	
107-14	19681-19689	unlikely	_	
107-15	19690-19693	due	_	
107-16	19694-19696	to	_	
107-17	19697-19710	antipsychotic	_	
107-18	19711-19721	medication	_	
107-19	19722-19725	and	_	
107-20	19726-19729	may	_	
107-21	19730-19737	instead	_	
107-22	19738-19740	be	_	
107-23	19741-19749	relevant	_	
107-24	19750-19752	to	_	
107-25	19753-19756	the	_	
107-26	19757-19772	pathophysiology	_	
107-27	19773-19775	of	_	
107-28	19776-19789	schizophrenia	_	
107-29	19789-19790	.	_	

#Text=Further supporting this interpretation, abnormal striatal connectivity correlated with clinical severity, specifically with severity of positive symptoms but not negative symptoms.
108-1	19791-19798	Further	_	
108-2	19799-19809	supporting	_	
108-3	19810-19814	this	_	
108-4	19815-19829	interpretation	_	
108-5	19829-19830	,	_	
108-6	19831-19839	abnormal	_	
108-7	19840-19848	striatal	_	
108-8	19849-19861	connectivity	_	
108-9	19862-19872	correlated	_	
108-10	19873-19877	with	_	
108-11	19878-19886	clinical	_	
108-12	19887-19895	severity	_	
108-13	19895-19896	,	_	
108-14	19897-19909	specifically	_	
108-15	19910-19914	with	_	
108-16	19915-19923	severity	_	
108-17	19924-19926	of	_	
108-18	19927-19935	positive	_	
108-19	19936-19944	symptoms	_	
108-20	19945-19948	but	_	
108-21	19949-19952	not	_	
108-22	19953-19961	negative	_	
108-23	19962-19970	symptoms	_	
108-24	19970-19971	.	_	

#Text=Finally, abnormal connectivity also correlated with lower density of D2Rs across cortical and extrastriatal subcortical brain regions within the same individuals.
109-1	19972-19979	Finally	_	
109-2	19979-19980	,	_	
109-3	19981-19989	abnormal	_	
109-4	19990-20002	connectivity	_	
109-5	20003-20007	also	_	
109-6	20008-20018	correlated	_	
109-7	20019-20023	with	_	
109-8	20024-20029	lower	_	
109-9	20030-20037	density	_	
109-10	20038-20040	of	_	
109-11	20041-20045	D2Rs	_	
109-12	20046-20052	across	_	
109-13	20053-20061	cortical	_	
109-14	20062-20065	and	_	
109-15	20066-20079	extrastriatal	_	
109-16	20080-20091	subcortical	_	
109-17	20092-20097	brain	_	
109-18	20098-20105	regions	_	
109-19	20106-20112	within	_	
109-20	20113-20116	the	_	
109-21	20117-20121	same	_	
109-22	20122-20133	individuals	_	
109-23	20133-20134	.	_	

#Text=Our results converge in suggesting that the healthy caudate, in particular the anterior caudate, is a connectivity hub.
110-1	20135-20138	Our	_	
110-2	20139-20146	results	_	
110-3	20147-20155	converge	_	
110-4	20156-20158	in	_	
110-5	20159-20169	suggesting	_	
110-6	20170-20174	that	_	
110-7	20175-20178	the	_	
110-8	20179-20186	healthy	_	
110-9	20187-20194	caudate	_	
110-10	20194-20195	,	_	
110-11	20196-20198	in	_	
110-12	20199-20209	particular	_	
110-13	20210-20213	the	_	
110-14	20214-20222	anterior	_	
110-15	20223-20230	caudate	_	
110-16	20230-20231	,	_	
110-17	20232-20234	is	_	
110-18	20235-20236	a	_	
110-19	20237-20249	connectivity	_	
110-20	20250-20253	hub	_	
110-21	20253-20254	.	_	

#Text=In health, connectivity of the anterior caudate with an extended set of higher-order associative regions was stronger than that of other striatal subregions.
111-1	20255-20257	In	_	
111-2	20258-20264	health	_	
111-3	20264-20265	,	_	
111-4	20266-20278	connectivity	_	
111-5	20279-20281	of	_	
111-6	20282-20285	the	_	
111-7	20286-20294	anterior	_	
111-8	20295-20302	caudate	_	
111-9	20303-20307	with	_	
111-10	20308-20310	an	_	
111-11	20311-20319	extended	_	
111-12	20320-20323	set	_	
111-13	20324-20326	of	_	
111-14	20327-20339	higher-order	_	
111-15	20340-20351	associative	_	
111-16	20352-20359	regions	_	
111-17	20360-20363	was	_	
111-18	20364-20372	stronger	_	
111-19	20373-20377	than	_	
111-20	20378-20382	that	_	
111-21	20383-20385	of	_	
111-22	20386-20391	other	_	
111-23	20392-20400	striatal	_	
111-24	20401-20411	subregions	_	
111-25	20411-20412	.	_	

#Text=In contrast, this primacy of the anterior caudate was not as apparent in patients.
112-1	20413-20415	In	_	
112-2	20416-20424	contrast	_	
112-3	20424-20425	,	_	
112-4	20426-20430	this	_	
112-5	20431-20438	primacy	_	
112-6	20439-20441	of	_	
112-7	20442-20445	the	_	
112-8	20446-20454	anterior	_	
112-9	20455-20462	caudate	_	
112-10	20463-20466	was	_	
112-11	20467-20470	not	_	
112-12	20471-20473	as	_	
112-13	20474-20482	apparent	_	
112-14	20483-20485	in	_	
112-15	20486-20494	patients	_	
112-16	20494-20495	.	_	

#Text=The pattern observed in health is consistent with previous work showing that the anterior caudate receives overlapping projections from various regions in fronto-parietal cortices.
113-1	20496-20499	The	_	
113-2	20500-20507	pattern	_	
113-3	20508-20516	observed	_	
113-4	20517-20519	in	_	
113-5	20520-20526	health	_	
113-6	20527-20529	is	_	
113-7	20530-20540	consistent	_	
113-8	20541-20545	with	_	
113-9	20546-20554	previous	_	
113-10	20555-20559	work	_	
113-11	20560-20567	showing	_	
113-12	20568-20572	that	_	
113-13	20573-20576	the	_	
113-14	20577-20585	anterior	_	
113-15	20586-20593	caudate	_	
113-16	20594-20602	receives	_	
113-17	20603-20614	overlapping	_	
113-18	20615-20626	projections	_	
113-19	20627-20631	from	_	
113-20	20632-20639	various	_	
113-21	20640-20647	regions	_	
113-22	20648-20650	in	_	
113-23	20651-20666	fronto-parietal	_	
113-24	20667-20675	cortices	_	
113-25	20675-20676	.	_	

#Text=This previous work suggests that in addition to the semi-segregated loops supporting specialization, convergence zones within the anterior caudate may serve as information-processing hubs relevant for integration.
114-1	20677-20681	This	_	
114-2	20682-20690	previous	_	
114-3	20691-20695	work	_	
114-4	20696-20704	suggests	_	
114-5	20705-20709	that	_	
114-6	20710-20712	in	_	
114-7	20713-20721	addition	_	
114-8	20722-20724	to	_	
114-9	20725-20728	the	_	
114-10	20729-20744	semi-segregated	_	
114-11	20745-20750	loops	_	
114-12	20751-20761	supporting	_	
114-13	20762-20776	specialization	_	
114-14	20776-20777	,	_	
114-15	20778-20789	convergence	_	
114-16	20790-20795	zones	_	
114-17	20796-20802	within	_	
114-18	20803-20806	the	_	
114-19	20807-20815	anterior	_	
114-20	20816-20823	caudate	_	
114-21	20824-20827	may	_	
114-22	20828-20833	serve	_	
114-23	20834-20836	as	_	
114-24	20837-20859	information-processing	_	
114-25	20860-20864	hubs	_	
114-26	20865-20873	relevant	_	
114-27	20874-20877	for	_	
114-28	20878-20889	integration	_	
114-29	20889-20890	.	_	

#Text=Given this, our results of abnormal striatal connectivity patterns in schizophrenia, and its relationship to positive symptoms, may suggest that a disruption affecting, among other regions, a striatal hub for information multiplexing is involved in psychosis, in line with dysconnectivity hypotheses.
115-1	20891-20896	Given	_	
115-2	20897-20901	this	_	
115-3	20901-20902	,	_	
115-4	20903-20906	our	_	
115-5	20907-20914	results	_	
115-6	20915-20917	of	_	
115-7	20918-20926	abnormal	_	
115-8	20927-20935	striatal	_	
115-9	20936-20948	connectivity	_	
115-10	20949-20957	patterns	_	
115-11	20958-20960	in	_	
115-12	20961-20974	schizophrenia	_	
115-13	20974-20975	,	_	
115-14	20976-20979	and	_	
115-15	20980-20983	its	_	
115-16	20984-20996	relationship	_	
115-17	20997-20999	to	_	
115-18	21000-21008	positive	_	
115-19	21009-21017	symptoms	_	
115-20	21017-21018	,	_	
115-21	21019-21022	may	_	
115-22	21023-21030	suggest	_	
115-23	21031-21035	that	_	
115-24	21036-21037	a	_	
115-25	21038-21048	disruption	_	
115-26	21049-21058	affecting	_	
115-27	21058-21059	,	_	
115-28	21060-21065	among	_	
115-29	21066-21071	other	_	
115-30	21072-21079	regions	_	
115-31	21079-21080	,	_	
115-32	21081-21082	a	_	
115-33	21083-21091	striatal	_	
115-34	21092-21095	hub	_	
115-35	21096-21099	for	_	
115-36	21100-21111	information	_	
115-37	21112-21124	multiplexing	_	
115-38	21125-21127	is	_	
115-39	21128-21136	involved	_	
115-40	21137-21139	in	_	
115-41	21140-21149	psychosis	_	
115-42	21149-21150	,	_	
115-43	21151-21153	in	_	
115-44	21154-21158	line	_	
115-45	21159-21163	with	_	
115-46	21164-21179	dysconnectivity	_	
115-47	21180-21190	hypotheses	_	
115-48	21190-21191	.	_	

#Text=Our findings may be consistent with findings of disrupted hemispheric specialization and decreased global connectivity of the caudate as well as those demonstrating deficient striato-cortical connectivity in schizophrenia and altered caudate-cortical connectivity in subjects at high-risk for psychosis.
116-1	21192-21195	Our	_	
116-2	21196-21204	findings	_	
116-3	21205-21208	may	_	
116-4	21209-21211	be	_	
116-5	21212-21222	consistent	_	
116-6	21223-21227	with	_	
116-7	21228-21236	findings	_	
116-8	21237-21239	of	_	
116-9	21240-21249	disrupted	_	
116-10	21250-21261	hemispheric	_	
116-11	21262-21276	specialization	_	
116-12	21277-21280	and	_	
116-13	21281-21290	decreased	_	
116-14	21291-21297	global	_	
116-15	21298-21310	connectivity	_	
116-16	21311-21313	of	_	
116-17	21314-21317	the	_	
116-18	21318-21325	caudate	_	
116-19	21326-21328	as	_	
116-20	21329-21333	well	_	
116-21	21334-21336	as	_	
116-22	21337-21342	those	_	
116-23	21343-21356	demonstrating	_	
116-24	21357-21366	deficient	_	
116-25	21367-21383	striato-cortical	_	
116-26	21384-21396	connectivity	_	
116-27	21397-21399	in	_	
116-28	21400-21413	schizophrenia	_	
116-29	21414-21417	and	_	
116-30	21418-21425	altered	_	
116-31	21426-21442	caudate-cortical	_	
116-32	21443-21455	connectivity	_	
116-33	21456-21458	in	_	
116-34	21459-21467	subjects	_	
116-35	21468-21470	at	_	
116-36	21471-21480	high-risk	_	
116-37	21481-21484	for	_	
116-38	21485-21494	psychosis	_	
116-39	21494-21495	.	_	

#Text=Although dysfunction and dysconnectivity of the (ventral) striatum may relate to negative symptoms, we failed to find such a relationship, although more work in this direction is warranted.
117-1	21496-21504	Although	_	
117-2	21505-21516	dysfunction	_	
117-3	21517-21520	and	_	
117-4	21521-21536	dysconnectivity	_	
117-5	21537-21539	of	_	
117-6	21540-21543	the	_	
117-7	21544-21545	(	_	
117-8	21545-21552	ventral	_	
117-9	21552-21553	)	_	
117-10	21554-21562	striatum	_	
117-11	21563-21566	may	_	
117-12	21567-21573	relate	_	
117-13	21574-21576	to	_	
117-14	21577-21585	negative	_	
117-15	21586-21594	symptoms	_	
117-16	21594-21595	,	_	
117-17	21596-21598	we	_	
117-18	21599-21605	failed	_	
117-19	21606-21608	to	_	
117-20	21609-21613	find	_	
117-21	21614-21618	such	_	
117-22	21619-21620	a	_	
117-23	21621-21633	relationship	_	
117-24	21633-21634	,	_	
117-25	21635-21643	although	_	
117-26	21644-21648	more	_	
117-27	21649-21653	work	_	
117-28	21654-21656	in	_	
117-29	21657-21661	this	_	
117-30	21662-21671	direction	_	
117-31	21672-21674	is	_	
117-32	21675-21684	warranted	_	
117-33	21684-21685	.	_	

#Text=Together with findings highlighting the role of striatal dopamine dysregulation in schizophrenia, our results suggest that disruptions of striatal circuitry may plausibly mediate the deleterious effects of dopamine dysregulation on cortical processes involved in perception and cognition.
118-1	21686-21694	Together	_	
118-2	21695-21699	with	_	
118-3	21700-21708	findings	_	
118-4	21709-21721	highlighting	_	
118-5	21722-21725	the	_	
118-6	21726-21730	role	_	
118-7	21731-21733	of	_	
118-8	21734-21742	striatal	_	
118-9	21743-21751	dopamine	_	
118-10	21752-21765	dysregulation	_	
118-11	21766-21768	in	_	
118-12	21769-21782	schizophrenia	_	
118-13	21782-21783	,	_	
118-14	21784-21787	our	_	
118-15	21788-21795	results	_	
118-16	21796-21803	suggest	_	
118-17	21804-21808	that	_	
118-18	21809-21820	disruptions	_	
118-19	21821-21823	of	_	
118-20	21824-21832	striatal	_	
118-21	21833-21842	circuitry	_	
118-22	21843-21846	may	_	
118-23	21847-21856	plausibly	_	
118-24	21857-21864	mediate	_	
118-25	21865-21868	the	_	
118-26	21869-21880	deleterious	_	
118-27	21881-21888	effects	_	
118-28	21889-21891	of	_	
118-29	21892-21900	dopamine	_	
118-30	21901-21914	dysregulation	_	
118-31	21915-21917	on	_	
118-32	21918-21926	cortical	_	
118-33	21927-21936	processes	_	
118-34	21937-21945	involved	_	
118-35	21946-21948	in	_	
118-36	21949-21959	perception	_	
118-37	21960-21963	and	_	
118-38	21964-21973	cognition	_	
118-39	21973-21974	.	_	

#Text=Our PET results indeed suggest that abnormal striatal connectivity in schizophrenia may depend on dopamine.
119-1	21975-21978	Our	_	
119-2	21979-21982	PET	_	
119-3	21983-21990	results	_	
119-4	21991-21997	indeed	_	
119-5	21998-22005	suggest	_	
119-6	22006-22010	that	_	
119-7	22011-22019	abnormal	_	
119-8	22020-22028	striatal	_	
119-9	22029-22041	connectivity	_	
119-10	22042-22044	in	_	
119-11	22045-22058	schizophrenia	_	
119-12	22059-22062	may	_	
119-13	22063-22069	depend	_	
119-14	22070-22072	on	_	
119-15	22073-22081	dopamine	_	
119-16	22081-22082	.	_	

#Text=We failed to detect a relationship between dysconnectivity and amphetamine-induced dopamine release, possibly due to the limited range of extrastriatal release in patients, who showed a marked deficit in release with preserved D2R levels.
120-1	22083-22085	We	_	
120-2	22086-22092	failed	_	
120-3	22093-22095	to	_	
120-4	22096-22102	detect	_	
120-5	22103-22104	a	_	
120-6	22105-22117	relationship	_	
120-7	22118-22125	between	_	
120-8	22126-22141	dysconnectivity	_	
120-9	22142-22145	and	_	
120-10	22146-22165	amphetamine-induced	_	
120-11	22166-22174	dopamine	_	
120-12	22175-22182	release	_	
120-13	22182-22183	,	_	
120-14	22184-22192	possibly	_	
120-15	22193-22196	due	_	
120-16	22197-22199	to	_	
120-17	22200-22203	the	_	
120-18	22204-22211	limited	_	
120-19	22212-22217	range	_	
120-20	22218-22220	of	_	
120-21	22221-22234	extrastriatal	_	
120-22	22235-22242	release	_	
120-23	22243-22245	in	_	
120-24	22246-22254	patients	_	
120-25	22254-22255	,	_	
120-26	22256-22259	who	_	
120-27	22260-22266	showed	_	
120-28	22267-22268	a	_	
120-29	22269-22275	marked	_	
120-30	22276-22283	deficit	_	
120-31	22284-22286	in	_	
120-32	22287-22294	release	_	
120-33	22295-22299	with	_	
120-34	22300-22309	preserved	_	
120-35	22310-22313	D2R	_	
120-36	22314-22320	levels	_	
120-37	22320-22321	.	_	

#Text=We did, however, observe more abnormal connectivity associated with lower baseline density of D2R across extrastriatal regions.
121-1	22322-22324	We	_	
121-2	22325-22328	did	_	
121-3	22328-22329	,	_	
121-4	22330-22337	however	_	
121-5	22337-22338	,	_	
121-6	22339-22346	observe	_	
121-7	22347-22351	more	_	
121-8	22352-22360	abnormal	_	
121-9	22361-22373	connectivity	_	
121-10	22374-22384	associated	_	
121-11	22385-22389	with	_	
121-12	22390-22395	lower	_	
121-13	22396-22404	baseline	_	
121-14	22405-22412	density	_	
121-15	22413-22415	of	_	
121-16	22416-22419	D2R	_	
121-17	22420-22426	across	_	
121-18	22427-22440	extrastriatal	_	
121-19	22441-22448	regions	_	
121-20	22448-22449	.	_	

#Text=Prefrontal dopamine exerts a bidirectional modulation of network activity by tuning recurrent network excitation, where D2 stimulation reduces inhibitory post-synaptic currents.
122-1	22450-22460	Prefrontal	_	
122-2	22461-22469	dopamine	_	
122-3	22470-22476	exerts	_	
122-4	22477-22478	a	_	
122-5	22479-22492	bidirectional	_	
122-6	22493-22503	modulation	_	
122-7	22504-22506	of	_	
122-8	22507-22514	network	_	
122-9	22515-22523	activity	_	
122-10	22524-22526	by	_	
122-11	22527-22533	tuning	_	
122-12	22534-22543	recurrent	_	
122-13	22544-22551	network	_	
122-14	22552-22562	excitation	_	
122-15	22562-22563	,	_	
122-16	22564-22569	where	_	
122-17	22570-22572	D2	_	
122-18	22573-22584	stimulation	_	
122-19	22585-22592	reduces	_	
122-20	22593-22603	inhibitory	_	
122-21	22604-22617	post-synaptic	_	
122-22	22618-22626	currents	_	
122-23	22626-22627	.	_	

#Text=Therefore, decreased D2Rs could potentially explain aberrant network activity propagating through BGTC circuits and leading to disruptions in activity-dependent plasticity consistent with the observed pattern of dysconnectivity in patients.
123-1	22628-22637	Therefore	_	
123-2	22637-22638	,	_	
123-3	22639-22648	decreased	_	
123-4	22649-22653	D2Rs	_	
123-5	22654-22659	could	_	
123-6	22660-22671	potentially	_	
123-7	22672-22679	explain	_	
123-8	22680-22688	aberrant	_	
123-9	22689-22696	network	_	
123-10	22697-22705	activity	_	
123-11	22706-22717	propagating	_	
123-12	22718-22725	through	_	
123-13	22726-22730	BGTC	_	
123-14	22731-22739	circuits	_	
123-15	22740-22743	and	_	
123-16	22744-22751	leading	_	
123-17	22752-22754	to	_	
123-18	22755-22766	disruptions	_	
123-19	22767-22769	in	_	
123-20	22770-22788	activity-dependent	_	
123-21	22789-22799	plasticity	_	
123-22	22800-22810	consistent	_	
123-23	22811-22815	with	_	
123-24	22816-22819	the	_	
123-25	22820-22828	observed	_	
123-26	22829-22836	pattern	_	
123-27	22837-22839	of	_	
123-28	22840-22855	dysconnectivity	_	
123-29	22856-22858	in	_	
123-30	22859-22867	patients	_	
123-31	22867-22868	.	_	

#Text=Furthermore, the generalized deficit in extrastriatal dopamine release in patients is likely to compound lower D2R expression, further dampening D2 function in those patients with more manifest dysconnectivity.
124-1	22869-22880	Furthermore	_	
124-2	22880-22881	,	_	
124-3	22882-22885	the	_	
124-4	22886-22897	generalized	_	
124-5	22898-22905	deficit	_	
124-6	22906-22908	in	_	
124-7	22909-22922	extrastriatal	_	
124-8	22923-22931	dopamine	_	
124-9	22932-22939	release	_	
124-10	22940-22942	in	_	
124-11	22943-22951	patients	_	
124-12	22952-22954	is	_	
124-13	22955-22961	likely	_	
124-14	22962-22964	to	_	
124-15	22965-22973	compound	_	
124-16	22974-22979	lower	_	
124-17	22980-22983	D2R	_	
124-18	22984-22994	expression	_	
124-19	22994-22995	,	_	
124-20	22996-23003	further	_	
124-21	23004-23013	dampening	_	
124-22	23014-23016	D2	_	
124-23	23017-23025	function	_	
124-24	23026-23028	in	_	
124-25	23029-23034	those	_	
124-26	23035-23043	patients	_	
124-27	23044-23048	with	_	
124-28	23049-23053	more	_	
124-29	23054-23062	manifest	_	
124-30	23063-23078	dysconnectivity	_	
124-31	23078-23079	.	_	

#Text=Finally, the observed relationships between D2R, deficient striatal connectivity, and psychosis are consistent with a study showing that improvement of psychosis following D2R-blocking medication correlated with strengthened caudate-prefrontal connectivity.
125-1	23080-23087	Finally	_	
125-2	23087-23088	,	_	
125-3	23089-23092	the	_	
125-4	23093-23101	observed	_	
125-5	23102-23115	relationships	_	
125-6	23116-23123	between	_	
125-7	23124-23127	D2R	_	
125-8	23127-23128	,	_	
125-9	23129-23138	deficient	_	
125-10	23139-23147	striatal	_	
125-11	23148-23160	connectivity	_	
125-12	23160-23161	,	_	
125-13	23162-23165	and	_	
125-14	23166-23175	psychosis	_	
125-15	23176-23179	are	_	
125-16	23180-23190	consistent	_	
125-17	23191-23195	with	_	
125-18	23196-23197	a	_	
125-19	23198-23203	study	_	
125-20	23204-23211	showing	_	
125-21	23212-23216	that	_	
125-22	23217-23228	improvement	_	
125-23	23229-23231	of	_	
125-24	23232-23241	psychosis	_	
125-25	23242-23251	following	_	
125-26	23252-23264	D2R-blocking	_	
125-27	23265-23275	medication	_	
125-28	23276-23286	correlated	_	
125-29	23287-23291	with	_	
125-30	23292-23304	strengthened	_	
125-31	23305-23323	caudate-prefrontal	_	
125-32	23324-23336	connectivity	_	
125-33	23336-23337	.	_	

#Text=Our study has several limitations.
126-1	23338-23341	Our	_	
126-2	23342-23347	study	_	
126-3	23348-23351	has	_	
126-4	23352-23359	several	_	
126-5	23360-23371	limitations	_	
126-6	23371-23372	.	_	

#Text=Our limited sample size may have increased the risk of false negatives and effect-size inflation.
127-1	23373-23376	Our	_	
127-2	23377-23384	limited	_	
127-3	23385-23391	sample	_	
127-4	23392-23396	size	_	
127-5	23397-23400	may	_	
127-6	23401-23405	have	_	
127-7	23406-23415	increased	_	
127-8	23416-23419	the	_	
127-9	23420-23424	risk	_	
127-10	23425-23427	of	_	
127-11	23428-23433	false	_	
127-12	23434-23443	negatives	_	
127-13	23444-23447	and	_	
127-14	23448-23459	effect-size	_	
127-15	23460-23469	inflation	_	
127-16	23469-23470	.	_	

#Text=Our choice of radiotracer precluded measures of striatal dopamine and of D1R, which would help better understand the relationship between dopamine and dysconnectivity.
128-1	23471-23474	Our	_	
128-2	23475-23481	choice	_	
128-3	23482-23484	of	_	
128-4	23485-23496	radiotracer	_	
128-5	23497-23506	precluded	_	
128-6	23507-23515	measures	_	
128-7	23516-23518	of	_	
128-8	23519-23527	striatal	_	
128-9	23528-23536	dopamine	_	
128-10	23537-23540	and	_	
128-11	23541-23543	of	_	
128-12	23544-23547	D1R	_	
128-13	23547-23548	,	_	
128-14	23549-23554	which	_	
128-15	23555-23560	would	_	
128-16	23561-23565	help	_	
128-17	23566-23572	better	_	
128-18	23573-23583	understand	_	
128-19	23584-23587	the	_	
128-20	23588-23600	relationship	_	
128-21	23601-23608	between	_	
128-22	23609-23617	dopamine	_	
128-23	23618-23621	and	_	
128-24	23622-23637	dysconnectivity	_	
128-25	23637-23638	.	_	

#Text=Nonetheless, this is to our knowledge the first multimodal study in schizophrenia combining molecular imaging and a systems-level, fMRI connectivity approach.
129-1	23639-23650	Nonetheless	_	
129-2	23650-23651	,	_	
129-3	23652-23656	this	_	
129-4	23657-23659	is	_	
129-5	23660-23662	to	_	
129-6	23663-23666	our	_	
129-7	23667-23676	knowledge	_	
129-8	23677-23680	the	_	
129-9	23681-23686	first	_	
129-10	23687-23697	multimodal	_	
129-11	23698-23703	study	_	
129-12	23704-23706	in	_	
129-13	23707-23720	schizophrenia	_	
129-14	23721-23730	combining	_	
129-15	23731-23740	molecular	_	
129-16	23741-23748	imaging	_	
129-17	23749-23752	and	_	
129-18	23753-23754	a	_	
129-19	23755-23768	systems-level	_	
129-20	23768-23769	,	_	
129-21	23770-23774	fMRI	_	
129-22	23775-23787	connectivity	_	
129-23	23788-23796	approach	_	
129-24	23796-23797	.	_	

#Text=Exploratory univariate analyses failed to find a group difference in contrast to our primary multivariate analysis.
130-1	23798-23809	Exploratory	_	
130-2	23810-23820	univariate	_	
130-3	23821-23829	analyses	_	
130-4	23830-23836	failed	_	
130-5	23837-23839	to	_	
130-6	23840-23844	find	_	
130-7	23845-23846	a	_	
130-8	23847-23852	group	_	
130-9	23853-23863	difference	_	
130-10	23864-23866	in	_	
130-11	23867-23875	contrast	_	
130-12	23876-23878	to	_	
130-13	23879-23882	our	_	
130-14	23883-23890	primary	_	
130-15	23891-23903	multivariate	_	
130-16	23904-23912	analysis	_	
130-17	23912-23913	.	_	

#Text=However, this could suggest that multivariate measures provide a more powerful way to interrogate circuit pathology.
131-1	23914-23921	However	_	
131-2	23921-23922	,	_	
131-3	23923-23927	this	_	
131-4	23928-23933	could	_	
131-5	23934-23941	suggest	_	
131-6	23942-23946	that	_	
131-7	23947-23959	multivariate	_	
131-8	23960-23968	measures	_	
131-9	23969-23976	provide	_	
131-10	23977-23978	a	_	
131-11	23979-23983	more	_	
131-12	23984-23992	powerful	_	
131-13	23993-23996	way	_	
131-14	23997-23999	to	_	
131-15	24000-24011	interrogate	_	
131-16	24012-24019	circuit	_	
131-17	24020-24029	pathology	_	
131-18	24029-24030	.	_	

#Text=Finally, a general limitation of resting-state studies is the lack of control over transient mental states experienced during data collection.
132-1	24031-24038	Finally	_	
132-2	24038-24039	,	_	
132-3	24040-24041	a	_	
132-4	24042-24049	general	_	
132-5	24050-24060	limitation	_	
132-6	24061-24063	of	_	
132-7	24064-24077	resting-state	_	
132-8	24078-24085	studies	_	
132-9	24086-24088	is	_	
132-10	24089-24092	the	_	
132-11	24093-24097	lack	_	
132-12	24098-24100	of	_	
132-13	24101-24108	control	_	
132-14	24109-24113	over	_	
132-15	24114-24123	transient	_	
132-16	24124-24130	mental	_	
132-17	24131-24137	states	_	
132-18	24138-24149	experienced	_	
132-19	24150-24156	during	_	
132-20	24157-24161	data	_	
132-21	24162-24172	collection	_	
132-22	24172-24173	.	_	

#Text=Although we did not debrief participants after scanning, psychotic symptoms experienced in the scanner tend to correlate highly with pre-scanning severity scores.
133-1	24174-24182	Although	_	
133-2	24183-24185	we	_	
133-3	24186-24189	did	_	
133-4	24190-24193	not	_	
133-5	24194-24201	debrief	_	
133-6	24202-24214	participants	_	
133-7	24215-24220	after	_	
133-8	24221-24229	scanning	_	
133-9	24229-24230	,	_	
133-10	24231-24240	psychotic	_	
133-11	24241-24249	symptoms	_	
133-12	24250-24261	experienced	_	
133-13	24262-24264	in	_	
133-14	24265-24268	the	_	
133-15	24269-24276	scanner	_	
133-16	24277-24281	tend	_	
133-17	24282-24284	to	_	
133-18	24285-24294	correlate	_	
133-19	24295-24301	highly	_	
133-20	24302-24306	with	_	
133-21	24307-24319	pre-scanning	_	
133-22	24320-24328	severity	_	
133-23	24329-24335	scores	_	
133-24	24335-24336	.	_	

#Text=Thus, our findings related to psychosis severity may partly reflect psychopathological states experienced in the scanner.
134-1	24337-24341	Thus	_	
134-2	24341-24342	,	_	
134-3	24343-24346	our	_	
134-4	24347-24355	findings	_	
134-5	24356-24363	related	_	
134-6	24364-24366	to	_	
134-7	24367-24376	psychosis	_	
134-8	24377-24385	severity	_	
134-9	24386-24389	may	_	
134-10	24390-24396	partly	_	
134-11	24397-24404	reflect	_	
134-12	24405-24423	psychopathological	_	
134-13	24424-24430	states	_	
134-14	24431-24442	experienced	_	
134-15	24443-24445	in	_	
134-16	24446-24449	the	_	
134-17	24450-24457	scanner	_	
134-18	24457-24458	.	_	

#Text=Conclusions
#Text=Unmedicated patients with schizophrenia display abnormalities in the functional topography of striatal connections.
135-1	24459-24470	Conclusions	_	
135-2	24471-24482	Unmedicated	_	
135-3	24483-24491	patients	_	
135-4	24492-24496	with	_	
135-5	24497-24510	schizophrenia	_	
135-6	24511-24518	display	_	
135-7	24519-24532	abnormalities	_	
135-8	24533-24535	in	_	
135-9	24536-24539	the	_	
135-10	24540-24550	functional	_	
135-11	24551-24561	topography	_	
135-12	24562-24564	of	_	
135-13	24565-24573	striatal	_	
135-14	24574-24585	connections	_	
135-15	24585-24586	.	_	

#Text=These abnormalities correlate specifically with more severe psychotic symptoms and lower density of extrastriatal D2R, suggesting the relevance of this neural phenotype to the pathophysiology of psychosis and potentially informing new therapeutic targets at the intersection between molecules and neural systems.
136-1	24587-24592	These	_	
136-2	24593-24606	abnormalities	_	
136-3	24607-24616	correlate	_	
136-4	24617-24629	specifically	_	
136-5	24630-24634	with	_	
136-6	24635-24639	more	_	
136-7	24640-24646	severe	_	
136-8	24647-24656	psychotic	_	
136-9	24657-24665	symptoms	_	
136-10	24666-24669	and	_	
136-11	24670-24675	lower	_	
136-12	24676-24683	density	_	
136-13	24684-24686	of	_	
136-14	24687-24700	extrastriatal	_	
136-15	24701-24704	D2R	_	
136-16	24704-24705	,	_	
136-17	24706-24716	suggesting	_	
136-18	24717-24720	the	_	
136-19	24721-24730	relevance	_	
136-20	24731-24733	of	_	
136-21	24734-24738	this	_	
136-22	24739-24745	neural	_	
136-23	24746-24755	phenotype	_	
136-24	24756-24758	to	_	
136-25	24759-24762	the	_	
136-26	24763-24778	pathophysiology	_	
136-27	24779-24781	of	_	
136-28	24782-24791	psychosis	_	
136-29	24792-24795	and	_	
136-30	24796-24807	potentially	_	
136-31	24808-24817	informing	_	
136-32	24818-24821	new	_	
136-33	24822-24833	therapeutic	_	
136-34	24834-24841	targets	_	
136-35	24842-24844	at	_	
136-36	24845-24848	the	_	
136-37	24849-24861	intersection	_	
136-38	24862-24869	between	_	
136-39	24870-24879	molecules	_	
136-40	24880-24883	and	_	
136-41	24884-24890	neural	_	
136-42	24891-24898	systems	_	
136-43	24898-24899	.	_	

#Text=Our results further suggest that the striatum contains connectivity hubs relevant for cognitive integration whose disruption may impair higher-order cortical processes involved in psychosis.
137-1	24900-24903	Our	_	
137-2	24904-24911	results	_	
137-3	24912-24919	further	_	
137-4	24920-24927	suggest	_	
137-5	24928-24932	that	_	
137-6	24933-24936	the	_	
137-7	24937-24945	striatum	_	
137-8	24946-24954	contains	_	
137-9	24955-24967	connectivity	_	
137-10	24968-24972	hubs	_	
137-11	24973-24981	relevant	_	
137-12	24982-24985	for	_	
137-13	24986-24995	cognitive	_	
137-14	24996-25007	integration	_	
137-15	25008-25013	whose	_	
137-16	25014-25024	disruption	_	
137-17	25025-25028	may	_	
137-18	25029-25035	impair	_	
137-19	25036-25048	higher-order	_	
137-20	25049-25057	cortical	_	
137-21	25058-25067	processes	_	
137-22	25068-25076	involved	_	
137-23	25077-25079	in	_	
137-24	25080-25089	psychosis	_	
137-25	25089-25090	.	_	

#Text=Supplementary Material
#Text=The nature of dopamine dysfunction in schizophrenia and what this means for treatment
#Text=Increased dopamine transmission in schizophrenia: relationship to illness phases
#Text=Striatal dopamine release in schizophrenia comorbid with substance dependence
#Text=The current status of the dopamine hypothesis of schizophrenia
#Text=Parallel organization of functionally segregated circuits linking basal ganglia and cortex
#Text=Cognitive functions and corticostriatal circuits: insights from Huntington’s disease
#Text=The primate basal ganglia: parallel and integrative networks
#Text=Estimates of projection overlap and zones of convergence within frontal-striatal circuits
#Text=Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning
#Text=Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection
#Text=Dopaminergic control of synaptic plasticity in the dorsal striatum
#Text=In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation
#Text=Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism
#Text=Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity
#Text=Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study
#Text=Dopamine-dependent architecture of cortico-subcortical network connectivity
#Text=L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study
#Text=Diagnostic interview for genetic studies.
138-1	25091-25104	Supplementary	_	
138-2	25105-25113	Material	_	
138-3	25114-25117	The	_	
138-4	25118-25124	nature	_	
138-5	25125-25127	of	_	
138-6	25128-25136	dopamine	_	
138-7	25137-25148	dysfunction	_	
138-8	25149-25151	in	_	
138-9	25152-25165	schizophrenia	_	
138-10	25166-25169	and	_	
138-11	25170-25174	what	_	
138-12	25175-25179	this	_	
138-13	25180-25185	means	_	
138-14	25186-25189	for	_	
138-15	25190-25199	treatment	_	
138-16	25200-25209	Increased	_	
138-17	25210-25218	dopamine	_	
138-18	25219-25231	transmission	_	
138-19	25232-25234	in	_	
138-20	25235-25248	schizophrenia	_	
138-21	25248-25249	:	_	
138-22	25250-25262	relationship	_	
138-23	25263-25265	to	_	
138-24	25266-25273	illness	_	
138-25	25274-25280	phases	_	
138-26	25281-25289	Striatal	_	
138-27	25290-25298	dopamine	_	
138-28	25299-25306	release	_	
138-29	25307-25309	in	_	
138-30	25310-25323	schizophrenia	_	
138-31	25324-25332	comorbid	_	
138-32	25333-25337	with	_	
138-33	25338-25347	substance	_	
138-34	25348-25358	dependence	_	
138-35	25359-25362	The	_	
138-36	25363-25370	current	_	
138-37	25371-25377	status	_	
138-38	25378-25380	of	_	
138-39	25381-25384	the	_	
138-40	25385-25393	dopamine	_	
138-41	25394-25404	hypothesis	_	
138-42	25405-25407	of	_	
138-43	25408-25421	schizophrenia	_	
138-44	25422-25430	Parallel	_	
138-45	25431-25443	organization	_	
138-46	25444-25446	of	_	
138-47	25447-25459	functionally	_	
138-48	25460-25470	segregated	_	
138-49	25471-25479	circuits	_	
138-50	25480-25487	linking	_	
138-51	25488-25493	basal	_	
138-52	25494-25501	ganglia	_	
138-53	25502-25505	and	_	
138-54	25506-25512	cortex	_	
138-55	25513-25522	Cognitive	_	
138-56	25523-25532	functions	_	
138-57	25533-25536	and	_	
138-58	25537-25552	corticostriatal	_	
138-59	25553-25561	circuits	_	
138-60	25561-25562	:	_	
138-61	25563-25571	insights	_	
138-62	25572-25576	from	_	
138-63	25577-25587	Huntington	_	
138-64	25587-25588	’	_	
138-65	25588-25589	s	_	
138-66	25590-25597	disease	_	
138-67	25598-25601	The	_	
138-68	25602-25609	primate	_	
138-69	25610-25615	basal	_	
138-70	25616-25623	ganglia	_	
138-71	25623-25624	:	_	
138-72	25625-25633	parallel	_	
138-73	25634-25637	and	_	
138-74	25638-25649	integrative	_	
138-75	25650-25658	networks	_	
138-76	25659-25668	Estimates	_	
138-77	25669-25671	of	_	
138-78	25672-25682	projection	_	
138-79	25683-25690	overlap	_	
138-80	25691-25694	and	_	
138-81	25695-25700	zones	_	
138-82	25701-25703	of	_	
138-83	25704-25715	convergence	_	
138-84	25716-25722	within	_	
138-85	25723-25739	frontal-striatal	_	
138-86	25740-25748	circuits	_	
138-87	25749-25763	Reward-related	_	
138-88	25764-25772	cortical	_	
138-89	25773-25779	inputs	_	
138-90	25780-25786	define	_	
138-91	25787-25788	a	_	
138-92	25789-25794	large	_	
138-93	25795-25803	striatal	_	
138-94	25804-25810	region	_	
138-95	25811-25813	in	_	
138-96	25814-25822	primates	_	
138-97	25823-25827	that	_	
138-98	25828-25837	interface	_	
138-99	25838-25842	with	_	
138-100	25843-25854	associative	_	
138-101	25855-25863	cortical	_	
138-102	25864-25875	connections	_	
138-103	25875-25876	,	_	
138-104	25877-25886	providing	_	
138-105	25887-25888	a	_	
138-106	25889-25898	substrate	_	
138-107	25899-25902	for	_	
138-108	25903-25918	incentive-based	_	
138-109	25919-25927	learning	_	
138-110	25928-25936	Dopamine	_	
138-111	25937-25940	and	_	
138-112	25941-25949	synaptic	_	
138-113	25950-25960	plasticity	_	
138-114	25961-25963	in	_	
138-115	25964-25970	dorsal	_	
138-116	25971-25979	striatal	_	
138-117	25980-25988	circuits	_	
138-118	25989-26000	controlling	_	
138-119	26001-26007	action	_	
138-120	26008-26017	selection	_	
138-121	26018-26030	Dopaminergic	_	
138-122	26031-26038	control	_	
138-123	26039-26041	of	_	
138-124	26042-26050	synaptic	_	
138-125	26051-26061	plasticity	_	
138-126	26062-26064	in	_	
138-127	26065-26068	the	_	
138-128	26069-26075	dorsal	_	
138-129	26076-26084	striatum	_	
138-130	26085-26087	In	_	
138-131	26088-26092	vivo	_	
138-132	26093-26111	activity-dependent	_	
138-133	26112-26122	plasticity	_	
138-134	26123-26125	at	_	
138-135	26126-26142	cortico-striatal	_	
138-136	26143-26154	connections	_	
138-137	26154-26155	:	_	
138-138	26156-26164	evidence	_	
138-139	26165-26168	for	_	
138-140	26169-26182	physiological	_	
138-141	26183-26192	long-term	_	
138-142	26193-26205	potentiation	_	
138-143	26206-26213	Dynamic	_	
138-144	26214-26222	dopamine	_	
138-145	26223-26233	modulation	_	
138-146	26234-26236	in	_	
138-147	26237-26240	the	_	
138-148	26241-26246	basal	_	
138-149	26247-26254	ganglia	_	
138-150	26254-26255	:	_	
138-151	26256-26257	a	_	
138-152	26258-26276	neurocomputational	_	
138-153	26277-26284	account	_	
138-154	26285-26287	of	_	
138-155	26288-26297	cognitive	_	
138-156	26298-26306	deficits	_	
138-157	26307-26309	in	_	
138-158	26310-26319	medicated	_	
138-159	26320-26323	and	_	
138-160	26324-26336	nonmedicated	_	
138-161	26337-26349	Parkinsonism	_	
138-162	26350-26358	Dopamine	_	
138-163	26359-26367	receptor	_	
138-164	26368-26378	activation	_	
138-165	26379-26381	is	_	
138-166	26382-26390	required	_	
138-167	26391-26394	for	_	
138-168	26395-26410	corticostriatal	_	
138-169	26411-26433	spike-timing-dependent	_	
138-170	26434-26444	plasticity	_	
138-171	26445-26453	Deficits	_	
138-172	26454-26456	in	_	
138-173	26457-26467	prefrontal	_	
138-174	26468-26476	cortical	_	
138-175	26477-26480	and	_	
138-176	26481-26494	extrastriatal	_	
138-177	26495-26503	dopamine	_	
138-178	26504-26511	release	_	
138-179	26512-26514	in	_	
138-180	26515-26528	schizophrenia	_	
138-181	26528-26529	:	_	
138-182	26530-26531	a	_	
138-183	26532-26540	positron	_	
138-184	26541-26549	emission	_	
138-185	26550-26561	tomographic	_	
138-186	26562-26572	functional	_	
138-187	26573-26581	magnetic	_	
138-188	26582-26591	resonance	_	
138-189	26592-26599	imaging	_	
138-190	26600-26605	study	_	
138-191	26606-26624	Dopamine-dependent	_	
138-192	26625-26637	architecture	_	
138-193	26638-26640	of	_	
138-194	26641-26660	cortico-subcortical	_	
138-195	26661-26668	network	_	
138-196	26669-26681	connectivity	_	
138-197	26682-26688	L-dopa	_	
138-198	26689-26698	modulates	_	
138-199	26699-26709	functional	_	
138-200	26710-26722	connectivity	_	
138-201	26723-26725	in	_	
138-202	26726-26734	striatal	_	
138-203	26735-26744	cognitive	_	
138-204	26745-26748	and	_	
138-205	26749-26754	motor	_	
138-206	26755-26763	networks	_	
138-207	26763-26764	:	_	
138-208	26765-26766	a	_	
138-209	26767-26779	double-blind	_	
138-210	26780-26798	placebo-controlled	_	
138-211	26799-26804	study	_	
138-212	26805-26815	Diagnostic	_	
138-213	26816-26825	interview	_	
138-214	26826-26829	for	_	
138-215	26830-26837	genetic	_	
138-216	26838-26845	studies	_	
138-217	26845-26846	.	_	

#Text=Rationale, unique features, and training.
139-1	26847-26856	Rationale	_	
139-2	26856-26857	,	_	
139-3	26858-26864	unique	_	
139-4	26865-26873	features	_	
139-5	26873-26874	,	_	
139-6	26875-26878	and	_	
139-7	26879-26887	training	_	
139-8	26887-26888	.	_	

#Text=NIMH Genetics Initiative
#Text=
#Text=
#Text=
#Text=The assessment and analysis of handedness: the Edinburgh inventory
#Text=The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112
#Text=Measurement of striatal and extrastriatal dopamine D-1 receptor binding potential with [C-11]NNC 112 in humans: Validation and reproducibility
#Text=Functional connectivity of human striatum: a resting state FMRI study
#Text=Automated Talairach atlas labels for functional brain mapping
#Text=An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets
#Text=A Rationale and Test for the Number of Factors in Factor Analysis
#Text=Converging structural and functional connectivity of orbitofrontal, dorsolateral prefrontal, and posterior parietal cortex in the human striatum
#Text=The neural network underlying incentive-based learning: implications for interpreting circuit disruptions in psychiatric disorders
#Text=Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
#Text=Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia
#Text=Resting-state fMRI connectivity impairment in schizophrenia and bipolar disorder
#Text=Task-related fronto-striatal functional connectivity during working memory performance in schizophrenia
#Text=Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis
#Text=Functional connectivity and grey matter volume of the striatum in schizophrenia
#Text=Functional dysconnectivity of the dorsolateral prefrontal cortex in first-episode schizophrenia using resting-state fMRI
#Text=Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis
#Text=Ventral Striatal Activation During Reward Processing in Psychosis: A Neurofunctional Meta-Analysis
#Text=Negative symptoms in schizophrenia are associated with aberrant striato-cortical connectivity in a rewarded perceptual decision-making task
#Text=Differential brain glucose metabolic patterns in antipsychotic-naive first-episode schizophrenia with and without auditory verbal hallucinations
#Text=Deficits in predictive coding underlie hallucinations in schizophrenia
#Text=Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis
#Text=Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex
#Text=Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex
#Text=Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia
#Text=Differences in multivariate pattern of striatal connections between unmedicated patients with schizophrenia and healthy controls
#Text=Top panel: coronal views of striatal subregion seeds; voxels identified as part of each subregion in at least half of the subjects are overlaid on a group-averaged T1-weighted image.
140-1	26889-26893	NIMH	_	
140-2	26894-26902	Genetics	_	
140-3	26903-26913	Initiative	_	
140-4	26917-26920	The	_	
140-5	26921-26931	assessment	_	
140-6	26932-26935	and	_	
140-7	26936-26944	analysis	_	
140-8	26945-26947	of	_	
140-9	26948-26958	handedness	_	
140-10	26958-26959	:	_	
140-11	26960-26963	the	_	
140-12	26964-26973	Edinburgh	_	
140-13	26974-26983	inventory	_	
140-14	26984-26987	The	_	
140-15	26988-26995	MATRICS	_	
140-16	26996-27005	Consensus	_	
140-17	27006-27015	Cognitive	_	
140-18	27016-27023	Battery	_	
140-19	27023-27024	,	_	
140-20	27025-27029	part	_	
140-21	27030-27031	1	_	
140-22	27031-27032	:	_	
140-23	27033-27037	test	_	
140-24	27038-27047	selection	_	
140-25	27047-27048	,	_	
140-26	27049-27060	reliability	_	
140-27	27060-27061	,	_	
140-28	27062-27065	and	_	
140-29	27066-27074	validity	_	
140-30	27075-27083	Spurious	_	
140-31	27084-27087	but	_	
140-32	27088-27098	systematic	_	
140-33	27099-27111	correlations	_	
140-34	27112-27114	in	_	
140-35	27115-27125	functional	_	
140-36	27126-27138	connectivity	_	
140-37	27139-27142	MRI	_	
140-38	27143-27151	networks	_	
140-39	27152-27157	arise	_	
140-40	27158-27162	from	_	
140-41	27163-27170	subject	_	
140-42	27171-27177	motion	_	
140-43	27178-27187	Increased	_	
140-44	27188-27198	prefrontal	_	
140-45	27199-27207	cortical	_	
140-46	27208-27209	D	_	
140-47	27209-27210	(	_	
140-48	27210-27211	1	_	
140-49	27211-27212	)	_	
140-50	27213-27222	receptors	_	
140-51	27223-27225	in	_	
140-52	27226-27230	drug	_	
140-53	27231-27236	naive	_	
140-54	27237-27245	patients	_	
140-55	27246-27250	with	_	
140-56	27251-27264	schizophrenia	_	
140-57	27264-27265	:	_	
140-58	27266-27267	a	_	
140-59	27268-27271	PET	_	
140-60	27272-27277	study	_	
140-61	27278-27282	with	_	
140-62	27283-27284	[	_	
140-63	27284-27285	(	_	
140-64	27285-27286	1	_	
140-65	27286-27287	)	_	
140-66	27287-27288	(	_	
140-67	27288-27289	1	_	
140-68	27289-27290	)	_	
140-69	27290-27291	C	_	
140-70	27291-27292	]	_	
140-71	27292-27298	NNC112	_	
140-72	27299-27310	Measurement	_	
140-73	27311-27313	of	_	
140-74	27314-27322	striatal	_	
140-75	27323-27326	and	_	
140-76	27327-27340	extrastriatal	_	
140-77	27341-27349	dopamine	_	
140-78	27350-27351	D	_	
140-79	27351-27352	-	_	
140-80	27352-27353	1	_	
140-81	27354-27362	receptor	_	
140-82	27363-27370	binding	_	
140-83	27371-27380	potential	_	
140-84	27381-27385	with	_	
140-85	27386-27387	[	_	
140-86	27387-27388	C	_	
140-87	27388-27389	-	_	
140-88	27389-27391	11	_	
140-89	27391-27392	]	_	
140-90	27392-27395	NNC	_	
140-91	27396-27399	112	_	
140-92	27400-27402	in	_	
140-93	27403-27409	humans	_	
140-94	27409-27410	:	_	
140-95	27411-27421	Validation	_	
140-96	27422-27425	and	_	
140-97	27426-27441	reproducibility	_	
140-98	27442-27452	Functional	_	
140-99	27453-27465	connectivity	_	
140-100	27466-27468	of	_	
140-101	27469-27474	human	_	
140-102	27475-27483	striatum	_	
140-103	27483-27484	:	_	
140-104	27485-27486	a	_	
140-105	27487-27494	resting	_	
140-106	27495-27500	state	_	
140-107	27501-27505	FMRI	_	
140-108	27506-27511	study	_	
140-109	27512-27521	Automated	_	
140-110	27522-27531	Talairach	_	
140-111	27532-27537	atlas	_	
140-112	27538-27544	labels	_	
140-113	27545-27548	for	_	
140-114	27549-27559	functional	_	
140-115	27560-27565	brain	_	
140-116	27566-27573	mapping	_	
140-117	27574-27576	An	_	
140-118	27577-27586	automated	_	
140-119	27587-27593	method	_	
140-120	27594-27597	for	_	
140-121	27598-27611	neuroanatomic	_	
140-122	27612-27615	and	_	
140-123	27616-27633	cytoarchitectonic	_	
140-124	27634-27645	atlas-based	_	
140-125	27646-27659	interrogation	_	
140-126	27660-27662	of	_	
140-127	27663-27667	fMRI	_	
140-128	27668-27672	data	_	
140-129	27673-27677	sets	_	
140-130	27678-27679	A	_	
140-131	27680-27689	Rationale	_	
140-132	27690-27693	and	_	
140-133	27694-27698	Test	_	
140-134	27699-27702	for	_	
140-135	27703-27706	the	_	
140-136	27707-27713	Number	_	
140-137	27714-27716	of	_	
140-138	27717-27724	Factors	_	
140-139	27725-27727	in	_	
140-140	27728-27734	Factor	_	
140-141	27735-27743	Analysis	_	
140-142	27744-27754	Converging	_	
140-143	27755-27765	structural	_	
140-144	27766-27769	and	_	
140-145	27770-27780	functional	_	
140-146	27781-27793	connectivity	_	
140-147	27794-27796	of	_	
140-148	27797-27810	orbitofrontal	_	
140-149	27810-27811	,	_	
140-150	27812-27824	dorsolateral	_	
140-151	27825-27835	prefrontal	_	
140-152	27835-27836	,	_	
140-153	27837-27840	and	_	
140-154	27841-27850	posterior	_	
140-155	27851-27859	parietal	_	
140-156	27860-27866	cortex	_	
140-157	27867-27869	in	_	
140-158	27870-27873	the	_	
140-159	27874-27879	human	_	
140-160	27880-27888	striatum	_	
140-161	27889-27892	The	_	
140-162	27893-27899	neural	_	
140-163	27900-27907	network	_	
140-164	27908-27918	underlying	_	
140-165	27919-27934	incentive-based	_	
140-166	27935-27943	learning	_	
140-167	27943-27944	:	_	
140-168	27945-27957	implications	_	
140-169	27958-27961	for	_	
140-170	27962-27974	interpreting	_	
140-171	27975-27982	circuit	_	
140-172	27983-27994	disruptions	_	
140-173	27995-27997	in	_	
140-174	27998-28009	psychiatric	_	
140-175	28010-28019	disorders	_	
140-176	28020-28033	Dysconnection	_	
140-177	28034-28036	in	_	
140-178	28037-28050	schizophrenia	_	
140-179	28050-28051	:	_	
140-180	28052-28056	from	_	
140-181	28057-28065	abnormal	_	
140-182	28066-28074	synaptic	_	
140-183	28075-28085	plasticity	_	
140-184	28086-28088	to	_	
140-185	28089-28097	failures	_	
140-186	28098-28100	of	_	
140-187	28101-28116	self-monitoring	_	
140-188	28117-28130	Abnormalities	_	
140-189	28131-28133	in	_	
140-190	28134-28145	hemispheric	_	
140-191	28146-28160	specialization	_	
140-192	28161-28163	of	_	
140-193	28164-28171	caudate	_	
140-194	28172-28179	nucleus	_	
140-195	28180-28192	connectivity	_	
140-196	28193-28195	in	_	
140-197	28196-28209	schizophrenia	_	
140-198	28210-28223	Resting-state	_	
140-199	28224-28228	fMRI	_	
140-200	28229-28241	connectivity	_	
140-201	28242-28252	impairment	_	
140-202	28253-28255	in	_	
140-203	28256-28269	schizophrenia	_	
140-204	28270-28273	and	_	
140-205	28274-28281	bipolar	_	
140-206	28282-28290	disorder	_	
140-207	28291-28303	Task-related	_	
140-208	28304-28319	fronto-striatal	_	
140-209	28320-28330	functional	_	
140-210	28331-28343	connectivity	_	
140-211	28344-28350	during	_	
140-212	28351-28358	working	_	
140-213	28359-28365	memory	_	
140-214	28366-28377	performance	_	
140-215	28378-28380	in	_	
140-216	28381-28394	schizophrenia	_	
140-217	28395-28405	Functional	_	
140-218	28406-28421	dysconnectivity	_	
140-219	28422-28424	of	_	
140-220	28425-28440	corticostriatal	_	
140-221	28441-28450	circuitry	_	
140-222	28451-28453	as	_	
140-223	28454-28455	a	_	
140-224	28456-28460	risk	_	
140-225	28461-28470	phenotype	_	
140-226	28471-28474	for	_	
140-227	28475-28484	psychosis	_	
140-228	28485-28495	Functional	_	
140-229	28496-28508	connectivity	_	
140-230	28509-28512	and	_	
140-231	28513-28517	grey	_	
140-232	28518-28524	matter	_	
140-233	28525-28531	volume	_	
140-234	28532-28534	of	_	
140-235	28535-28538	the	_	
140-236	28539-28547	striatum	_	
140-237	28548-28550	in	_	
140-238	28551-28564	schizophrenia	_	
140-239	28565-28575	Functional	_	
140-240	28576-28591	dysconnectivity	_	
140-241	28592-28594	of	_	
140-242	28595-28598	the	_	
140-243	28599-28611	dorsolateral	_	
140-244	28612-28622	prefrontal	_	
140-245	28623-28629	cortex	_	
140-246	28630-28632	in	_	
140-247	28633-28646	first-episode	_	
140-248	28647-28660	schizophrenia	_	
140-249	28661-28666	using	_	
140-250	28667-28680	resting-state	_	
140-251	28681-28685	fMRI	_	
140-252	28686-28693	Altered	_	
140-253	28694-28702	striatal	_	
140-254	28703-28713	functional	_	
140-255	28714-28726	connectivity	_	
140-256	28727-28729	in	_	
140-257	28730-28738	subjects	_	
140-258	28739-28743	with	_	
140-259	28744-28746	an	_	
140-260	28747-28754	at-risk	_	
140-261	28755-28761	mental	_	
140-262	28762-28767	state	_	
140-263	28768-28771	for	_	
140-264	28772-28781	psychosis	_	
140-265	28782-28789	Ventral	_	
140-266	28790-28798	Striatal	_	
140-267	28799-28809	Activation	_	
140-268	28810-28816	During	_	
140-269	28817-28823	Reward	_	
140-270	28824-28834	Processing	_	
140-271	28835-28837	in	_	
140-272	28838-28847	Psychosis	_	
140-273	28847-28848	:	_	
140-274	28849-28850	A	_	
140-275	28851-28866	Neurofunctional	_	
140-276	28867-28880	Meta-Analysis	_	
140-277	28881-28889	Negative	_	
140-278	28890-28898	symptoms	_	
140-279	28899-28901	in	_	
140-280	28902-28915	schizophrenia	_	
140-281	28916-28919	are	_	
140-282	28920-28930	associated	_	
140-283	28931-28935	with	_	
140-284	28936-28944	aberrant	_	
140-285	28945-28961	striato-cortical	_	
140-286	28962-28974	connectivity	_	
140-287	28975-28977	in	_	
140-288	28978-28979	a	_	
140-289	28980-28988	rewarded	_	
140-290	28989-28999	perceptual	_	
140-291	29000-29015	decision-making	_	
140-292	29016-29020	task	_	
140-293	29021-29033	Differential	_	
140-294	29034-29039	brain	_	
140-295	29040-29047	glucose	_	
140-296	29048-29057	metabolic	_	
140-297	29058-29066	patterns	_	
140-298	29067-29069	in	_	
140-299	29070-29089	antipsychotic-naive	_	
140-300	29090-29103	first-episode	_	
140-301	29104-29117	schizophrenia	_	
140-302	29118-29122	with	_	
140-303	29123-29126	and	_	
140-304	29127-29134	without	_	
140-305	29135-29143	auditory	_	
140-306	29144-29150	verbal	_	
140-307	29151-29165	hallucinations	_	
140-308	29166-29174	Deficits	_	
140-309	29175-29177	in	_	
140-310	29178-29188	predictive	_	
140-311	29189-29195	coding	_	
140-312	29196-29204	underlie	_	
140-313	29205-29219	hallucinations	_	
140-314	29220-29222	in	_	
140-315	29223-29236	schizophrenia	_	
140-316	29237-29245	Cortical	_	
140-317	29246-29257	activations	_	
140-318	29258-29264	during	_	
140-319	29265-29273	auditory	_	
140-320	29274-29280	verbal	_	
140-321	29281-29295	hallucinations	_	
140-322	29296-29298	in	_	
140-323	29299-29312	schizophrenia	_	
140-324	29312-29313	:	_	
140-325	29314-29315	a	_	
140-326	29316-29332	coordinate-based	_	
140-327	29333-29346	meta-analysis	_	
140-328	29347-29364	Dopamine-mediated	_	
140-329	29365-29378	stabilization	_	
140-330	29379-29381	of	_	
140-331	29382-29394	delay-period	_	
140-332	29395-29403	activity	_	
140-333	29404-29406	in	_	
140-334	29407-29408	a	_	
140-335	29409-29416	network	_	
140-336	29417-29422	model	_	
140-337	29423-29425	of	_	
140-338	29426-29436	prefrontal	_	
140-339	29437-29443	cortex	_	
140-340	29444-29454	Mechanisms	_	
140-341	29455-29465	underlying	_	
140-342	29466-29478	differential	_	
140-343	29479-29481	D1	_	
140-344	29482-29488	versus	_	
140-345	29489-29491	D2	_	
140-346	29492-29500	dopamine	_	
140-347	29501-29509	receptor	_	
140-348	29510-29520	regulation	_	
140-349	29521-29523	of	_	
140-350	29524-29534	inhibition	_	
140-351	29535-29537	in	_	
140-352	29538-29548	prefrontal	_	
140-353	29549-29555	cortex	_	
140-354	29556-29569	Antipsychotic	_	
140-355	29570-29579	treatment	_	
140-356	29580-29583	and	_	
140-357	29584-29594	functional	_	
140-358	29595-29607	connectivity	_	
140-359	29608-29610	of	_	
140-360	29611-29614	the	_	
140-361	29615-29623	striatum	_	
140-362	29624-29626	in	_	
140-363	29627-29640	first-episode	_	
140-364	29641-29654	schizophrenia	_	
140-365	29655-29666	Differences	_	
140-366	29667-29669	in	_	
140-367	29670-29682	multivariate	_	
140-368	29683-29690	pattern	_	
140-369	29691-29693	of	_	
140-370	29694-29702	striatal	_	
140-371	29703-29714	connections	_	
140-372	29715-29722	between	_	
140-373	29723-29734	unmedicated	_	
140-374	29735-29743	patients	_	
140-375	29744-29748	with	_	
140-376	29749-29762	schizophrenia	_	
140-377	29763-29766	and	_	
140-378	29767-29774	healthy	_	
140-379	29775-29783	controls	_	
140-380	29784-29787	Top	_	
140-381	29788-29793	panel	_	
140-382	29793-29794	:	_	
140-383	29795-29802	coronal	_	
140-384	29803-29808	views	_	
140-385	29809-29811	of	_	
140-386	29812-29820	striatal	_	
140-387	29821-29830	subregion	_	
140-388	29831-29836	seeds	_	
140-389	29836-29837	;	_	
140-390	29838-29844	voxels	_	
140-391	29845-29855	identified	_	
140-392	29856-29858	as	_	
140-393	29859-29863	part	_	
140-394	29864-29866	of	_	
140-395	29867-29871	each	_	
140-396	29872-29881	subregion	_	
140-397	29882-29884	in	_	
140-398	29885-29887	at	_	
140-399	29888-29893	least	_	
140-400	29894-29898	half	_	
140-401	29899-29901	of	_	
140-402	29902-29905	the	_	
140-403	29906-29914	subjects	_	
140-404	29915-29918	are	_	
140-405	29919-29927	overlaid	_	
140-406	29928-29930	on	_	
140-407	29931-29932	a	_	
140-408	29933-29947	group-averaged	_	
140-409	29948-29950	T1	_	
140-410	29950-29951	-	_	
140-411	29951-29959	weighted	_	
140-412	29960-29965	image	_	
140-413	29965-29966	.	_	

#Text=Middle panels: patterns of striatal connectivity are shown in controls (top) and patients (bottom) as bar plots of connectivity strength (group mean beta ± S.E.M.) by striatal subregion (using the same color scheme as in the top panel) and target region on the X axis (from left to right, cortical Brodmann areas [BA] followed by hippocampus, globus pallidus, and thalamic nuclei).
141-1	29967-29973	Middle	_	
141-2	29974-29980	panels	_	
141-3	29980-29981	:	_	
141-4	29982-29990	patterns	_	
141-5	29991-29993	of	_	
141-6	29994-30002	striatal	_	
141-7	30003-30015	connectivity	_	
141-8	30016-30019	are	_	
141-9	30020-30025	shown	_	
141-10	30026-30028	in	_	
141-11	30029-30037	controls	_	
141-12	30038-30039	(	_	
141-13	30039-30042	top	_	
141-14	30042-30043	)	_	
141-15	30044-30047	and	_	
141-16	30048-30056	patients	_	
141-17	30057-30058	(	_	
141-18	30058-30064	bottom	_	
141-19	30064-30065	)	_	
141-20	30066-30068	as	_	
141-21	30069-30072	bar	_	
141-22	30073-30078	plots	_	
141-23	30079-30081	of	_	
141-24	30082-30094	connectivity	_	
141-25	30095-30103	strength	_	
141-26	30104-30105	(	_	
141-27	30105-30110	group	_	
141-28	30111-30115	mean	_	
141-29	30116-30120	beta	_	
141-30	30121-30122	±	_	
141-31	30123-30128	S.E.M	_	
141-32	30128-30129	.	_	
141-33	30129-30130	)	_	
141-34	30131-30133	by	_	
141-35	30134-30142	striatal	_	
141-36	30143-30152	subregion	_	
141-37	30153-30154	(	_	
141-38	30154-30159	using	_	
141-39	30160-30163	the	_	
141-40	30164-30168	same	_	
141-41	30169-30174	color	_	
141-42	30175-30181	scheme	_	
141-43	30182-30184	as	_	
141-44	30185-30187	in	_	
141-45	30188-30191	the	_	
141-46	30192-30195	top	_	
141-47	30196-30201	panel	_	
141-48	30201-30202	)	_	
141-49	30203-30206	and	_	
141-50	30207-30213	target	_	
141-51	30214-30220	region	_	
141-52	30221-30223	on	_	
141-53	30224-30227	the	_	
141-54	30228-30229	X	_	
141-55	30230-30234	axis	_	
141-56	30235-30236	(	_	
141-57	30236-30240	from	_	
141-58	30241-30245	left	_	
141-59	30246-30248	to	_	
141-60	30249-30254	right	_	
141-61	30254-30255	,	_	
141-62	30256-30264	cortical	_	
141-63	30265-30273	Brodmann	_	
141-64	30274-30279	areas	_	
141-65	30280-30281	[	_	
141-66	30281-30283	BA	_	
141-67	30283-30284	]	_	
141-68	30285-30293	followed	_	
141-69	30294-30296	by	_	
141-70	30297-30308	hippocampus	_	
141-71	30308-30309	,	_	
141-72	30310-30316	globus	_	
141-73	30317-30325	pallidus	_	
141-74	30325-30326	,	_	
141-75	30327-30330	and	_	
141-76	30331-30339	thalamic	_	
141-77	30340-30346	nuclei	_	
141-78	30346-30347	)	_	
141-79	30347-30348	.	_	

#Text=Bottom panel: betas weights (log Odds Ratio or log OR) corresponding to each of the predictor variables or regressors included in the final logistic-regression model predicting group membership (controls=1, patients=0); this final (most parsimonious) model included only striatal-target pairs related to the anterior caudate (blue) and posterior caudate (fuchsia; see eMethods).
142-1	30349-30355	Bottom	_	
142-2	30356-30361	panel	_	
142-3	30361-30362	:	_	
142-4	30363-30368	betas	_	
142-5	30369-30376	weights	_	
142-6	30377-30378	(	_	
142-7	30378-30381	log	_	
142-8	30382-30386	Odds	_	
142-9	30387-30392	Ratio	_	
142-10	30393-30395	or	_	
142-11	30396-30399	log	_	
142-12	30400-30402	OR	_	
142-13	30402-30403	)	_	
142-14	30404-30417	corresponding	_	
142-15	30418-30420	to	_	
142-16	30421-30425	each	_	
142-17	30426-30428	of	_	
142-18	30429-30432	the	_	
142-19	30433-30442	predictor	_	
142-20	30443-30452	variables	_	
142-21	30453-30455	or	_	
142-22	30456-30466	regressors	_	
142-23	30467-30475	included	_	
142-24	30476-30478	in	_	
142-25	30479-30482	the	_	
142-26	30483-30488	final	_	
142-27	30489-30508	logistic-regression	_	
142-28	30509-30514	model	_	
142-29	30515-30525	predicting	_	
142-30	30526-30531	group	_	
142-31	30532-30542	membership	_	
142-32	30543-30544	(	_	
142-33	30544-30552	controls	_	
142-34	30552-30553	=	_	
142-35	30553-30554	1	_	
142-36	30554-30555	,	_	
142-37	30556-30564	patients	_	
142-38	30564-30565	=	_	
142-39	30565-30566	0	_	
142-40	30566-30567	)	_	
142-41	30567-30568	;	_	
142-42	30569-30573	this	_	
142-43	30574-30579	final	_	
142-44	30580-30581	(	_	
142-45	30581-30585	most	_	
142-46	30586-30598	parsimonious	_	
142-47	30598-30599	)	_	
142-48	30600-30605	model	_	
142-49	30606-30614	included	_	
142-50	30615-30619	only	_	
142-51	30620-30635	striatal-target	_	
142-52	30636-30641	pairs	_	
142-53	30642-30649	related	_	
142-54	30650-30652	to	_	
142-55	30653-30656	the	_	
142-56	30657-30665	anterior	_	
142-57	30666-30673	caudate	_	
142-58	30674-30675	(	_	
142-59	30675-30679	blue	_	
142-60	30679-30680	)	_	
142-61	30681-30684	and	_	
142-62	30685-30694	posterior	_	
142-63	30695-30702	caudate	_	
142-64	30703-30704	(	_	
142-65	30704-30711	fuchsia	_	
142-66	30711-30712	;	_	
142-67	30713-30716	see	_	
142-68	30717-30725	eMethods	_	
142-69	30725-30726	)	_	
142-70	30726-30727	.	_	

#Text=Asterisks denote logistic-regression beta estimates significantly different than zero (single asterisks denote p<0.05; double asterisks denote p<0.01; post-hoc tests of individual beta estimates adjusted their degrees of freedom based on the total number of predictor variables, thus controlling for multiple comparisons).
143-1	30728-30737	Asterisks	_	
143-2	30738-30744	denote	_	
143-3	30745-30764	logistic-regression	_	
143-4	30765-30769	beta	_	
143-5	30770-30779	estimates	_	
143-6	30780-30793	significantly	_	
143-7	30794-30803	different	_	
143-8	30804-30808	than	_	
143-9	30809-30813	zero	_	
143-10	30814-30815	(	_	
143-11	30815-30821	single	_	
143-12	30822-30831	asterisks	_	
143-13	30832-30838	denote	_	
143-14	30839-30840	p	_	
143-15	30840-30841	<	_	
143-16	30841-30845	0.05	_	
143-17	30845-30846	;	_	
143-18	30847-30853	double	_	
143-19	30854-30863	asterisks	_	
143-20	30864-30870	denote	_	
143-21	30871-30872	p	_	
143-22	30872-30873	<	_	
143-23	30873-30877	0.01	_	
143-24	30877-30878	;	_	
143-25	30879-30887	post-hoc	_	
143-26	30888-30893	tests	_	
143-27	30894-30896	of	_	
143-28	30897-30907	individual	_	
143-29	30908-30912	beta	_	
143-30	30913-30922	estimates	_	
143-31	30923-30931	adjusted	_	
143-32	30932-30937	their	_	
143-33	30938-30945	degrees	_	
143-34	30946-30948	of	_	
143-35	30949-30956	freedom	_	
143-36	30957-30962	based	_	
143-37	30963-30965	on	_	
143-38	30966-30969	the	_	
143-39	30970-30975	total	_	
143-40	30976-30982	number	_	
143-41	30983-30985	of	_	
143-42	30986-30995	predictor	_	
143-43	30996-31005	variables	_	
143-44	31005-31006	,	_	
143-45	31007-31011	thus	_	
143-46	31012-31023	controlling	_	
143-47	31024-31027	for	_	
143-48	31028-31036	multiple	_	
143-49	31037-31048	comparisons	_	
143-50	31048-31049	)	_	
143-51	31049-31050	.	_	

#Text=GP: globus pallidus; VPL: ventral posterior lateral nucleus; VPM : ventral posterior medial; MD: mediodorsal; VL: ventrolateral; VA: ventral anterior.
144-1	31051-31053	GP	_	
144-2	31053-31054	:	_	
144-3	31055-31061	globus	_	
144-4	31062-31070	pallidus	_	
144-5	31070-31071	;	_	
144-6	31072-31075	VPL	_	
144-7	31075-31076	:	_	
144-8	31077-31084	ventral	_	
144-9	31085-31094	posterior	_	
144-10	31095-31102	lateral	_	
144-11	31103-31110	nucleus	_	
144-12	31110-31111	;	_	
144-13	31112-31115	VPM	_	
144-14	31116-31117	:	_	
144-15	31118-31125	ventral	_	
144-16	31126-31135	posterior	_	
144-17	31136-31142	medial	_	
144-18	31142-31143	;	_	
144-19	31144-31146	MD	_	
144-20	31146-31147	:	_	
144-21	31148-31159	mediodorsal	_	
144-22	31159-31160	;	_	
144-23	31161-31163	VL	_	
144-24	31163-31164	:	_	
144-25	31165-31178	ventrolateral	_	
144-26	31178-31179	;	_	
144-27	31180-31182	VA	_	
144-28	31182-31183	:	_	
144-29	31184-31191	ventral	_	
144-30	31192-31200	anterior	_	
144-31	31200-31201	.	_	

#Text=Correlations of striatal connectivity pattern with symptom severity and D2 receptor density measured with [11C]FLB457 PET
#Text=Scatterplots show relationships between connectivity pattern (log odds of belonging to the healthy group based on the multivariate pattern of striatal connectivity) and (A) severity of positive symptoms based on the PANSS-PT scores in patients, (B) severity of negative symptoms based on the PANSS-NT scores in patients, and (C) baseline BPND (corresponding to the first principal component score), adjusted by group and fMRI-data-quality score, across all subjects (note that group adjustment shifts the group means such that the connectivity pattern appears to overlap between the groups along the X axis).
145-1	31202-31214	Correlations	_	
145-2	31215-31217	of	_	
145-3	31218-31226	striatal	_	
145-4	31227-31239	connectivity	_	
145-5	31240-31247	pattern	_	
145-6	31248-31252	with	_	
145-7	31253-31260	symptom	_	
145-8	31261-31269	severity	_	
145-9	31270-31273	and	_	
145-10	31274-31276	D2	_	
145-11	31277-31285	receptor	_	
145-12	31286-31293	density	_	
145-13	31294-31302	measured	_	
145-14	31303-31307	with	_	
145-15	31308-31309	[	_	
145-16	31309-31312	11C	_	
145-17	31312-31313	]	_	
145-18	31313-31319	FLB457	_	
145-19	31320-31323	PET	_	
145-20	31324-31336	Scatterplots	_	
145-21	31337-31341	show	_	
145-22	31342-31355	relationships	_	
145-23	31356-31363	between	_	
145-24	31364-31376	connectivity	_	
145-25	31377-31384	pattern	_	
145-26	31385-31386	(	_	
145-27	31386-31389	log	_	
145-28	31390-31394	odds	_	
145-29	31395-31397	of	_	
145-30	31398-31407	belonging	_	
145-31	31408-31410	to	_	
145-32	31411-31414	the	_	
145-33	31415-31422	healthy	_	
145-34	31423-31428	group	_	
145-35	31429-31434	based	_	
145-36	31435-31437	on	_	
145-37	31438-31441	the	_	
145-38	31442-31454	multivariate	_	
145-39	31455-31462	pattern	_	
145-40	31463-31465	of	_	
145-41	31466-31474	striatal	_	
145-42	31475-31487	connectivity	_	
145-43	31487-31488	)	_	
145-44	31489-31492	and	_	
145-45	31493-31494	(	_	
145-46	31494-31495	A	_	
145-47	31495-31496	)	_	
145-48	31497-31505	severity	_	
145-49	31506-31508	of	_	
145-50	31509-31517	positive	_	
145-51	31518-31526	symptoms	_	
145-52	31527-31532	based	_	
145-53	31533-31535	on	_	
145-54	31536-31539	the	_	
145-55	31540-31548	PANSS-PT	_	
145-56	31549-31555	scores	_	
145-57	31556-31558	in	_	
145-58	31559-31567	patients	_	
145-59	31567-31568	,	_	
145-60	31569-31570	(	_	
145-61	31570-31571	B	_	
145-62	31571-31572	)	_	
145-63	31573-31581	severity	_	
145-64	31582-31584	of	_	
145-65	31585-31593	negative	_	
145-66	31594-31602	symptoms	_	
145-67	31603-31608	based	_	
145-68	31609-31611	on	_	
145-69	31612-31615	the	_	
145-70	31616-31624	PANSS-NT	_	
145-71	31625-31631	scores	_	
145-72	31632-31634	in	_	
145-73	31635-31643	patients	_	
145-74	31643-31644	,	_	
145-75	31645-31648	and	_	
145-76	31649-31650	(	_	
145-77	31650-31651	C	_	
145-78	31651-31652	)	_	
145-79	31653-31661	baseline	_	
145-80	31662-31666	BPND	_	
145-81	31667-31668	(	_	
145-82	31668-31681	corresponding	_	
145-83	31682-31684	to	_	
145-84	31685-31688	the	_	
145-85	31689-31694	first	_	
145-86	31695-31704	principal	_	
145-87	31705-31714	component	_	
145-88	31715-31720	score	_	
145-89	31720-31721	)	_	
145-90	31721-31722	,	_	
145-91	31723-31731	adjusted	_	
145-92	31732-31734	by	_	
145-93	31735-31740	group	_	
145-94	31741-31744	and	_	
145-95	31745-31762	fMRI-data-quality	_	
145-96	31763-31768	score	_	
145-97	31768-31769	,	_	
145-98	31770-31776	across	_	
145-99	31777-31780	all	_	
145-100	31781-31789	subjects	_	
145-101	31790-31791	(	_	
145-102	31791-31795	note	_	
145-103	31796-31800	that	_	
145-104	31801-31806	group	_	
145-105	31807-31817	adjustment	_	
145-106	31818-31824	shifts	_	
145-107	31825-31828	the	_	
145-108	31829-31834	group	_	
145-109	31835-31840	means	_	
145-110	31841-31845	such	_	
145-111	31846-31850	that	_	
145-112	31851-31854	the	_	
145-113	31855-31867	connectivity	_	
145-114	31868-31875	pattern	_	
145-115	31876-31883	appears	_	
145-116	31884-31886	to	_	
145-117	31887-31894	overlap	_	
145-118	31895-31902	between	_	
145-119	31903-31906	the	_	
145-120	31907-31913	groups	_	
145-121	31914-31919	along	_	
145-122	31920-31923	the	_	
145-123	31924-31925	X	_	
145-124	31926-31930	axis	_	
145-125	31930-31931	)	_	
145-126	31931-31932	.	_	

#Text=Values in A and B are ranked given that the appropriate corresponding tests are non-parametric.
146-1	31933-31939	Values	_	
146-2	31940-31942	in	_	
146-3	31943-31944	A	_	
146-4	31945-31948	and	_	
146-5	31949-31950	B	_	
146-6	31951-31954	are	_	
146-7	31955-31961	ranked	_	
146-8	31962-31967	given	_	
146-9	31968-31972	that	_	
146-10	31973-31976	the	_	
146-11	31977-31988	appropriate	_	
146-12	31989-32002	corresponding	_	
146-13	32003-32008	tests	_	
146-14	32009-32012	are	_	
146-15	32013-32027	non-parametric	_	
146-16	32027-32028	.	_	

#Text=Voxelwise connectivity of striatal subregions in patients and healthy controls
#Text=Top panel: regions showing significant connectivity with each of the 5 striatal subregions (each in a different color) are depicted in controls (left) and patients (right) and overlaid onto an inflated brain surface (using the PALS-B12 atlas in Caret 5.65).
147-1	32029-32038	Voxelwise	_	
147-2	32039-32051	connectivity	_	
147-3	32052-32054	of	_	
147-4	32055-32063	striatal	_	
147-5	32064-32074	subregions	_	
147-6	32075-32077	in	_	
147-7	32078-32086	patients	_	
147-8	32087-32090	and	_	
147-9	32091-32098	healthy	_	
147-10	32099-32107	controls	_	
147-11	32108-32111	Top	_	
147-12	32112-32117	panel	_	
147-13	32117-32118	:	_	
147-14	32119-32126	regions	_	
147-15	32127-32134	showing	_	
147-16	32135-32146	significant	_	
147-17	32147-32159	connectivity	_	
147-18	32160-32164	with	_	
147-19	32165-32169	each	_	
147-20	32170-32172	of	_	
147-21	32173-32176	the	_	
147-22	32177-32178	5	_	
147-23	32179-32187	striatal	_	
147-24	32188-32198	subregions	_	
147-25	32199-32200	(	_	
147-26	32200-32204	each	_	
147-27	32205-32207	in	_	
147-28	32208-32209	a	_	
147-29	32210-32219	different	_	
147-30	32220-32225	color	_	
147-31	32225-32226	)	_	
147-32	32227-32230	are	_	
147-33	32231-32239	depicted	_	
147-34	32240-32242	in	_	
147-35	32243-32251	controls	_	
147-36	32252-32253	(	_	
147-37	32253-32257	left	_	
147-38	32257-32258	)	_	
147-39	32259-32262	and	_	
147-40	32263-32271	patients	_	
147-41	32272-32273	(	_	
147-42	32273-32278	right	_	
147-43	32278-32279	)	_	
147-44	32280-32283	and	_	
147-45	32284-32292	overlaid	_	
147-46	32293-32297	onto	_	
147-47	32298-32300	an	_	
147-48	32301-32309	inflated	_	
147-49	32310-32315	brain	_	
147-50	32316-32323	surface	_	
147-51	32324-32325	(	_	
147-52	32325-32330	using	_	
147-53	32331-32334	the	_	
147-54	32335-32343	PALS-B12	_	
147-55	32344-32349	atlas	_	
147-56	32350-32352	in	_	
147-57	32353-32358	Caret	_	
147-58	32359-32363	5.65	_	
147-59	32363-32364	)	_	
147-60	32364-32365	.	_	

#Text=Connectivity maps show effects corresponding to p<0.05, FDR-corrected.
148-1	32366-32378	Connectivity	_	
148-2	32379-32383	maps	_	
148-3	32384-32388	show	_	
148-4	32389-32396	effects	_	
148-5	32397-32410	corresponding	_	
148-6	32411-32413	to	_	
148-7	32414-32415	p	_	
148-8	32415-32416	<	_	
148-9	32416-32420	0.05	_	
148-10	32420-32421	,	_	
148-11	32422-32435	FDR-corrected	_	
148-12	32435-32436	.	_	

#Text=Bottom panel: t maps show regions with significantly stronger connectivity to the anterior caudate than to the other 4 striatal subregions in warm colors in controls (left) and patients (right).
149-1	32437-32443	Bottom	_	
149-2	32444-32449	panel	_	
149-3	32449-32450	:	_	
149-4	32451-32452	t	_	
149-5	32453-32457	maps	_	
149-6	32458-32462	show	_	
149-7	32463-32470	regions	_	
149-8	32471-32475	with	_	
149-9	32476-32489	significantly	_	
149-10	32490-32498	stronger	_	
149-11	32499-32511	connectivity	_	
149-12	32512-32514	to	_	
149-13	32515-32518	the	_	
149-14	32519-32527	anterior	_	
149-15	32528-32535	caudate	_	
149-16	32536-32540	than	_	
149-17	32541-32543	to	_	
149-18	32544-32547	the	_	
149-19	32548-32553	other	_	
149-20	32554-32555	4	_	
149-21	32556-32564	striatal	_	
149-22	32565-32575	subregions	_	
149-23	32576-32578	in	_	
149-24	32579-32583	warm	_	
149-25	32584-32590	colors	_	
149-26	32591-32593	in	_	
149-27	32594-32602	controls	_	
149-28	32603-32604	(	_	
149-29	32604-32608	left	_	
149-30	32608-32609	)	_	
149-31	32610-32613	and	_	
149-32	32614-32622	patients	_	
149-33	32623-32624	(	_	
149-34	32624-32629	right	_	
149-35	32629-32630	)	_	
149-36	32630-32631	.	_	

#Text=Global brain connectivity of striatal subregions in patients and healthy controls
#Text=Absolute beta values averaged across all extrastriatal brain voxels (± S.E.M.) are plotted by striatal subregion and group.
150-1	32632-32638	Global	_	
150-2	32639-32644	brain	_	
150-3	32645-32657	connectivity	_	
150-4	32658-32660	of	_	
150-5	32661-32669	striatal	_	
150-6	32670-32680	subregions	_	
150-7	32681-32683	in	_	
150-8	32684-32692	patients	_	
150-9	32693-32696	and	_	
150-10	32697-32704	healthy	_	
150-11	32705-32713	controls	_	
150-12	32714-32722	Absolute	_	
150-13	32723-32727	beta	_	
150-14	32728-32734	values	_	
150-15	32735-32743	averaged	_	
150-16	32744-32750	across	_	
150-17	32751-32754	all	_	
150-18	32755-32768	extrastriatal	_	
150-19	32769-32774	brain	_	
150-20	32775-32781	voxels	_	
150-21	32782-32783	(	_	
150-22	32783-32784	±	_	
150-23	32785-32790	S.E.M	_	
150-24	32790-32791	.	_	
150-25	32791-32792	)	_	
150-26	32793-32796	are	_	
150-27	32797-32804	plotted	_	
150-28	32805-32807	by	_	
150-29	32808-32816	striatal	_	
150-30	32817-32826	subregion	_	
150-31	32827-32830	and	_	
150-32	32831-32836	group	_	
150-33	32836-32837	.	_	

#Text=Sociodemographic, clinical, and other relevant characteristics of healthy controls and patients with schizophrenia
#Text=Means ± S.E.M. are presented for continuous variables.
151-1	32838-32854	Sociodemographic	_	
151-2	32854-32855	,	_	
151-3	32856-32864	clinical	_	
151-4	32864-32865	,	_	
151-5	32866-32869	and	_	
151-6	32870-32875	other	_	
151-7	32876-32884	relevant	_	
151-8	32885-32900	characteristics	_	
151-9	32901-32903	of	_	
151-10	32904-32911	healthy	_	
151-11	32912-32920	controls	_	
151-12	32921-32924	and	_	
151-13	32925-32933	patients	_	
151-14	32934-32938	with	_	
151-15	32939-32952	schizophrenia	_	
151-16	32953-32958	Means	_	
151-17	32959-32960	±	_	
151-18	32961-32966	S.E.M	_	
151-19	32966-32967	.	_	
151-20	32968-32971	are	_	
151-21	32972-32981	presented	_	
151-22	32982-32985	for	_	
151-23	32986-32996	continuous	_	
151-24	32997-33006	variables	_	
151-25	33006-33007	.	_	

#Text=P-values correspond to two-sample t-tests for continuous variables and χ2 tests for categorical variables.
152-1	33008-33016	P-values	_	
152-2	33017-33027	correspond	_	
152-3	33028-33030	to	_	
152-4	33031-33041	two-sample	_	
152-5	33042-33049	t-tests	_	
152-6	33050-33053	for	_	
152-7	33054-33064	continuous	_	
152-8	33065-33074	variables	_	
152-9	33075-33078	and	_	
152-10	33079-33081	χ2	_	
152-11	33082-33087	tests	_	
152-12	33088-33091	for	_	
152-13	33092-33103	categorical	_	
152-14	33104-33113	variables	_	
152-15	33113-33114	.	_	

#Text=Mean framewise displacement is given for scrubbed fMRI frames.
153-1	33115-33119	Mean	_	
153-2	33120-33129	framewise	_	
153-3	33130-33142	displacement	_	
153-4	33143-33145	is	_	
153-5	33146-33151	given	_	
153-6	33152-33155	for	_	
153-7	33156-33164	scrubbed	_	
153-8	33165-33169	fMRI	_	
153-9	33170-33176	frames	_	
153-10	33176-33177	.	_	

#Text=All 18 patients met DSM-IV criteria for schizophrenia (versus other disorders in the schizophrenia spectrum).
154-1	33178-33181	All	_	
154-2	33182-33184	18	_	
154-3	33185-33193	patients	_	
154-4	33194-33197	met	_	
154-5	33198-33204	DSM-IV	_	
154-6	33205-33213	criteria	_	
154-7	33214-33217	for	_	
154-8	33218-33231	schizophrenia	_	
154-9	33232-33233	(	_	
154-10	33233-33239	versus	_	
154-11	33240-33245	other	_	
154-12	33246-33255	disorders	_	
154-13	33256-33258	in	_	
154-14	33259-33262	the	_	
154-15	33263-33276	schizophrenia	_	
154-16	33277-33285	spectrum	_	
154-17	33285-33286	)	_	
154-18	33286-33287	.	_	

#Text=C: Caucasian; AA: African-American; Hisp: Hispanic; As: Asian.
155-1	33288-33289	C	_	
155-2	33289-33290	:	_	
155-3	33291-33300	Caucasian	_	
155-4	33300-33301	;	_	
155-5	33302-33304	AA	_	
155-6	33304-33305	:	_	
155-7	33306-33322	African-American	_	
155-8	33322-33323	;	_	
155-9	33324-33328	Hisp	_	
155-10	33328-33329	:	_	
155-11	33330-33338	Hispanic	_	
155-12	33338-33339	;	_	
155-13	33340-33342	As	_	
155-14	33342-33343	:	_	
155-15	33344-33349	Asian	_	
155-16	33349-33350	.	_	

#Text=See eTable 1 relevant information for the subset of participants with fMRI and PET data.
156-1	33351-33354	See	_	
156-2	33355-33361	eTable	_	
156-3	33362-33363	1	_	
156-4	33364-33372	relevant	_	
156-5	33373-33384	information	_	
156-6	33385-33388	for	_	
156-7	33389-33392	the	_	
156-8	33393-33399	subset	_	
156-9	33400-33402	of	_	
156-10	33403-33415	participants	_	
156-11	33416-33420	with	_	
156-12	33421-33425	fMRI	_	
156-13	33426-33429	and	_	
156-14	33430-33433	PET	_	
156-15	33434-33438	data	_	
156-16	33438-33439	.	_	

#Text=See eTable 2 for PET scanning parameters and additional data.
157-1	33440-33443	See	_	
157-2	33444-33450	eTable	_	
157-3	33451-33452	2	_	
157-4	33453-33456	for	_	
157-5	33457-33460	PET	_	
157-6	33461-33469	scanning	_	
157-7	33470-33480	parameters	_	
157-8	33481-33484	and	_	
157-9	33485-33495	additional	_	
157-10	33496-33500	data	_	
157-11	33500-33501	.	_	

#Text=Sociodemographic and clinical characteristics\tControls (n=24)\tPatients (n=18)\tp-value\t \tAge (years)\t33.7 ± 8.8\t35.6 ± 11.8\t0.54\t \tSex (female/male)\t14/10\t9/9\t0.59\t \tEthnicity (C/AA/Hisp/As/mixed)\t6/8/5/3/2\t1/9/4/1/2\t0.28\t \tParental SES\t39.0 ± 13.9\t45.6 ± 11.7\t0.13\t \tHandedness (right/left)\t23/1\t16/2\t0.39\t \tNicotine smoking (no/yes)\t21/3\t13/5\t0.21\t \tPANSS positive symptoms total [range, 7–49]\t7.0 ± 0.0 [7–8]\t13.6 ± 6.4 [9–23]\t<0.001\t \tPANSS negative symptoms total [range, 7–49]\t8.8 ± 1.4 [7–16]\t15.1 ± 5.8 [7–25]\t<0.001\t \tPANSS general symptoms total [range, 16–112]\t17.0 ± 1.4 [16–25]\t29.1 ± 7.8 [18–53]\t<0.001\t \tMATRICS (MCBB) composite T scores\t46.3 ± 2.5\t33.3 ± 3.7\t0.02\t \tMedication status (drug-naïve/drug-free)\t-\t6/12\t\t \tOnset psychotic symptoms (years)\t-\t16.4 ± 5.2\t\t \tDuration of psychotic illness (years)\t-\t18.7 ± 12.2\t\t \tCensored data (number of ‘scrubbed’ volumes)\t64.3 ± 13.5\t99.5 ± 21.7\t0.16\t \tFramewise displacement after censoring (FD)\t0.29 ± 0.0\t0.30 ± 0.0\t0.76\t \tInterval between MRI and PET scans (days)\t20.5 ± 24.8\t7.2 ± 2.6\t0.67
158-1	33502-33518	Sociodemographic	_	
158-2	33519-33522	and	_	
158-3	33523-33531	clinical	_	
158-4	33532-33547	characteristics	_	
158-5	33548-33556	Controls	_	
158-6	33557-33558	(	_	
158-7	33558-33559	n	_	
158-8	33559-33560	=	_	
158-9	33560-33562	24	_	
158-10	33562-33563	)	_	
158-11	33564-33572	Patients	_	
158-12	33573-33574	(	_	
158-13	33574-33575	n	_	
158-14	33575-33576	=	_	
158-15	33576-33578	18	_	
158-16	33578-33579	)	_	
158-17	33580-33587	p-value	_	
158-18	33590-33593	Age	_	
158-19	33594-33595	(	_	
158-20	33595-33600	years	_	
158-21	33600-33601	)	_	
158-22	33602-33606	33.7	_	
158-23	33607-33608	±	_	
158-24	33609-33612	8.8	_	
158-25	33613-33617	35.6	_	
158-26	33618-33619	±	_	
158-27	33620-33624	11.8	_	
158-28	33625-33629	0.54	_	
158-29	33632-33635	Sex	_	
158-30	33636-33637	(	_	
158-31	33637-33643	female	_	
158-32	33643-33644	/	_	
158-33	33644-33648	male	_	
158-34	33648-33649	)	_	
158-35	33650-33652	14	_	
158-36	33652-33653	/	_	
158-37	33653-33655	10	_	
158-38	33656-33657	9	_	
158-39	33657-33658	/	_	
158-40	33658-33659	9	_	
158-41	33660-33664	0.59	_	
158-42	33667-33676	Ethnicity	_	
158-43	33677-33678	(	_	
158-44	33678-33679	C	_	
158-45	33679-33680	/	_	
158-46	33680-33682	AA	_	
158-47	33682-33683	/	_	
158-48	33683-33687	Hisp	_	
158-49	33687-33688	/	_	
158-50	33688-33690	As	_	
158-51	33690-33691	/	_	
158-52	33691-33696	mixed	_	
158-53	33696-33697	)	_	
158-54	33698-33699	6	_	
158-55	33699-33700	/	_	
158-56	33700-33701	8	_	
158-57	33701-33702	/	_	
158-58	33702-33703	5	_	
158-59	33703-33704	/	_	
158-60	33704-33705	3	_	
158-61	33705-33706	/	_	
158-62	33706-33707	2	_	
158-63	33708-33709	1	_	
158-64	33709-33710	/	_	
158-65	33710-33711	9	_	
158-66	33711-33712	/	_	
158-67	33712-33713	4	_	
158-68	33713-33714	/	_	
158-69	33714-33715	1	_	
158-70	33715-33716	/	_	
158-71	33716-33717	2	_	
158-72	33718-33722	0.28	_	
158-73	33725-33733	Parental	_	
158-74	33734-33737	SES	_	
158-75	33738-33742	39.0	_	
158-76	33743-33744	±	_	
158-77	33745-33749	13.9	_	
158-78	33750-33754	45.6	_	
158-79	33755-33756	±	_	
158-80	33757-33761	11.7	_	
158-81	33762-33766	0.13	_	
158-82	33769-33779	Handedness	_	
158-83	33780-33781	(	_	
158-84	33781-33786	right	_	
158-85	33786-33787	/	_	
158-86	33787-33791	left	_	
158-87	33791-33792	)	_	
158-88	33793-33795	23	_	
158-89	33795-33796	/	_	
158-90	33796-33797	1	_	
158-91	33798-33800	16	_	
158-92	33800-33801	/	_	
158-93	33801-33802	2	_	
158-94	33803-33807	0.39	_	
158-95	33810-33818	Nicotine	_	
158-96	33819-33826	smoking	_	
158-97	33827-33828	(	_	
158-98	33828-33830	no	_	
158-99	33830-33831	/	_	
158-100	33831-33834	yes	_	
158-101	33834-33835	)	_	
158-102	33836-33838	21	_	
158-103	33838-33839	/	_	
158-104	33839-33840	3	_	
158-105	33841-33843	13	_	
158-106	33843-33844	/	_	
158-107	33844-33845	5	_	
158-108	33846-33850	0.21	_	
158-109	33853-33858	PANSS	_	
158-110	33859-33867	positive	_	
158-111	33868-33876	symptoms	_	
158-112	33877-33882	total	_	
158-113	33883-33884	[	_	
158-114	33884-33889	range	_	
158-115	33889-33890	,	_	
158-116	33891-33892	7	_	
158-117	33892-33893	–	_	
158-118	33893-33895	49	_	
158-119	33895-33896	]	_	
158-120	33897-33900	7.0	_	
158-121	33901-33902	±	_	
158-122	33903-33906	0.0	_	
158-123	33907-33908	[	_	
158-124	33908-33909	7	_	
158-125	33909-33910	–	_	
158-126	33910-33911	8	_	
158-127	33911-33912	]	_	
158-128	33913-33917	13.6	_	
158-129	33918-33919	±	_	
158-130	33920-33923	6.4	_	
158-131	33924-33925	[	_	
158-132	33925-33926	9	_	
158-133	33926-33927	–	_	
158-134	33927-33929	23	_	
158-135	33929-33930	]	_	
158-136	33931-33932	<	_	
158-137	33932-33937	0.001	_	
158-138	33940-33945	PANSS	_	
158-139	33946-33954	negative	_	
158-140	33955-33963	symptoms	_	
158-141	33964-33969	total	_	
158-142	33970-33971	[	_	
158-143	33971-33976	range	_	
158-144	33976-33977	,	_	
158-145	33978-33979	7	_	
158-146	33979-33980	–	_	
158-147	33980-33982	49	_	
158-148	33982-33983	]	_	
158-149	33984-33987	8.8	_	
158-150	33988-33989	±	_	
158-151	33990-33993	1.4	_	
158-152	33994-33995	[	_	
158-153	33995-33996	7	_	
158-154	33996-33997	–	_	
158-155	33997-33999	16	_	
158-156	33999-34000	]	_	
158-157	34001-34005	15.1	_	
158-158	34006-34007	±	_	
158-159	34008-34011	5.8	_	
158-160	34012-34013	[	_	
158-161	34013-34014	7	_	
158-162	34014-34015	–	_	
158-163	34015-34017	25	_	
158-164	34017-34018	]	_	
158-165	34019-34020	<	_	
158-166	34020-34025	0.001	_	
158-167	34028-34033	PANSS	_	
158-168	34034-34041	general	_	
158-169	34042-34050	symptoms	_	
158-170	34051-34056	total	_	
158-171	34057-34058	[	_	
158-172	34058-34063	range	_	
158-173	34063-34064	,	_	
158-174	34065-34067	16	_	
158-175	34067-34068	–	_	
158-176	34068-34071	112	_	
158-177	34071-34072	]	_	
158-178	34073-34077	17.0	_	
158-179	34078-34079	±	_	
158-180	34080-34083	1.4	_	
158-181	34084-34085	[	_	
158-182	34085-34087	16	_	
158-183	34087-34088	–	_	
158-184	34088-34090	25	_	
158-185	34090-34091	]	_	
158-186	34092-34096	29.1	_	
158-187	34097-34098	±	_	
158-188	34099-34102	7.8	_	
158-189	34103-34104	[	_	
158-190	34104-34106	18	_	
158-191	34106-34107	–	_	
158-192	34107-34109	53	_	
158-193	34109-34110	]	_	
158-194	34111-34112	<	_	
158-195	34112-34117	0.001	_	
158-196	34120-34127	MATRICS	_	
158-197	34128-34129	(	_	
158-198	34129-34133	MCBB	_	
158-199	34133-34134	)	_	
158-200	34135-34144	composite	_	
158-201	34145-34146	T	_	
158-202	34147-34153	scores	_	
158-203	34154-34158	46.3	_	
158-204	34159-34160	±	_	
158-205	34161-34164	2.5	_	
158-206	34165-34169	33.3	_	
158-207	34170-34171	±	_	
158-208	34172-34175	3.7	_	
158-209	34176-34180	0.02	_	
158-210	34183-34193	Medication	_	
158-211	34194-34200	status	_	
158-212	34201-34202	(	_	
158-213	34202-34212	drug-naïve	_	
158-214	34212-34213	/	_	
158-215	34213-34222	drug-free	_	
158-216	34222-34223	)	_	
158-217	34224-34225	-	_	
158-218	34226-34227	6	_	
158-219	34227-34228	/	_	
158-220	34228-34230	12	_	
158-221	34234-34239	Onset	_	
158-222	34240-34249	psychotic	_	
158-223	34250-34258	symptoms	_	
158-224	34259-34260	(	_	
158-225	34260-34265	years	_	
158-226	34265-34266	)	_	
158-227	34267-34268	-	_	
158-228	34269-34273	16.4	_	
158-229	34274-34275	±	_	
158-230	34276-34279	5.2	_	
158-231	34283-34291	Duration	_	
158-232	34292-34294	of	_	
158-233	34295-34304	psychotic	_	
158-234	34305-34312	illness	_	
158-235	34313-34314	(	_	
158-236	34314-34319	years	_	
158-237	34319-34320	)	_	
158-238	34321-34322	-	_	
158-239	34323-34327	18.7	_	
158-240	34328-34329	±	_	
158-241	34330-34334	12.2	_	
158-242	34338-34346	Censored	_	
158-243	34347-34351	data	_	
158-244	34352-34353	(	_	
158-245	34353-34359	number	_	
158-246	34360-34362	of	_	
158-247	34363-34364	‘	_	
158-248	34364-34372	scrubbed	_	
158-249	34372-34373	’	_	
158-250	34374-34381	volumes	_	
158-251	34381-34382	)	_	
158-252	34383-34387	64.3	_	
158-253	34388-34389	±	_	
158-254	34390-34394	13.5	_	
158-255	34395-34399	99.5	_	
158-256	34400-34401	±	_	
158-257	34402-34406	21.7	_	
158-258	34407-34411	0.16	_	
158-259	34414-34423	Framewise	_	
158-260	34424-34436	displacement	_	
158-261	34437-34442	after	_	
158-262	34443-34452	censoring	_	
158-263	34453-34454	(	_	
158-264	34454-34456	FD	_	
158-265	34456-34457	)	_	
158-266	34458-34462	0.29	_	
158-267	34463-34464	±	_	
158-268	34465-34468	0.0	_	
158-269	34469-34473	0.30	_	
158-270	34474-34475	±	_	
158-271	34476-34479	0.0	_	
158-272	34480-34484	0.76	_	
158-273	34487-34495	Interval	_	
158-274	34496-34503	between	_	
158-275	34504-34507	MRI	_	
158-276	34508-34511	and	_	
158-277	34512-34515	PET	_	
158-278	34516-34521	scans	_	
158-279	34522-34523	(	_	
158-280	34523-34527	days	_	
158-281	34527-34528	)	_	
158-282	34529-34533	20.5	_	
158-283	34534-34535	±	_	
158-284	34536-34540	24.8	_	
158-285	34541-34544	7.2	_	
158-286	34545-34546	±	_	
158-287	34547-34550	2.6	_	
158-288	34551-34555	0.67	_	
